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1
HPV infection and anogenital cancer
Infection with the human papillomavirus (HPV) can cause a variety of anogenital can-
cers such as cervical cancer, anal cancer and vulvar cancer, and other cancers such as 
oropharyngeal cancer. Other HPV’s cause genital warts and are only rarely found in can-
cers 1, 2. Over 200 different types of HPV have been identified3, of which 14 alpha types 
are recognised as carcinogens and are called high-risk (hr)HPV types 4. Low-risk HPV 
types are known to cause genital warts and laryngeal papillomatosis 5. hrHPV is found 
in virtually all squamous cell cervical carcinomas and almost 90% of anal carcinomas, 
with HPV16 and HPV18 accounting for over 70% of cervical carcinomas6, 7 and HPV16 
alone detected in almost all HPV-positive anal cancers8, 9. HPV is also the most common 
sexually transmitted infection, with a lifetime risk of a hrHPV infection around 80% in 
women 10, 11.
HPV and development of cervical cancer
With <1% of HPV infections leading to cervical cancer, the development of a cervical 
carcinoma is the most well-known but rare complication of a hrHPV infection. Most 
infections are cleared by the host immune system within 2 years and do not produce 
detected dysplastic lesions at all12, 13. Several determinants have been found to influence 
the progression of oncogenic HPV infection to a dysplastic lesion, such as smoking, and 
contraceptive use 14-16. If not cleared by the immune system, cervical cancer develops 
through a series of stages and a complex process of different events including chromo-
somal loss, somatic gene activation and suppression, somatic mutation, viral integration 
and methylation17. hrHPV virions enter the basal cell layer of the transformation zone 
of the cervical epithelium through a micro-laceration or specifically susceptible cells at 
the squamocolumnar junction, such as, in the endocervix, reserve cells or the region of 
immature metaplasia. The development of cancer after hrHPV infection usually takes 
about 15 years and is a complex process driven by the genes of hrHPV, but progression 
is variable and occasionally is very rapid 18.
HPV and prevention of invasive cervical cancer
There are two current approaches to preventing cervical cancer which have been largely 
implemented in many wealthy, developed countries and to a limited degree in low and 
middle income countries (LMIC) across the world. Secondary prevention through cervi-
cal screening was first developed in the 1950’s and implemented more effectively in an 
organised way in the 1980’s in most HIC (higher income countries) countries and used 
cytology to detect women with precursor lesions. The introduction of screening pro-
grammes has greatly reduced cervical cancer incidence in the developed world20-24, but 
these programmes are costly, require multiple screening rounds and have the side effect 
of overdiagnosis and overtreatment of lesions which will never progress to cancer25. 
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Interpretation of cytology is subjective and variable, depending on individual skill in 
interpreting microscopic changes in individual cells. Searching for a molecular alterna-
tive, a hrHPV test, which detects the causative agent of cervical cancer and precursors, 
was found to have a higher sensitivity for detection of high-grade cervical intraepithelial 
neoplasia (CIN2+), also known as high-grade squamous intraepithelial lesions (HSIL) but 
also has a lower specificity than cytology, detecting many transient infections rather 
than those progressing to cancer 26, 27.
Primary prevention is achieved via HPV vaccination of either girls and women only or 
including boys. Three vaccines are available that all protect against at least HPV16/18, 
thus reducing about 50% of CIN2+ and at least 70% of all cervical carcinomas28.
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Figure 1. Cervical epithelium and the transformation zone. Schematic representation of the ectocervix, 
transformation zone, squamocolumnar junction (SCJ) and the endocervix. Human papillomavirus virions 
enter the basal layer through a micro-laceration in the squamous epithelium. Adapted from Schiffman et 
al. 19
HPV and secondary prevention through screening
The usually slow progression from cervical hrHPV infection to cancer offers usually a 
large window for detection and treatment of precursor lesions, which is what large 
population-based screening programmes aim to do to prevent cervical cancer. First 
cervical cancer screening programs were cytology-based and involved the cytological 
evaluation of cervical smears containing squamous and columnar epithelial cells from 
13
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1the transformation zone collected by a physician. Cytological assessment however, requires a subjective interpretation and lacks sensitivity for the detection of high-grade precursor lesions as well as requiring triage of uncertain, borderline cytological abnor-
malities (ASC-US). The development of highly sensitive and reproducible laboratory-
based hrHPV tests has led to the replacement of cytology screening by hrHPV screening 
in several higher income countries with established screening programmes, such as The 
Netherlands, Australia and more recently the UK. This development is also likely to be 
more cost-effective than cytology in vaccinated populations29. The use of hrHPV as a 
screening tool could be applied in LMICs where there is no or very limited screening and 
the requirements of training and adequate sampling for cytology render this an unsuit-
able approach. In these countries it is being evaluated against other direct approaches 
to screening such as visual inspection of cervix with acetic acid (VIA) 30, 31.
Since the late 90’s several large randomized controlled trials (RCTs) have been performed 
that compared hrHPV testing and hrHPV testing plus cytology (co-testing) with cytology 
alone. The most important studies have been carried out in Canada, Italy, the Nether-
lands, England and Sweden32-35 36; countries with different screening programs, different 
outcome measures and different hrHPV tests. Both baseline and follow-up results from 
the large RCTs showed similar results: the hrHPV-based screening offers better detection 
of HSIL and offers longer protection in case of a hrHPV negative screening result 37, 38. 
HPV-based screening provides 60–70% greater protection against invasive cervical car-
cinomas compared with cytology and can start from the age of 30 years with screening 
intervals of at least 5 years. In addition, primary hrHPV screening can be performed on 
self-collected material. The introduction of self-sampling, which is much more suited to 
hrHPV screening than to cytology, into the screening program is expected to result in a 
higher participation rate, offering a better protection against cervical cancer for former 
non-responders of the screening programs39-43. Currently, the only self-sampling tool 
implemented in a screening program is a brush which collects cervicovaginal cells from 
the vagina (Evalyn Brush, Rovers, Oss, The Netherlands) 44. The search for less invasive 
and more user-friendly self-sampling methods is ongoing and might include the use of 
urine samples for hrHPV-screening.
hrHPV-testing as a screening test has a lower specificity compared to cytology and 
therefore requires a triage test for hrHPV-positive women to avoid unnecessary referral 
for colposcopy of women without clinically relevant disease45. The most frequently used 
triage strategy currently is cytology with or without HPV16/18 genotyping34, 46, 47 but 
the search for a better strategy is ongoing and largely focusses on the use of molecular 
markers such as methylation of human tumour suppressor genes 48. The need to perform 
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cytology as a triage test and the requirement for good morphological preservation also 
limits the development of further approaches to self-sampling.
HPV and primary prevention through vaccination
Prophylactic HPV vaccination can, as well as reducing cervical cancer incidence, also 
reduce the burden of other HPV-related cancers such as vulvar, vaginal, penile, anal 
and oropharyngeal cancers 49, 50. By including antigens for low-risk HPV types, HPV6 
and HPV11, vaccination can also help prevent genital warts 51. Since 2006, three HPV 
vaccines were approved: the quadrivalent Gardasil (HPV6/11/16/18) 52, 53, the bivalent 
Cervarix (HPV16/18) 54 and the nonavalent Gardasil 9 (HPV6/11/16/18/31/33/45/52/58) 
55. All have been found highly effective when given in a three-dose or two-dose sched-
ule, and new studies show comparable effectiveness for one dose 56. Many countries 
have implemented a prophylactic HPV vaccination programme, most of them offering 
vaccination to young girls in three doses. Several countries, including Australia and Aus-
tria, have implemented a gender-neutral approach, also vaccinating boys. Exact target 
populations and coverage levels vary between countries 57. Group-protection has been 
seen in populations with a high vaccination coverage, with lower infection rates and 
precursor lesion incidence in both the vaccinated and unvaccinated population 58.
HPV vaccination is expected to reduce the lifetime risk of cervical cancer by 52% in vac-
cinated populations compared to unvaccinated populations, with uptake rates of about 
80% in girls and 76% in boys. With these preventive approaches, elimination of cervical 
cancer is within reach. In Australia, one of the first countries to introduce a national 
HPV vaccination programme, simultaneous use of both hrHPV-based screening and 
HPV vaccination is believed to lower the cervical cancer incidence below the threshold 
of four new cases per 100 000 women annually, within the next 20 years 59. Achieving 
this requires high vaccination coverage of both girls and boys with the 9vHPV vaccine, 
whether or not there is cervical screening every 5 years. The HPV Faster approach pro-
poses to extend the routine vaccination programmes to women of up to 30 years of age, 
paired with at least one HPV-screening test at the age of ≥30, aiming to accelerate the 
decline in cervical cancer incidence 60.
Prevention of anal cancer
HPV does not only infect the cervical epithelium, it infects other anogenital sites and the 
oro-pharyngeal mucosa61. Persisting infections in these anatomic sites can lead to precur-
sor lesions and/or cancer. HPV infections of the anal epithelium however, have received 
far less attention over the years due to both the social taboo on sexually-transmitted 
anal disease, and the much lower incidence and prevalence of anal cancer in the general 
population62. Anal cancer is more prevalent among high-risk subpopulations such as 
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1men who have sex with men (MSM) 
63, immunocompromised patients such as those 
living with HIV and women with a history of cervical, vulvar or vaginal hrHPV-related 
disease 64. The incidence of anal cancer dramatically increased among HIV positive MSM 
in the antiretroviral therapy (ART) era, although the exact relationship between ART and 
anal cancer remains uncertain 65. It is possible that earlier HIV control by ART results in 
lower cumulative risk, that is counterbalanced by longer survival and the increasing risk 
of anal cancer development with age. Anal cancer incidence is also increasing in the 
general population, and the disease is only now getting more attention in research.
similarities and differences between anal and cervical cancer
One of the most important similarities between cervical- and anal cancer, is that most 
hrHPV lesions are found at the morphologically similar transformation zones in both 
sites. This has led to most of the tools developed over decades to assess cervical lesions 
being directly extrapolated to the anus. Years of research on cervical cancer led to the 
development of widely implemented and very successful screening programs, aiming to 
detect women at risk of precursor lesions of cervical cancer through the identification of 
abnormal squamous cells or the presence of hrHPV in cervical smears. The problems of 
cervical cancer screening with cytology largely focus on the subjectivity of cytological 
interpretation of specimens and its poor sensitivity. Problems with the more ‘upstream’ 
hrHPV test are decreased specificity and the need for a triage test to focus the referral 
rate for colposcopic examination.
Figure 2. The anatomy of the cervix and its transformation zone and the anatomy of the anal canal with 
its transformation zone.
Anal cancer screening faces the same challenges but is in addition more complicated 
by the anatomical location of the anal mucosal transformation zone. The circular folded 
nature of the surface and the hypocellularity of the resulting anal cytological specimens 
form challenges for a proper diagnosis. Sensitivity for the detection of high-grade pre-
cursor lesions through cytological examination is low and repeat sampling is needed 66 
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67. Guidelines for anal cancer screening are available but are much more limited and are 
different from those for the cervix 68. Individuals at increased risk, like HIV positive MSM, 
are advised to annually undergo digital anal rectal examination (DARE), looking for hard 
lumps or masses, which can be further examined by high-resolution anoscopy (HRA) in a 
similar way to colposcopy with biopsy sampling of lesions suspected of high-grade anal 
intraepithelial neoplasia (HGAIN) dysplasia 69.
The anal canal appears to be very frequently infected with HPV, either through receptive 
anal intercourse or autoinoculation from cervical or vulvar infection, and might even 
function as a reservoir for HPV infection 70. Despite the high prevalence of anal HPV infec-
tion with a high frequency of multiple infections and multiple lesions of different grades 
of AIN, the incidence of anal cancer is relatively low compared with cervical cancer per 
HPV infection, while the same HPV types are involved in the development of cervical 
and anal cancer, with a major role for HPV 16 71. Several factors including influences of 
hormones such as estrogen, the large differences in the microbiome colonizing cervix 
and anal canal, differences in microanatomy or a difference in local immune response 
among others might partially explain this difference in risk of development of cancer 
after hrHPV infection 72.
Among HIV positive MSM, the incidence of anal cancer exceeds the cervical cancer 
incidence found among women before screening was introduced 73.
Treatment of anal precancer is more difficult than cervical precancer 74, 75. Since excision 
of the entire transformation zone as done in treatment of cervical HSIL is not possible, 
targeted ablation is the treatment of choice in anal precancerous lesions. The recurrence 
rate after ablation of anal HSIL is high and new HSIL in proximity of the earlier treated 
lesion are found frequently 76. Therefore it is uncertain whether screening for and treat-
ment of anal HSIL will reduce the incidence of cancer in the same way as screening for 
and treatment of cervical HSIL.
Histological classification of anogenital precursor lesions
Histopathology is important in distinguishing lesions that are likely to progress to cancer 
and require treatment, from self-limiting and regressing lesions. The large majority of 
lesions that are detected on either cervical or anal biopsy are productive lesions which 
produce and shed viral particles without signs of cellular transformation 77, 78. These le-
sions might show morphology which is hard to distinguish from transforming lesions, 
but have a high chance of spontaneous regression. Regression rates of CIN2 lesions have 
been reported in several studies and vary between younger women (<25 years) and 
17
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1older women from 30-50% to 70%, with lesions caused by HPV16 being less likely to regress 79.
Transforming lesions are characterized by viral oncogene E6 and E7 overexpression in 
dividing cells and may lead to cancer if not treated 2. Which hrHPV infections lead to 
productive infections that will never progress and which infections lead to progressive 
transforming lesions and warrant treatment is not clear. Hypotheses that have been 
formulated discuss the site of infection and the type of epithelial cells that are infected. 
In the cervix, cells at the squamo-columnar junction (SCJ), localized between ectocervi-
cal squamous epithelium and endocervical glandular epithelium, in the zone of active 
squamous metaplasia, are thought to be highly susceptible to transforming HPV infec-
tion while productive infections are thought to arise from squamous epithelium from 
the ectocervix 80 80. The exact nature of these cells remains uncertain.
Normal epithelium Anogenital intraepithelial lesion 
Squamous epithelium
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Infectious viral particles
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Invasive cancer
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Figure 3. The development of invasive anogenital cancer through intraepithelial neoplasia (-IN) grade 1, 
grade 2 and grade 3 on histology after HPV infectious particles enter the basal layer of the squamous epi-
thelium. Adapted from Woodman et al. 18
In both cervical and anal biopsies, dysplastic lesions are currently classified by agreed 
cytologic and histomorphological criteria based on observable microscopic cellular 
changes. The classification describes the stage of lesion development on the biological 
continuum through which an hrHPV infection develops into cancer according to the 
concept: hrHPV persistence, hrHPV-mediated epithelial transformation, development of 
precancerous lesions and finally invasive cancer 81 82. For histology, two schemes are 
used to describe severity of a precancerous lesion: intraepithelial neoplasia (-IN; anal 
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called AIN and cervical called CIN) grade 1-3 83, and squamous intraepithelial lesion (SIL), 
low-grade or high-grade. Lesions that have similar histologic features as -IN 1 are called 
low-grade SIL (LSIL), and lesions with similar histologic features as -IN2 and -IN3 are 
called high-grade SIL (HSIL). This broad grouping was done since histologic distinction 
between -IN2 and -IN3 is poorly reproducible and has led to all -IN2+ lesions are treated 
84, 85 86. However, neither of these schemes directly reflect cellular transformation and the 
schemes do not distinguish accurately between productive and transforming lesions. 
Thus, histology as a sole diagnostic method does not provide adequate information to 
categorize lesions according to biologic behaviour, and malignant potential. Therefore, 
molecular markers that would make diagnoses more accurate, reflect cellular transfor-
mation, and are more reproducible among pathologists would have a significant impact 
on management of women with CIN/SIL and men and women with AIN/SIL.
Ideally, these markers would in an early stage identify hrHPV infections that will persist 
and eventually cause a transforming lesion if not treated. Overexpression of HPV E6 
and E7, seen in transforming infections, leads to chromosomal instability and increased 
susceptibility to accumulation of alterations in cancer genes of the host cell increas-
ing cancer risk. However, no reliable antibodies are currently available for HPV E6 and 
E7 overexpression, or other specific markers that distinguish between cells that have 
undergone malignant transformation by hrHPV and cells in which HPV will not cause 
dysplasia.
Molecular markers with the ability to differentiate between productive and transforming 
lesions that have been identified so far, are either focussed around the detection of the 
associated genotype, viral genes involved in productive infection, the overexpression of 
viral oncogenes seen in transforming infection, or the identification of viral or cellular 
changes required for the progression of transforming infection to cancer.
19
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Figure 4. Human papillomavirus-mediated cervical carcinogenesis. After infection, viral persistence with 
overexpression of viral oncogenes E6 and E6 and viral transformation as a result can lead to the devel-
opment of productive and transforming precancerous lesions and invasive cervical cancer. Adapted from 
Steenbergen et al. 17
biomarkers for transforming HPV-infections: p16InK4a and Ki-67
p16INK4a (p16) is a cyclin-dependent kinase inhibitor and an integral component of 
normal cell cycle control. It inhibits phosphorylation of the cyclin D-dependent kinase 
4 and 6 complex, which hyperphosphorylates the pRB gene product, resulting in the 
inactivation of pRB and the release of bound E2F transcription factors. Increased free 
levels of E2F lead to activation of S-phase progression genes which pushes the cell 
into the S-phase of the cell cycle. Increased levels of p16 result in cell cycle arrest and 
induction of senescence which protects the cell against genomic damage as a result of 
oncogenic stress such as oncogene activation or aging of the cell. Enhanced expression 
of HPV E7 also leads to oncogenic stress and in addition inactivates the essential pRB-
mediated control functions of the cell cycle, leading to continued proliferative activity 
despite high levels of p16 expression 87. This makes p16 a highly valuable biomarker for 
clinical detection of high-grade precursor lesions, used as a surrogate marker for the 
overexpression of hrHPV E7 88-90.
p16 has become an important tool in diagnosing histological HSIL, as there is a strong 
correlation with diffuse strong p16 positive staining in the lower third of the epithelium 
or more with HSIL87, 91. Even though scoring p16 staining has an excellent interobserver 
reproducibility92, there is currently insufficient evidence to support or discourage its 
use as a standalone marker to prospectively determine high-grade versus low-grade 
disease. Its current place in diagnostic medicine was described in the the Lower Ano-
genital Squamous Terminology (LAST) recommendations, which recommends its use 
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when the H&E morphologic differential diagnosis is between precancer (–IN 2 or –IN 
3) and a mimic of precancer84. Strong and diffuse block-positive p16 results support a 
categorization of precancer (HSIL), but any identified p16 positive area must meet H&E 
morphologic criteria for a high-grade lesion to be reinterpreted as such. At the same 
time, recommendations against the use of p16 IHC as a routine adjunct to histologic 
assessment of biopsy specimens with morphologic interpretations of negative, -IN1, 
or -IN3 are made. The natural history of p16-positive –IN 1 and p16-negative –IN 3 are 
uncertain, and so the use of p16 to upgrade an unequivocal -IN1 or downgrade an 
unequivocal –IN 3 is not recommended. In addition, without interpretation of morphol-
ogy, p16 cannot differentiate between CIN2 and CIN3 and cannot separate transforming 
from productive infections, which leads to the lack of important information that holds 
implications for progression risk93. p16 is therefore an important marker in daily practice 
for diagnosing HSIL, but there is still a need for objective, reproducible markers that 
show distinguishing expression patterns between productive lesions with a higher 
chance of spontaneous regression and transforming lesions which might progress to 
cancer and should be treated.
biomarkers for productive HPV-infections: HPV e4
HPV E4 is an accessory protein which is highly expressed in productive HPV infections 
and marks the initiation of the late stage of the virus life cycle94. HPV infects the basal layer 
through a micro laceration and first maintains itself episomally at a low copy number. As 
epithelial cells differentiate, mature and migrate towards the surface of the epithelium, 
high-risk-HPV expresses E6 and E7 proteins that stimulate cell proliferation and ensure 
that cells in the superficial cell layers are retained in the cell cycle. Overexpression of E6 
and E7 stimulates the synthesis of cellular proteins that are necessary for S-phase entry, 
allowing the replication of viral episomes and initiation of the productive viral phase. 
In LSIL/-IN cases, overexpression of E6 and E7 is restricted to the lower layers of the 
epithelium, still allowing for a productive virus life cycle in the upper epithelial layers. 
In the superficial layers of the epithelium, the hrHPV infected cells elevate viral replica-
tion by an increase in late promotor activity and accessory proteins (E1, E2, E4), after 
which the infectious virions are assembled and shed. Late proteins (L1 and L2, but also 
E4 which is more abundant) of the virus can only be expressed in terminally differenti-
ated squamous epithelial cells which are capable of replicating the HPV-particles94, 95. 
Therefore, the detection of the late gene products E4 and L1 has been suggested as a 
marker for productive HPV-infections.
21
General introduction and thesis outline  
1
Figure 5. The high-risk human papillomavirus life cycle. After infection, different viral genes are expressed, 
leading to genome replication and transcription, control of cell growth and differentiation, reactivation of 
cell division, inhibition of apoptosis and epithelial differentiation, viral assemblage and release. Adapted 
from Doorbar et al. 95
When E6 and E7 overexpression is not restricted to the lower parts of the epithelium, 
but extends into the upper two thirds of the epithelium or even in the full thickness, 
as is seen in persisting HPV infections resulting in HSIL/-IN2+ lesions, this is associated 
with increased risk of transforming the phenotype of the cell which then no longer al-
lows for initiation of the productive phase of the HPV life cycle. p16 is a protein which 
is activated in cells overexpressing viral oncogenes E6 and E7 and is therefore useful as 
a marker of transforming infection when diffusely present 96. This marker is widely used 
in histology to identify transforming infections classified as HSIL/CIN2+ lesions which in 
current practice are eligible for treatment 84, 97. However, far from all HSIL/CIN2+ lesion 
will progress to cancer and by setting the treatment threshold at HSIL/CIN2, most likely 
many self-limiting productive infections are overtreated 98-100. With a set of complemen-
tary markers that can both identify the transforming aspect of the lesion (p16), but can 
also show viral production in the upper layers of the epithelium (HPV E4), persisting 
transforming infections with a chance of progression to cancer could be distinguished 
from productive HPV infections in which spontaneous regression is more likely.
biomarkers for transforming HPV-infections: methylation of cellular genes
Where E6 and E7 initially endorse replication of viral episomes and initiation of the 
productive viral phase in differentiated cells, long duration of their overexpression in 
dividing cells can lead to oncogenic events that drive the progression from transform-
ing precancer to cancer through human chromosome instability. This instability allows 
for accumulation of aberrations that can result in loss of function of human tumour 
suppressor genes or activation of human oncogenes17, 101. Human DNA methylation is 
among these aberrations and involves the addition of a methyl group (CH3) on specific 
cytosine nucleotides located 5’ of a guanine to generate a 5-methylcytosine 102. These 
so-called CG dyads are connected by a phosphodiester bond (p), forming a CpG site. 
Methylation of CpG sites often occurs in CpG islands which are regions with multiple 
Chapter 1
22
CpG’s allocated in the gene promoter. The DNA methyltransferases (DNMTs) responsible 
for CpG methylation can be activated by hrHPV E6 via p53 and directly by E7103, 104. The 
addition of multiple methyl groups on a given CpG island will make the DNA sequence 
less accessible for proteins or even entirely transcriptionally inert, leading to temporary 
or permanent changes in expression of genes and in addition, DNA instability.
Over the last years, many studies have focussed on DNA methylation of cellular genes as 
a molecular marker of cervical cancer and precancer. These mostly involved methylation 
of human tumour suppressor genes which were identified as markers of other human 
cancers. Hypermethylation patterns of these genes were studied in cervical cancer cell 
lines, cervical tissue samples and cervical scrapes. To date, over 100 human genes have 
been proposed as possible cervical cancer markers and the list is getting longer. Markers 
are often presented as a panel of multiple tumour suppressor genes. This clustering is 
done in the search for a highly sensitive and specific marker for disease detection, aim-
ing to identify all cervical cancer and all precancer that the screenings programs target 
for (CIN2+/HSIL). The use of methylation markers in anal disease is not yet as advanced 
as in cervical disease. Studies so far mostly have been exploratory, using a set of markers 
identified as of value in cervical disease, on anal tissue specimens 106, 107. First results 
show that a methylation marker panel, including ZNF582, can identify anal cancer and 






























TRENDS in Genetics 
Figure 6. DNA methylation in a normal cell and the changes in a cancer cell. CpG islands in the promo-
tor region of tumor suppressor genes unmethylated and expressed in normal cells (A) (green). In cancer 
cells (B), CpG islands are prone to DNA hypermethylation, which results in aberrant gene silencing of tumor 
suppressor genes. Adapted from Stirzaker et al. 105
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1The most frequently used technique to detect hypermethylation is through bisulphite conversion of DNA during which unmethylated cytosines only are conversed to uracil, followed by quantitative methylation-specific polymerase chain reaction (qMS-PCR). 
Hypermethylation of multiple genes can be detected in one test using a multiplex PCR, 
and such a test can be performed on tissue samples as well as liquid-based samples such 
as physician-taken cervical scrapes and self-collected cervicovaginal samples. Several 
marker combinations have been studied extensively in triage populations, mostly con-
sisting of hrHPV-positive women: JAM3/EPB41L3/TERT/C13ORF18, JAM3/C13ORF18/
ANKRD18CP109-112 and several CADM1, MAL and miR124-2 and FAM19A4 combina-
tions113-122. Asian studies more often focussed on SOX1 and PAX1 in several combina-
tions123, 124, and single markers among which POU4F3 have shown promising results in 
smaller studies but have not yet been confirmed by large prospective follow-up stud-
ies125, 126. To improve the performance of methylation marker panels, combinations with 
the detection of viral hypermethylation and hrHPV genotyping show potential. As an 
example, studies have explored the combination of hypermethylation of EPB41L3 and 
L1 and L2 regions of HPV16/18/31/33 127. And FAM19A4/miR124-2 in combination with 
HPV16/18 genotyping, showed a higher sensitivity of 84.7% and a decreased specificity 
of 54.9% for the detection of ≥CIN3 compared to methylation testing only 118.
A limitation of studies of methylation of cellular genes done so far is that hypermethyl-
ation levels and diagnostic performance of methylation of most of the identified genes 
vary between studies. This may not only have to do with storage and test characteristics 
but may also represent differences between populations and heterogeneity of cervical 
cancer and precancer development or other unknown factors. New techniques and 
platforms for discovery of new marker genes allow for agnostic profiling studies that 
specifically focus on cervical carcinogenesis. Genome-wide methylation profiling using 
next-generation sequencing of methyl-binding domain-enriched DNA studies are now 
being conducted to identify novel markers which can be used for screening or triage 
purposes128.
Another use of methylation markers may be found in the identification of precursor le-
sions with a higher risk of progression to cancer. Increasing levels of hypermethylation 
have not only been correlated to increasing grade of cervical intraepithelial neoplasia, 
but also to duration of hrHPV infection (>5 years) 129. Early productive viral infections 
with CIN1 or CIN2 lesions as a result have a low risk of progression and can be distin-
guished from more advanced transforming CIN (CIN2-3/HSIL) by methylation levels 130. 
Advanced transforming CIN has a higher chance of progression to cancer and detection 
of increased methylation of tumour suppressor genes could be used as an indication for 
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treatment while absence of hypermethylation could allow for close follow-up, prevent-
ing unnecessary treatment of women of reproductive age.
HPV genotype
The development of anal and cervical HSIL requires the persistence of a type-specific 
hrHPV infection over months and years. How this is defined and detected is important 
for determining the strength of association between hrHPV infection, its persistence and 
development of HSIL 131. However, hrHPV positive smears are often positive for multiple 
hrHPV genotypes when genotyped with a sensitive test 132, 133. In serial swabs, genotyp-
ing is important for the identification of genotype specific persistent infections. Deter-
mining the genotypes present in a single sample is also important for risk stratification 
as underlying lesion severity varies with the associated HPV type, with non-HPV16/18 
types accounting for a high percentage of ≤LSIL of which many will regress without 
interference 46, 134. In addition, knowing the role of each HPV genotype in cervical and 
anal cancer and precancer development can help select types to be included in vaccines 
and in genotyping assays for triage.
Detection of the causative HPV genotype of the lesion: laser capture 
microdissection
In the presence of multiple HPV infections, determining which genotype is the causative 
genotype of the worst underlying lesion can only be determined when genotyping the 
biopsy material, firstly genotyping the entire biopsy in a whole tissue section PCR (WTS-
PCR) and in case of multiple HPV infections on biopsy level, genotyping only the worst 
lesion present in a biopsy 135. The most precise approach to do this lies in laser capture 
microdissection PCR (LCM-PCR) 136, in which a microbeam UV laser micro-dissection sys-
tem is used to excise and transfer a selected region to a tube, after which it is genotyped 
using an analytically sensitive HPV genotyping assay (SPF10-PCR-DEIA-LiPA25version1) 
137. It is known that each HPV genotype involved in a multiple infection is associated with 
an independent CIN or AIN lesion 135, 138, and knowing the causative HPV genotype of 
the worst lesion is important for risk stratification, as different genotypes entail different 
risks of cancer development 139. In both cervical and anal cancer, HPV 16 is the most 
important oncogenic HPV genotype and is found in 60% of cervical and over 90% of 
anal cancer 140.
With the increasing use of HPV genotyping as a triage test on smears and self-samples 
after a screening-positive result, it is meaningful to study if the HPV genotypes present 
on screening samples are representative of the HPV genotype causing the worst under-
lying, high-grade lesion. In addition, HSIL lesions in HIV positive MSM can be caused by 
not only hrHPV but also lrHPV infections, and clinically benign appearing warts can har-
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141. In the search for improved tests for the selection 
of patients and distinguishing biomarker expression patterns of transforming HPV infec-
tions with a higher risk of progression to cancer, identification of the causative genotype 
of the lesion could play an important role. The pattern of genotypes will change when 
HPV vaccinated women and men are screened.
aIms anD OuTlIne Of THIs THesIs
Identification of molecular differences that can distinguish between productive lesions 
which might regress spontaneously and advanced transforming lesions with a higher 
risk of progression to cancer could help identify those patients that require treatment 
and differentiate those patients in which close follow-up would be more appropriate. 
This would help to avoid overtreatment which is costly, unpleasant and has its own risks. 
This thesis aimed to identify biomarker expression patterns corresponding with different 
grades of cervical and anal precursor lesions in cytological and histological specimens, 
proposing an important tool for diagnosis and clinical management of patients at risk 
of cervical and anal cancer.
This thesis consists of three parts. The first part consists of Chapters 2, 3 and 4 and 
focusses on cervical cancer screening and triage. Chapter 2 compares the sensitivity 
of hrHPV and genotyping in self-collected urine samples in the morning and later on 
during the day, brush-based self-samples, and clinician-taken smears for the detection 
of CIN2+ in a cytology-screened colposcopic referral population. Chapter 3 investigates 
hrHPV detection with genotyping and methylation of FAM19A4/miR124-2 for detection 
of CIN3+ in women from a similar population. Chapter 4 describes the study of whether 
HPV genotypes detected on self-samples represent the hrHPV type causing the worst 
cervical lesion, and whether any differences in hypermethylation of FAM19A4/miR124-2 
exist between CIN lesions caused by different hrHPV types.
The second part of this thesis describes how the use of immunohistochemical markers 
can be used to identify differences in biomarker expression patterns between different 
grades of anal intraepithelial neoplasia. Chapter 5 studied the immunohistochemical 
staining patterns in AIN, adding a novel marker for initiation of the productive phase of 
the HPV life cycle (HPV E4) to those for cell cycle activity (Ki-67) and transforming activity 
of HPVE7 gene (p16). In Chapter 6, we focused on immunohistochemical markers HPV E4 
and p16, using them on a set of anal biopsies aiming to improve the definition of HGAIN 
and show differences between lesions graded as AIN2 and AIN3.
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The final part of this thesis describes the use of combinations of different molecular 
markers in a study of cytology-screened women, involving both cytology and histol-
ogy samples. In Chapter 7, immunohistochemical staining patterns of markers HPV E4 
and p16 in cervical biopsies are correlated to results of methylation markers FAM19A4/
miR124-2 on smears. We aimed to describe biomarker expression patterns of women 
with different grades of CIN and negative controls, combining the results of immunohis-
tochemistry and methylation. In the general discussion described in Chapter 8, findings 
from all chapters are discussed and future perspectives are outlined.
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HPV testing in fi rst-void urine provides 
sensitivity for CIN2+ detection comparable with 
a smear taken by a clinician or a brush-based 
self-sample: cross-sectional data from a triage 
population




Objectives: To compare sensitivity of high-risk HPV (hrHPV) and genotype detection in 
self-collected morning (U1) and later (U2) urine samples, brush-based self-samples (SS) 
and physician-taken smears (PTS) for detecting CIN2+ in a colposcopic referral popula-
tion.
Design: Cross-sectional single centre study.
Setting: A colposcopy clinic in Spain.
Population: 113 women referred for colposcopy after an abnormal Pap-smear.
Methods: Women undergoing colposcopy with biopsy for abnormal Pap-smears were 
sent a device (Colli-Pee™, Novosanis, Wijnegem, Belgium) to collect U1 on the morn-
ing of colposcopy. U2, PTS and SS (Evalyn brush™, Rovers Medical Devices B.V., Oss, 
The Netherlands). All samples were tested for HPV DNA using the analytically sensitive 
SPF10-DEIA-LiPA25 version1 assay and the clinically validated GP5+/6+-EIA-LMNX.
Main outcome measures: Histologically confirmed CIN2+ and hrHPV positivity for 14 
high-risk HPV types.
Results: Samples from 91 patients were analysed. All CIN3 (N=6) were hrHPV positive in 
PTS, SS, U1 and U2 with both HPV assays. Sensitivity for CIN2+ with the SPF10 system 
was 100%, 100%, 95% and 100% respectively. With the GP5+/6+ assay, sensitivity was 
95% in all sample types. The sensitivities and specificities for both tests on each of the 
sample types were not significantly different. There was 10-14% discordance on hrHPV 
genotype.
Conclusions: CIN2+ detection using HPV testing in first-void urine shows sensitivity 
similar to that of physician-taken smears or brush-based self-samples and is convenient. 
There was substantial to almost excellent agreement between all samples on genotype 
with both hrHPV assays. There was no advantage in testing morning first-void urine over 
later samples.
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Cervical cancer is the fourth leading cause of cancer death in women worldwide. Its 
incidence and mortality has decreased in countries with organized cytology screen-
ing. 1,2 However, the sensitivity of a single smear for high-grade cervical intraepithelial 
neoplasia (CIN 2+) varies and requires a visit to a physician, leading to frequent repeats 
of Pap-smears over a life-time. 3 Testing for high-risk human papillomavirus (hrHPV) in 
physician taken smears (PTS) is more sensitive than cytology for CIN2+ and CIN3+ and 
results from randomized controlled trials have led to foreseeable implementation of 
the hrHPV test in several screening programmes. 4-7 Yet, its requirement for visits to a 
primary care centre may still be a barrier for participation.
Participation is the main impediment of a programme’s effectiveness, since even in 
countries with well-organized screening programmes, half of all potentially detectable 
carcinomas are found in women who have not attended screening programmes. 2 Self-
sampling has been proposed to increase participation as non-responders are more likely 
to hand in a self-collected sample of cervico-vaginal cells (SS) than to respond to recall 
for a Pap smear. 8 Testing SS for hrHPV was found to be well accepted among these 
women and comparable in performance to a PTS 9, 10, 11.
A novel, alternative method of self-sampling is collecting urine. The main advantage 
of this method over SS is that the procedure is non-invasive. A recent study showed 
that first-void urine contained higher concentrations of human and HPV DNA than 
midstream urine. This fraction contains most cervico-vaginal cells, because it is the first 
to pass the external genitalia, taking mucus adherent to the surface. 12 Whether the first 
fraction of urine of the first void of the day, after the mucus has remained unmoved 
during the night (U1), contains a higher concentration of DNA than that of later during 
the day (U2) remains to be determined.
The objective of this study was to determine the sensitivity and specificity of hrHPV-test-
ing in first-void urine for the detection of CIN2+ in women with an abnormal Pap-smear. 
In addition, we compared HPV detection results of morning first-void urine (U1) with 
either urine voided later that day (U2), physician taken sample (PTS) or cervico-vaginal 





Women included in the study were part of a prospective cohort of women included in 
a multicenter study of triage and colposcopic management of women with abnormal 
smears conducted between August 2010 and September 2015 (EVAH study 13). The EVAH 
study aims to evaluate colposcopic visual appearance of cervical lesions in relation to 
underlying histology, HPV genotype(s) and molecular parameters, and to study cervical 
HPV at the tissue level. Women included were aged 18 years and older and had been 
referred for colposcopy to the Hospital Clínic, Barcelona, Spain because of abnormal 
cervical cytology.
For the present study, a total of 113 women between 18-60 years of age were recruited 
from the EVAH study. Specimens were collected between September 2014 and March 
2015 in Hospital Clínic, Barcelona, Spain. The medical ethical board of the Hospital Clínic 
approved this study. All women gave signed informed consent.
sample collection
For urine sample collection a device that allows the collection of first-void urine (Colli-
Pee™, Novosanis, Wijnegem, Belgium) was sent to participating women. This device was 
delivered to home, accompanied by an information letter and instructions on use. Col-
lection tubes contained 4mL of a buffered lithium dodecyl sulfate solution containing 
RNA preservative. Women were asked to collect a urine sample of the very first void on 
the morning of their visit (U1), and to take the sample to the outpatient clinic. The day 
before their visit women received a telephone call to clarify ambiguities and answer 
questions.
At the outpatient clinic, women were asked to hand in another first-void urine sample 
(U2) using the same device and a brush-based self-sample of cervico-vaginal cells with 
the Evalyn brush™ (Rovers Medical Devices B.V., Oss, The Netherlands).
Women then underwent a pelvic examination with a PTS using a Cervex-Brush (Rovers 
Medical Devices B.V., Oss, The Netherlands). Women also underwent colposcopy-direct-
ed biopsy after application of acetic acid 5% to elicit the acetowhite epithelial response. 
Colposcopy findings were described following the criteria of the IFCPC. 14 Up to four 
colposcopy directed biopsies (CDB) were collected from different lesions or different 
regions presenting different colposcopy patterns within one lesion. Distinct areas within 
a large complex lesion were biopsied separately. When the transformation zone (TZ) was 
not visible, an endocervical curettage (ECC) was collected. If fewer than four directed 
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biopsies were taken, a biopsy was taken from normal appearing epithelium of the SCJ 
(non-directed biopsy).
Questionnaires
To investigate the acceptability of the Colli-Pee and the Evalyn Brush, all women were 
asked to fill out a short questionnaire (Appendix S1) using a 5-point ordinal scale on 
their general experience, the instructions, and the convenience of both. Participants 
were also asked for their preferred sampling method.
urine processing
Samples of 16 mL urine were stored in 4 mL of an in-house RNA preserving medium 
containing a buffered lithium dodecyl sulfate solution at -80 degrees Celsius within 
48 hours of collection for up to three months before shipping to the Netherlands on 
dry ice. Molecular testing was performed at DDL Diagnostic Laboratory, Rijswijk, The 
Netherlands. For DNA isolation from the urine samples, 1000 µL was used to obtain 50 
µL of eluate with the MagNa Pure 96 instrument.
ss processing
Brush-based self-samples were stored dry at room temperature for up to 3 months. 
For shipment to DDL Diagnostic Laboratory, brushes were placed in a vial containing 
1 ml of Thinprep. Vials were vortexed twice for 15 seconds, stored at room temperature 
for 30 minutes and then vortexed again, twice for 15 seconds. Vials were shipped to 
DDL Diagnostic Laboratory, where 250 µl was used for DNA isolation using NucliSENS 
easyMAG to obtain 100 µl DNA.
PTs processing
Cervical samples were transferred to PreservCyt solution (Hologic Corp, Marlborough, 
MA, USA) for ThinPrep liquid-based cytology and hrHPV testing.
Liquid-based cytology’s were aliquoted (2mL) and stored at room temperature until 
shipment to DDL Diagnostic Laboratory for molecular testing. Thin-layer cytology slides 
were prepared using the Thinprep T2000 slide processor (Hologic), stained using the 
Papanicolaou method, evaluated by a cytotechnologist and confirmed by a pathologist 
using the revised Bethesda nomenclature. 15 At DDL Diagnostic Laboratory, 250 µl of 





All biopsy specimens were collected in separate vials and fixed in 10% formalin before 
processing and embedding in paraffin wax. Hematoxylin-eosin (H&E) sections were 
examined by a local pathologist and classified as normal, CIN1, CIN2, CIN3, or invasive 
carcinoma. In this study, the overall histological diagnosis per case was based on the 
worst diagnosis found in any specimen from each woman. All biopsies were indepen-
dently reviewed by a second central gynaecological pathologist. In case of disagree-
ment between the original and review diagnosis, a third central pathologist reviewed 
the discordant cases independently. Diagnosis was determined by the agreement of 
two of three interpretations. In the case of three different diagnoses, the two central 
pathologists came to a consensus after joint review of the discordant case.
HPV Dna testing
SPF10 PCR-DEIA-LiPA25 version 1
HPV SPF10-LiPA25 version 1 (Labo Bio-medical Products, Rijswijk, the Netherlands, 
based on licensed Innogenetics technology) uses a short-PCR-fragment assay to per-
form broad-spectrum HPV DNA amplification. With this assay a 65-bp fragment of the 
L1 open reading frame of HPV genotypes is amplified, allowing us to detect at least 
69 anogenital HPV genotypes using 9 conservative probes in a microtiter hybridization 
assay (DNAenzyme immunoassay: DEIA). 16 Line probe assay (LiPA25) was then used to 
analyse the samples found positive for HPV by DEIA by reverse hybridization with type-
specific probes for 25 hrHPV and low-risk types: HPV 6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 
42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68/73, 70, and 74. 17
GP5+/6+-LMNX
The GP5+/6+ primer-mediated PCR assay (Labo Bio-medical Products, Rijswijk, Nether-
lands) detects DNA from 14 hrHPV genotypes: HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 
58, 59, 66, and 68. From each DNA isolate, 10 µL was used for DNA amplification with the 
biotin-labelled GP5+/6+ primer set. 18 Genotyping of the amplimers was done using the 
LMNX kit HPV GP HR test using xMAP technology for high-throughput screening (Labo 
Bio-medical Products, Rijswijk, Netherlands). 19, 20
RNase P
The adequacy of amplifiable human DNA in the urine samples was assessed using a 
qPCR of the reference human gene RNase P. 21 The PCR mix contained a plasmid spiked 
at a fixed concentration that functioned as an internal control to detect PCR-inhibition. 
All samples were positive for RNase P and no PCR inhibition was observed.
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Comparison of sampling methods and HPV tests
All samples were tested with the same algorithms. In order to evaluate the concordance 
of the HPV testing results of all four (PTS, SS, U1, U2) samples, positivity for 14 hrHPV gen-
otypes detected with the SPF10 algorithm were compared with the 14 hrHPV types (16, 
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) detected with the GP5+/6+ algorithm 
and considered important for the detection of CIN2+ lesions. For comparison of hrHPV 
positivity, results were concordant, when both samples were either hrHPV positive, or 
hrHPV negative, or discordant, when one of the sample types was hrHPV positive and 
the other was not. For comparison of detected genotypes, results were then classified as 
identical, compatible (at least one type found in both samples) or discordant.
statistical analysis
Results were analysed using IBM SPSS version 22.0 for Windows (Chicago, IL). The level of 
statistical significance was set at p≤0.05 for all tests. The level of agreement was deter-
mined using Cohen’s kappa statistics. For comparison of positivity rates the two-tailed 
McNemar’s test was used.
The κ value with a 95% confidence interval (CI) was calculated as a measure of agree-
ment between the HPV genotypes observed in the different sampling methods. HPV 
agreement was defined as slight (κ ≤0.20), weak (κ = 0.21- 0.40), moderate (κ = 0.41 
-0.60), strong (κ = 0.61-0.80), near perfect (κ 0.81-0.99), and perfect (κ = 1.000) 22. The 
efficacy of hrHPV testing for CIN2+ detection of PTS, SS, U1 and U2 was evaluated as 
sensitivity, specificity and positive (PPV) and negative predictive value (NPV).
ResulTs
study Cohort
From 91 out of 113 women, a complete set of PTS, SS, U1 and U2 samples were available 
for analysis. Twelve women were excluded because at least one of the samples had not 
been collected. All samples were positive for RNase P and suitable for analysis. The hu-
man DNA concentrations of the morning first-void urine sample and the first-void urine 
sample from later during the day were compared. The average human DNA concentra-
tion in U1 was 15 ng/µl and 21 ng/µl in U2 (p=0.225, 95% CI (-16.61;3.93)).
All patients completed the questionnaire and had a cytological diagnosis: 28 (30.8%) 
were classified as negative, 11 (12.1%) as ASC-US, 9 (9.9%) as ASC-H, 28 (30.8%) as LSIL 
and 15 (16.5%) as HSIL. The worst histological diagnosis was negative in 50 women 




Comparison of hrHPV tests
Without consideration of genotype, 68 women tested hrHPV positive on the PTS, 66 
women tested positive on the SS, 67 on U1 and 70 on U2 with the SPF10-assay. With 
the GP5+/6+-assay, 62 women tested positive on the PTS, 59 on the SS, 60 on U1 and 
60 on U2. The comparison of hrHPV detection between SPF10 and GP5+/6+ for PTS, SS, 
U1 and U2 is shown in Table 1. Good agreement for all sample types was found, with 
kappa values between 0.74-0.82. The SPF10 test showed more HPV positivity than the 
GP5+/6+, which was expected given the difference sensitivity. Nonetheless, the agree-
ment between both hrHPV assays was strong to near perfect for all sample types.
Furthermore, all samples were compared for concordance of positivity for the 14 hrHPV 
genotypes detected by the SPF10 and GP5+/6+ systems (Table 2) between sample types 
(PTS vs U1, U2 or SS, SS ys U1 or U2, U2 vs U1) . With the SPF10 system the agreement 
between all sample types was near perfect with kappa values between 0.81-0.92. With the 
GP5+/6+ system, strong to near perfect agreement was found, with kappa values 0.73-0.85.
Table 1. Agreement between the analytically sensitive SPF10 test and the clinically validated GP5+/6+ test 
on the detection of 14 hrHPV genotypes, for clinician-taken smear (CTS), self-sample (SS), morning first-
void urine (U1), and first void-urine from later during the day (U2)








j (95% CI) P
CTS 61 6 1 23 0.81 (0.76–0.88) 0.125
SS 59 7 0 25 0.82 (0.76–0.89) 0.016
U1 59 8 1 23 0.77 (0.70–0.84) 0.039
U2 60 10 0 21 0.74 (0.66–0.81) 0.002
n = 91.
Table 2. Agreement on hrHPV positivity, not considering genotyping, in clinician-taken smear (CTS), self-














j (95% CI) P
CTS versus U1 85 6 0.83 (0.70–0.96) 1 81 10 0.75 (0.61–0.90) 0.754
CTS versus U2 86 5 0.85 (0.73–0.98) 0.375 82 9 0.78 (0.64–0.92) 1
CTS versus SS 88 3 0.92 (0.822–1.01) 1 84 7 0.80 (0.68–0.93) 0.727
SS versus U1 84 7 0.81 (0.67–0.94) 1 78 13 0.68 (0.53–0.84) 1
SS versus U2 85 6 0.83 (0.69–0.96) 0.219 80 11 0.73 (0.59–0.88) 1
U1 versus U2 88 3 0.91 (0.81–1.01) 0.25 85 6 0.85 (0.740–0.97) 1
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hrHPV Genotype Concordance between specimen types
Comparisons between different sample types for detection of 14 individual hrHPV geno-
types by SPF10 and GP5+/6+ were made. There was near perfect agreement on genotype 
between U1 and U2 with both the SPF10 system (kappa value=0.90) and the GP5+/6+ 
system (kappa-value=0.85). The comparison of the GP5+/6+ results of SS and PTS for any 
genotype shows near perfect agreement (kappa-value=0.81). All other comparisons for 
genotype between sample types result in strong agreements (kappa-values 0.74-0.77).
We compared sample types at genotype level with the SPF10 assay and with the GP5+/6+ 
assay. With both tests, most samples show identical genotyping results. Most discordant 
results rely on one of the two samples being hrHPV negative, with the other sample 
being hrHPV positive rather than both samples showing different hrHPV genotypes.
Detection of CIN lesions
All women have been biopsied. In this group of 91 women, CIN3 was detected in 6 (6.6%) 
women and CIN2 was detected in 13 (14.2%) women. All CIN 3 lesions were found hrHPV 
positive by SPF10 and GP5+/6+ in PTS, SS, U1 and U2 (Table 3). All four types of sample 
show a high sensitivity for the detection of CIN2+ lesions with both SPF10 and GP5+/6+ 
(Table 4), without any significant differences. The specificities for CIN2+ detection in PTS, 
SS, U1 and U2 when using SPF10 or GP5+/6+ were not significantly different.
Table 3. Overall positivity for 14 hrHPV genotypes by SPF10 and GP5+/6+ assay in clinician-taken smear 
(CTS), self-sample (SS), morning first-void urine (U1), and first-void urine from later during the day (U2)
Histological diagnosis CTS SS U1 U2
SPF10 GP5+/6+ SPF10 GP5+/6+ SPF10 GP5+/6+ SPF10 GP5+/6+
Negative (n = 50) 58.0% 52.0% 56.0% 50.0% 60.0% 46.0% 64.0% 50.0%
CIN1 (n = 22) 86.4% 81.8% 86.4% 72.7% 86.4% 86.4% 86.4% 77.3%
CIN2 (n = 13) 100.0% 92.3% 100.0% 92.3% 92.3% 92.3% 100.0% 92.3%
CIN3 (n = 6) 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Total (n = 91) n = 67 n = 62 n = 66 n = 59 n = 67 n = 60 n = 70 n = 60
Table 4. Sensitivity and specificity of hrHPV testing for CIN2+ detection in clinician-taken smear (CTS), 
self-sample (SS), morning first-void urine (U1), and first-void urine from later during the day (U2), tested 
with SPF10 and GP5+/6+
Sample SPF10 GP5+/6+
Sensitivity Specificity Sensitivity Specificity
% 95% CI % 95% CI % 95% CI % 95% CI
CTS 100 83–100 33 24–45 95 75–99 39 28–50
SS 100 83–100 35 25–46 95 75–99 43 32–55
U1 95 75–99 32 22–43 95 75–99 42 31–53




Overall rating of the PTS, SS and urine sampling by all 91 women resulted in an average 
score of 7.6 out of 10 for the PTS, 8.1 for the SS and 8.6 for the urine sampling (p<0.005). 
A total of 82 (90.1%) women rated the convenience of the SS compared to a PTS as good 
to excellent and 81 (89.0%) women rated the urine sampling good to excellent when 
compared to a PTS. Two women rated the convenience of the SS compared to the PTS as 
poor. No other sampling issues were scored poor.
DIsCussIOn
main findings
Physician-taken smears, brush-based self-sampling, morning first-void urine and first-
void urine from later during the day all showed similar high sensitivity for the detection 
of CIN2+ in this referral population, measured with two different hrHPV tests (the highly 
sensitive SPF10 LiPA 25 version 1 assay and the clinically validated GP5+/6+ assay). None 
of the samples or assays missed CIN3.
For SPF10 the sensitivity for CIN2+ detection in PTS, SS and U2 was all 100%, with a near 
perfect agreement between the four different types of samples (Kappa=NC-1.00). With 
the GP5+/6+ assay, the sensitivity was 95% for all sample types, with a strong agreement 
between all samples (kappa=NC-1.00).
strengths and limitations
The main strength of this study is that we used paired urine samples, vaginal samples 
and cervical samples that were all collected and stored at the same time and under the 
same circumstances. The collection of first-void urine was standardized using a device 
that was developed to collect only the first fraction of urine. Samples were all stored 
in a preservative and stored at -80°C shortly after collection, optimizing storage condi-
tions. Additionally, both a cytological and histological sample were taken, providing a 
histological endpoint for all women.
A limitation of our study is that it was conducted in a small population of women referred 
to one colposcopy clinic after an abnormal Pap-smear. In this selected population, the 
(hr)HPV positivity rate and CIN2+ rate are high (73.6% and 20.8%, resp.) and these results 
cannot be directly extrapolated to a screening population. The confidence intervals 
around both sensitivity and specificity are quite wide and a larger study of a screening 
population is needed.
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Several studies focused on the role of self-sampling in screening have been published. 
Bosgraaf et al. 23 showed that the Evalyn-brush is also suitable for screening purposes and 
Burroni et al. 24 found that urine is suitable for HPV detection and has high concordance 
with HPV detected in physician-taken smears. No histological diagnoses were available 
for that study. A study by Stanczuk et al. found the detection of CIN3+ was >90% when 
testing urine samples with the for cervical smears clinically validated Cobas 4800 assay. 
25 There is need for a study focusing on the detection of CIN2+ and CIN3+ lesions in a 
screening population, including those who do not attend for a PTS, that should include 
validated clinical hrHPV testing and sensitive HPV detection systems such as SPF10 to 
assess the utility of urine sampling in cervical cancer prevention through screening.
Our results match with results previously found by Stanczuk et al. 25 and are higher than 
sensitivities previously found in other studies comparing HPV detection in SS to PTS. 26, 
27 The specificity with the GP5+/6+ was higher than with the SPF10 assay (42% and 32% 
in U1 and 42% and 29% in U2, respectively), but no significant differences were found 
between the different types of samples. On genotype level a strong to near perfect 
agreement was found between all samples, for both SPF10 and GP5+6+ with discordant 
results not showing any particular pattern with regard to type of sample.
COnClusIOn
In this study, first-void urine samples appeared suitable for CIN2+ detection through 
HPV testing with a test with a high analytical sensitivity and a test with a high clinical 
sensitivity, validated for physician taken samples. Analyses performed on genotype 
concordance imply that the HPV found in urine is representative of the HPV in the cervix, 
with the high concordance between the two urine samples demonstrating reproduc-
ibility of results. When comparing morning first-void urine to first-void urine from later 
in the day, 5.5% of the patients showed discordant results with SPF10. All five patients 
had a HPV negative U1 and HPV positive U2, with histological diagnoses negative in 
four patients and CIN2 in one. With the GP5+/6+, 8.8% of the patients had discordant 
HPV results in U1 and U2, with U2 being the only sample positive in half of the cases. 
Our results suggest that there is no advantage in testing morning first-void urine over a 
portion of first-void urine that was collected at a later time during the day. The fraction 
of the urine appears to be more important than the timing, which is in line with results 
from a recent study by Senkomago et al., comparing different fractions and collecting 
times. 28 A similar amount of human DNA was collected in both samples but the propor-
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tion of cells originating from the urinary tract or the genital tract and cervix remains to 
be determined.
Both the SS and the urine sampling were rated as excellent overall by most of the 
women. Instructions were clear and the devices were easy to use. A great advantage of 
both samples is that they can be sent by mail for collecting samples at home.
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Reliable identifi cation of women with CIN3+ 
using hrHPV genotyping and methylation 
markers in a cytology-screened referral 
population




Cervical screening aims to identify women with high-grade squamous intraepithelial le-
sion/cervical intraepithelial neoplasia 2-3 (HSIL/CIN2-3) or invasive cervical cancer (ICC). 
Identification of women with severe premalignant lesions or ICC (CIN3+) could ensure 
their rapid treatment and prevent overtreatment. We investigated high-risk human pap-
illomavirus (hrHPV) detection with genotyping and methylation of FAM19A4/miR124-2 
for detection of CIN3+ in 538 women attending colposcopy for abnormal cytology. All 
women had an additional cytology with hrHPV testing (GP5+/6+-PCR-EIA+), genotyp-
ing (HPV16/18, HPV16/18/31/45), and methylation analysis (FAM19A4/miR124-2) and 
at least one biopsy. CIN3+ detection was studied overall and in women <30 (n=171) 
and ≥30 years (n=367). Positivity for both rather than just one methylation markers 
increased in CIN3, and all ICC was positive for both. Overall sensitivity and specificity for 
CIN3+ were respectively 90.3% (95%CI 81.3-95.2) and 31.8% (95%CI 27.7-36.1) for hrHPV, 
77.8% (95%CI 66.9-85.8) and 69.3% (95%CI 65.0-73.3) for methylation biomarkers, and 
93.1% (95%CI 84.8-97.0) and 49.4% (95%CI 44.8-53.9) for combined HPV16/18 and/or 
methylation positivity. For CIN3, hrHPV was found in 90.9% (95%CI 81.6-95.8), methyla-
tion positivity in 75.8% (95%CI 64.2-84.5) and HPV16/18 and/or methylation positivity in 
92.4% (95%CI 83.5-96.7). In women aged ≥30, the sensitivity of combined HPV16/18 and 
methylation was increased (98.2%, 95%CI 90.6-99.7) with a specificity of 46.3% (95%CI 
40.8-51.9). Combination of HPV16/18 and methylation analysis was very sensitive and 
offered improved specificity for CIN3+, opening the possibility of rapid treatment for 
these women and follow-up for women with potentially regressive, less advanced, HSIL/
CIN2 lesions.
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The mortality rate from invasive cervical cancer (ICC) has decreased significantly in de-
veloped countries through the introduction of organized cervical screening programs, 
mostly based on conventional cytology 1, 2. Women with abnormal cytology or with 
a positive result in the testing for high-risk human papillomavirus (hrHPV), are either 
referred directly, or after triage, for colposcopy and biopsy to identify high-grade squa-
mous intraepithelial lesion/cervical intraepithelial neoplasia grade 2 or 3 (HSIL/CIN2-3) 
or ICC 3. A biopsy diagnosis of HSIL/CIN2-3 is the current threshold for excision of a 
precancerous lesion 4 .
However, most HSIL/CIN2-3 will not progress to ICC if not treated 5, 6. HSIL/CIN2-3 le-
sions are heterogeneous, especially those graded as CIN2, and include both productive 
hrHPV infections as well as early and advanced transforming hrHPV lesions. Productive 
infections and early transforming infections may regress spontaneously and immediate 
surgical removal may incur harm and increase the risk of adverse outcome for any future 
pregnancy 7. Preventing such unwanted outcomes would be valuable. In contrast, ad-
vanced transforming lesions with a high short-term risk of progression should be treated 
without delay. A triage strategy able to provide accurate risk stratification, identifying 
the different subgroups of women with HSIL/CIN2-3, could reduce harm, especially in 
young women of reproductive age.
A number of different molecular markers are currently being investigated to optimize 
risk stratification for patients with hrHPV infection and cervical lesions. These include 
hrHPV genotyping, expression of viral genes, and methylation of viral genes or human 
tumor suppressor genes 8. A high proportion of ICC and a large number of HSIL are as-
sociated with HPV16/18, even in the presence of multiple HPV infections, and HPV16 
is also associated with larger HSIL/CIN3 lesions in younger women 9-11. Several human 
tumor suppressor genes have shown hypermethylation of the CpG islands in the pro-
motor regions, which are of value in identifying women with ICC and advanced HSIL/
CIN3 defined as long duration of preceding hrHPV infection 12. Hypermethylation of the 
genes FAM19A4 and miR124-2 have shown promising results as single triage markers 
or in combination with other tumour suppressor genes in physician-taken samples in 
detecting HSIL/CIN3, particularly in women with HPV infections of long duration 13-15.
The EVAH study (Evaluating the Visual Appearance of Cervical Lesions in Relation its 
Histological Diagnosis, Human Papillomavirus Genotype and Other Viral Parameters) 16 
provides a basis for the evaluation of various tests that could be used for risk stratifica-
tion. It allows comparison of standard clinical and pathological information with new 
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molecular tests and colposcopy follow-up for up to two years and provides a framework 
for the long-term outcome of different triage tests.
The present study aimed to detect women with HSIL/CIN3 or ICC (CIN3+) in a cytology-
screened (atypical squamous cells of unknown significance or more severe lesions 
[≥ASC-US]) referral population by using referral cytological grade, hrHPV-testing and 
genotyping, and methylation testing of human tumor suppressor genes FAM19A4 and 
miR124-2 performed on physician-taken smears obtained at colposcopy. Sensitivities, 
specificities, positive and negative predictive values (PPV and NPV) of the different tri-
age tests for CIN3+ detection were calculated for women <30 and ≥30 years of age.
meTHODs
The EVAH study is a prospective multicenter observational cohort study 16 conducted in 
Voorburg, The Netherlands, and Barcelona, Spain. Inclusion criteria were: 1) an abnormal 
cytological test result (≥ASC-US), 2) 18 years of age or older. The criteria of exclusion 
were: 1) previous diagnosis of ICC, 2) history of surgery to the cervix or previous pelvic 
radiotherapy, 3) current pregnancy or pregnancy in the previous 3 months, 4) current 
breastfeeding or breastfeeding in the previous 3 months, and 5) insufficient material for 
hrHPV testing and methylation analysis.
From each subject, data were collected on ethnicity, relevant medical history, number of 
sexual partners and contraception, using a standardized questionnaire. Results from the 
first 601 inclusions from Barcelona were analyzed in the current study.
Colposcopy
Women included in the study were seen in the colposcopy clinic, where a physician-
taken smear was collected and digital colposcopy was performed. During colposcopy, 
at least one cervical biopsy was taken from each patient. Up to four directed biopsies 
were taken from suspected lesions. If less than four directed biopsies were taken, a 
random biopsy was also taken from normal appearing tissue. Colposcopy findings were 
described using the criteria of the International Federation for Cervical Pathology and 
Colposcopy (IFCPC) 17.
Physician-taken smear
A trained physician collected a cervical smear using a Cervex-Brush (Rovers Medical 
Devices B.V., Oss, The Netherlands). The Cervex-Brush was rinsed in 20mL of ThinPrep 
medium (Hologic, Marlborough, MA). Samples were stored at room temperature for up 
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to 6 months. An aliquot of 2mL was sent to DDL Diagnostic Laboratory, Rijswijk, the 
Netherlands for molecular testing. At arrival at DDL, the samples were stored at 4°C.
biopsy
Biopsies were fixed in 10% formalin, embedded in paraffin and sectioned for hematoxylin 
and eosin (H&E) and additional immunohistochemical staining at the local laboratory. 
p16 immunohistochemical staining was performed and slides were scored as negative, 
patchy staining, block staining restricted to lower 1/3, the lower 2/3, or extending above 
the lower 2/3 of the epithelium up to full thickness staining. Sections were reviewed 
independently by two expert gynecological pathologists and classified as either normal, 
CIN 1, CIN 2, CIN 3, adenocarcinoma in situ (AIS) or ICC. In case of discrepancies between 
the two pathologists, a third gynecological expert pathologist was consulted, resulting 
in a majority consensus diagnosis.
sample preparation and hrHPV detection
From the physician-taken smears, DNA was isolated for hrHPV testing. An input volume 
of 250 μL was used to obtain 100 μL of eluate with the QIAamp MinElute Virus Spin kit 
(QIAgen Inc., Valencia, CA). hrHPV detection was performed using the GP5+/6+-PCR-EIA 
(Labo Bio-medical Products, Rijswijk, Netherlands). The EIA-positive GP5+/6+ amplim-
ers were genotyped using a strip-based test by the Genotyping kit HPV GP (Labo Bio-
medical Products, Rijswijk, Netherlands) genotyping hrHPV types 16, 18, 31, 33, 35, 39, 
45, 51, 52, 56, 58, 59, 66 and 68.
methylation
The residual cervical sample was concentrated at Hospital Clínic and sent to DDL Diag-
nostic Laboratory for methylation testing.
DNA was isolated using the MagNA Pure 96 (500µL input, 50 µL eluate) for methylation 
testing. The level of amplifiable human DNA was assessed using a qPCR of the in-house 
reference gene RNaseP with the Phocine herpesvirus as an internal control for the ab-
sence of PCR-inhibition 18.
All samples with a DNA concentration of 5.5 ng/µL or higher were subjected to bisulfite 
conversion using the EZ DNA Methylation kit (Zymo Research, Orange, CA, USA). Up to 
250 ng/45µL of DNA was used. A standardized multiplex qMSP (QIAsure), targeting for 
the promotor regions of FAM19A4 and miR124-2 (QIAgen Inc., Valencia, CA, USA), was 
performed on the bisulfite converted DNA according to the manufacturer’s protocol. 
The bisulfite-converted human reference gene beta-actin (ACTB) was included in the 
multiplex to determine the total amount of converted human DNA. The samples were 
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scored hypermethylation positive when CT value of the housekeeping gene β-actin was 
≤26.4 and at least one of the marker genes (i.e. FAM19A4 and hsa-mir124-2) had a ΔΔCT 
below the cut-off according to the kit insert. Methylation positivity was then correlated 
to the histological diagnosis outcome.
statistical analysis
Results of cytology, hrHPV testing and methylation testing were studied for their perfor-
mance in the detection of CIN3+ lesions. For analysis cytological outcome was classified 
as ASC-US/LSIL (ASC-US and LSIL) or ASC-H/HSIL (HSIL, ASC-H and AGC). Interpretation of 
the hrHPV testing resulted in hrHPV positive or negative and interpretation of the geno-
typing resulted in HPV16/18/31/45 or no-HPV16/18/31/45 and HPV16/18 or no-HPV16/18. 
Smears that tested positive for FAM19A and/or miR124-2 according to the standardized 
criteria were considered as methylation positive, whereas methylation negative smears 
were defined as samples negative for both markers. After categorizing women using 
these test results, different combinations were made to compute sensitivity, specificity, 
positive predictive value (PPV) and negative predictive value (NPV) with corresponding 
95% confidence intervals. Diagnostic performance was calculated for the entire cohort 
and for women aged <30y or ≥30y. In addition, results are shown for all women with 
ASC-US/LSIL referral cytology and women with ASC-H/HSIL referral cytology.
Statistical analysis was performed using the SPSS software (Version 22.0, SPSS, Inc, Chi-
cago, IL, USA). The results are presented as absolute numbers and percentages or mean 
and standard deviation. χ2 tests, independent sample t-tests, and McNemar’s tests were 
used, as appropriate, for comparisons between categorical, between scale variables 
and for comparison of the performance of diagnostic tests. A p-value below 0.05 was 
considered statistically significant.
ResulTs
Characteristics of the EVAH study participants
Of the 601 selected women, 540 (89.8%) had a physician-taken smear with a DNA con-
centration ≥5.5 ng/µL and were suitable for methylation testing. Methylation testing 
resulted in 538 valid results (340, 63.2% negative; 198, 36.8% positive) that were used 
for further analysis. Two invalid results based on a negative result of the reference gene 
ACTB were excluded. The flowchart of the women included in the study with the cross-
sectional results of the referral smear, hrHPV testing and genotyping, and methylation 
testing are shown in Figure 1.
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Mean age of women at the time of the first visit to the colposcopy clinic was 36.2 years 
(95% CI 35.3-37.2; Range 18-75). Histological diagnoses of the cervical biopsies were 
normal squamous epithelium in 234 women (43.5%), CIN1 in 101 (18.8%), CIN2 in 131 
(24.3%), CIN3 in 66 (12.3%) and ICC (invasive cervical carcinoma) in 6 (1.1%).
hrHPV testing using the clinical test GP5+/6+-PCR-EIA, was positive in 383 women 
(71.2%), and the remaining 155 women (28.8%) were hrHPV negative. Of the hrHPV posi-
tive samples, 188 (49.1%) tested positive for HPV16/18 and 195 (50.9%) tested positive 
for non-HPV16/18 hrHPV genotypes.
Sensitivity and specificity of hrHPV testing and methylation for the detection of CIN3+ 
in women with abnormal cytology
Single triage markers
The performance of hrHPV detection, genotyping for HPV16/18 and HPV16/18/31/45 and 
methylation testing as single triage tests were explored for this population for the outcome 
of CIN3+ including CIN3 lesions and carcinomas (Table 1a) and for CIN3 only (Table 2a). hrHPV 
positivity with GP5+/6+-PCR-EIA was found in 65/72 women with CIN3+ and in 148/466 of 
the women with a ≤CIN2 lesion no hrHPV was found (sensitivity 90.3%, specificity 31.8%). 
HPV16/18/31/45 was detected in the physician-taken smear in 54/72 women with CIN3+ 
lesions and in 259/466 with ≤CIN2 lesions these types were not detected (sensitivity 75.0%, 
specificity 55.6%). HPV16/18 was present in 45/72 of women with CIN3+ lesions and 323/466 
women with ≤CIN2 lesions were HPV16/18 negative (sensitivity 62.5%, specificity 69.3%).
Methylation testing was positive in 56/72 of women CIN3+ lesions and 323/466 of wom-
en with ≤CIN2 lesions were methylation negative overall (sensitivity 77.8%, specificity 
69.3%). Methylation detected all ICC and 75.8% (50/66) of CIN3. There was a significant 
difference in mean age between women with a methylation positive CIN3+ lesion (41 
years) and women with methylation negative CIN3+ lesions (30 years, p<0.001). Among 
the women with ≤CIN2, methylation was positive in 24.4% of women with negative 
and CIN1 biopsies and in 44.3% of women with CIN2. Again, a significant difference in 
mean age between methylation positive (41 years) and methylation negative women 
(34 years) was found (p<0.001).
FAM19A4 and miR124-2 positivity in different grades of CIN were assessed separately 
in order to detect trends in positivity of the individual markers and the combination 
of the two biomarkers (Figure 2). FAM19A4 was the commonest individual positive 
marker. 50/85 (58.8%) biopsies without dysplastic lesions and CIN1 lesions that were 
methylation positive showed positivity for FAM19A4 only. Positivity for both FAM19A4 
and miR124-2 was seen in most CIN3 lesions and all ICC. We found that 19.7% (13/66) of 
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CIN3 lesions were detected by FAM19A4 only, while miR124-2 only showed positivity in 
five low-grade lesions and one CIN2 lesion but no CIN3+. Recalculation of sensitivity and 
specificity when assessing FAM19A4 only resulted in an identical sensitivity of 77.8% 


























Negative (234) CIN 1 (101) CIN 2 (131) CIN 3 (66) ICC (6)
Neither positive FAM19A4 only positive
miR124-2 only positive FAM19A4 and miR124-2 positive
Figure 2. FAM19A4 and miR124-2 positivity (%) in different grades of CIN in all women.
Combinations of triage markers
Table 1b shows the sensitivity, specificity, PPV and NPV of different combinations of 
hrHPV testing, hrHPV genotyping and methylation testing for the detection of CIN3+ 
in biopsies of women referred after abnormal cytology, and Table 2b shows this for the 
outcome of CIN3 only. Among the different combinations that were made, the combina-
tion of HPV16/18 and/or methylation positivity had the highest specificity (49.4%, 95% 
CI 44.8-53.9), while sensitivity was comparable to that of methylation testing combined 
with testing for all hrHPV or HPV16/18/31/45.
Since the combination of HPV16/18 and/or methylation positivity performed best 
among the combinations, with the highest specificity and comparable sensitivity, PPV, 
and NPV, this combination was used in further analyses. In these analyses, the combina-
tion of HPV16/18 and/or methylation was compared to the single triage markers with 
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Table 3. Comparison of sensitivity, specificity, positive predictive value (PPV) and negative predictive val-
ue (NPV) for the detection of CIN3+ of hrHPV testing and methylation, and combined HPV16/18 and meth-
ylation testing in women <30 and ≥30 years of age with ASC-US/LSIL cytology and ASC-H/HSIL cytology.
Triage test
Referral cytology ≥ASC-US







































hrHPV testing 93.8 71.7 – 98.9 26.5 20.1 – 33.9 11.6 7.2 – 18.3 97.6 87.7 – 99.6
Methylation 37.5 18.5 – 61.4 85.8 79.4 – 90.4 21.4 10.2 – 39.5 93.0 87.6 – 96.2
HPV16/18 and/or methylation 75.0 50.5 – 89.8 55.5 47.6 – 63.1 14.8 8.7 – 24.1 95.6 89.1 – 98.3
Triage test







































hrHPV testing 89.3 78.5 - 95.0 34.4 29.3 - 39.9 19.7 15.3 - 25.0 94.7 88.9 - 97.5
Methylation 89.3 78.5 - 95.0 61.1 55.6 - 66.3 30.4 24.0 - 37.7 98 94.9 - 99.2
HPV16/18 and/or methylation 98.2 90.6 – 99.7 46.3 40.8 – 51.9 24.8 19.6 – 30.9 99.3 96.2 – 99.9
Triage test
Referral cytology ASC-US/LSIL







































hrHPV testing 33.3 6.2 – 79.2 89.9 8.2 – 94.4 9.1 1.6 – 37.7 97.8 92.3 – 99.4
Methylation 100 43.9 - 100 32.3 23.9 – 42.1 4.3 1.5 – 11.9 100 89.3 - 100
HPV16/18 and/or methylation 66.7 20.8 – 93.9 64.7 54.8 – 73.4 5.4 1.5 – 17.7 98.5 91.8 – 99.7
Triage test







































hrHPV testing 66.7 20.8 – 93.9 41.2 34.1 – 48.7 2.0 0.5 – 6.9 98.6 92.4 – 99.8
Methylation 66.7 20.8 – 93.9 71.2 64.0 – 77.5 3.9 1.1 – 13.2 99.2 95.5 – 99.9
HPV16/18 and/or methylation 100 43.9 - 100 58.2 50.7 – 65.4 4.1 1.4 – 11.3 100 96.3 - 100
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Women <30 years of age
Performance of hrHPV testing and methylation for the detection of CIN3+ in women 
<30 and ≥30 years of age with ASC-US/LSIL and ASC-H/HSIL cytology Table 3 shows the 
sensitivity, specificity, PPV and NPV for the detection of CIN3+ by hrHPV testing, hrHPV 
genotyping and methylation in women <30 and ≥30 years of age with ASC-US/LSIL and 
ASCH/HSIL referral cytology.
Women <30 years of age
The group of women <30 years of age consisted of 171 women of whom 16 had a HSIL/
CIN3 lesion and none had ICC. Age ranged from 18-29 with a mean of 25.4 years. In this 
group, HPV16/18 was found in 68.8% of the women with CIN3+. Sensitivity of hrHPV 
testing (93.8%, 95% CI 71.7-98.9) was significantly higher than that of methylation test-
ing (37.5%, 95% CI 18.5-61.4) (p=0.004), whereas the specificity of methylation analysis 
(85.8%, 95% CI 79.4-90.4) was significantly higher than that of hrHPV testing (26.5%, 
95% CI 20.1-33.9) (p<0.001). The performance of the combination of HPV16/18 and/or 
methylation positivity provided the optimal balance between sensitivity (75.0%, 95%CI 
50.5-89.8) compared to methylation analysis (p=0.031) and specificity (55.5%, 95% CI 
47.6-63.1) compared to hrhHPV testing (p<0.001).
Only 3/16 CIN3+ lesions were found among women with ASC-US/LSIL referral cytology 
and therefore 95% confidence intervals in this group are wide making the performance 
Triage test
Referral cytology ASC-H/HSIL







































hrHPV testing 76.9 49.7 – 91.8 39.3 27.6 – 52.4 22.7 12.8 – 37.0 88.0 70.0 – 95.8
Methylation 38.5 17.7 – 64.5 78.6 66.2 – 87.3 29.4 13.3 – 53.1 84.6 72.5 – 92.0
HPV16/18 and/or methylation 92.3 66.7 – 98.6 16.1 8.7 – 27.8 20.3 12.0 – 32.3 90.0 59.6 – 98.2
Triage test







































hrHPV testing 90.6 79.8 – 95.9 26.2 19.7 – 34.1 31.6 24.7 – 39.5 88.1 75.0 – 94.8
Methylation 90.6 79.8 – 95.9 48.9 40.8 – 57.1 40.0 31.7 – 48.9 93.2 85.1 – 97.1
HPV16/18 and/or methylation 98.1 90.1 – 99.7 31.9 24.8 – 40.0 35.1 27.9 – 43.1 97.8 88.7 – 99.6
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of all markers as a triage test for CIN3+ detection comparable. However, the specificity 
of HPV16/18 and/or methylation (64.75, 95% CI 54.8-73.4) was significantly higher than 
that of methylation analysis (32.3%, 95% CI 23.9-42.1) (p<0.001). Most CIN3+ lesions 
were found in women with ASC-H/HSIL referral cytology (13/16 CIN3+ lesions). In this 
group, the sensitivity of HPV16/18 and/or methylation (92.3%, 95% CI 66.7-98.6) was 
higher than that of methylation analysis (38.5%, 95% CI 17.7-64.5) (p=0.061), but the 
specificity of methylation analysis (87.6%, 95%CI 66.2-87.3) was significantly higher than 
that of HPV16/18 and/or methylation (16.1%, 95% CI 8.8-27.8) (p<0.001) and hrHPV test-
ing (39.3%, 95% CI 27.6-52.4) (p<0.001).
Women ≥30 years of age
The group of women ≥30y (mean 41.3y, range 30-75) consisted of 367 women, 56 of 
whom had CIN3+ (50 CIN3, 6 ICC). HPV16/18 was detected in the smear of 60.7% of the 
women with CIN3+. Sensitivity of hrHPV testing and methylation analysis in this popula-
tion were the same (89.3%, 95% CI 78.5-95.0), but the specificity of methylation analysis 
(61.1%, 95% CI 55.6-66.3) was significantly higher than that of hrHPV testing (34.4%, 95% 
CI 29.3-39.9) (p<0.001). The combination of HPV16/18 and/or methylation positivity, 
resulted in an increase in sensitivity to 98.2% (p=0.063) and specificity of 46.3% which 
was improved compared to hrHPV testing (p<0.001).
In this group, 3/56 CIN3+ lesions were found in women with ASC-US/LSIL cytology lead-
ing to overlapping 95% confidence intervals of the performance of all three markers. 
The only woman with ASC-US cytology and a CIN3 lesion was among these women, 
with a smear which was hrHPV negative and methylation positive. 53/56 CIN3+ lesions 
were found in women with ASC-H/HSIL. All three tests performed equally well regarding 
sensitivity, PPV and NPV, but the specificity of methylation analysis (48.9%, 40.8-57.1) 
was significantly higher than that of HPV16/18 and/or methylation (31.9%, 95% CI 24.8-
40.0) (p<0.001) and hrHPV testing (26.2%, 95% CI 19.7-34.1) (p<0.001).
DIsCussIOn
This study explored different triage tests and combinations for CIN3+ detection in a 
population of women referred to colposcopy because of abnormal cytology, including 
women younger and older than 30 years. Many studies have investigated repeated 
cytology, reflex hrHPV testing and genotyping for HPV16/18 as triage tests in patients 
referred to colposcopy clinic 19, 20. The present study examined, in addition, the value of a 
test for methylation of two specific tumor suppressor genes (FAM19A4 and miR124-2). It 
compared the results with those of hrHPV triage, and evaluated the potential combina-
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tions of hrHPV testing, including genotyping, with methylation analysis. A combination 
of HPV16/18 genotyping and/or methylation positivity performed well, with a high 
sensitivity (93.1%) and moderate specificity (49.4%) for ≥CIN3. This combination per-
formed particularly well in women ≥30 years of age (sensitivity 98.2%, specificity 46.3%). 
In women with ≤LSIL, the combination offered an adequate balance between sensitivity 
(83.3%) and specificity (60.6%). The results indicate that the combination of the two bio-
markers (HPV16/18 genotyping and/or methylation positivity) could separate women 
into risk groups more accurately than either HPV genotyping or methylation analysis 
alone.
The diagnostic performance of the combined testing is based on the importance of 
HPV16/18 in ICC and in HSIL/CIN3 21, 22, and the presence of methylation in advanced 
precancers and ICC. Methylation testing with markers FAM19A4 and miR124-2 on 
physician-taken smears had a sensitivity for ASC-H/HSIL/CIN3 detection of 77.8% and 
a specificity of 69.3% for the overall population. Interestingly, the sensitivity and speci-
ficity of the methylation analysis in women 30 years of age and over were particularly 
high (89.3% and 61.1%, respectively). This is in line with findings by Luttmer et al., who 
found an association between age and the performance of FAM19A4 as a triage test in 
hrHPV-screened women, making it an attractive marker for women ≥30 years 23. Positiv-
ity for miR124-2 and/or FAM19A4 detected all ICC, and 75.8% of HSIL/CIN3 lesions in the 
overall population, suggesting that the combination of these biomarkers identifies the 
most severe precancerous lesions.
The accurate identification of women who have histological HSIL/CIN3, within the sub-
set of women with abnormal smears prior to colposcopy and biopsy, is potentially very 
important in avoiding over-investigation and overtreatment. Even among women with 
cytological HSIL, many will not have HSIL/CIN3 or ICC. In this study, only 25% of these 
women had histological ASC-H/HSIL/CIN3. hrHPV testing has shown high sensitivity for 
HSIL/CIN3 detection 24-27 and in many Western countries, hrHPV testing already has a 
place in screening, either as a stand-alone screening test or in combination with cytol-
ogy, or in triage. However, using the clinically validated GP5+/6+-PCR-EIA for triage of 
women with ≥ASC-US on screening, hrHPV positivity showed high sensitivity (90.3%) 
but the lowest specificity (31.8%). This results in potential overtreatment of a large 
number of women who are not at high short-term risk of cancer, and who may have 
regressing lesions.
The results obtained in this study are in keeping with previous evidence showing that 
older age and longer duration of hrHPV infection are associated with methylation 
positive HSIL/CIN3+ 14, 28, 29. These findings suggest that further investigation of whether 
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the current practice of treating all histologically confirmed ASC-H/HSIL/CIN2 by LLETZ 
could be modified to provide more selective individual management of women with 
screen-detected cervical abnormalities. Current thresholds for referral to colposcopy 
and treatment are based on the risk of HSIL/CIN2+ 30. This leads to unnecessary referral 
and overtreatment of women with lesions that have a low short-term risk of progres-
sion and a definite probability of regression 31. Our methylation results demonstrate 
heterogeneity in HSIL/CIN2 and HSIL/CIN3. It is important to investigate in prospective 
studies whether combined methylation and HPV16/18 testing could be used in practice 
to distinguish methylation positive women, who need urgent further investigation and 
treatment, from women who are methylation-negative but positive for HPV16/18 and 
could be followed at appropriate intervals for regression to avoid unnecessary treat-
ment.
This study has a number of limitations. The study was relatively small and only one 
woman with ASC-US and five women with LSIL cytology had HSIL/CIN3+. Also, patients 
were not selected for treatment on the basis of the results of the methylation biomark-
ers. When the methylation biomarkers were studied individually, FAM19A4 was positive 
in all methylation-positive HSIL/CIN3+ lesions, but only miR124-2 was positive in five 
women with negative and LSIL/CIN1 biopsies. In the studied population, the additive 
value of miR124-2 in the detection of CIN3+ and squamous cell carcinoma seems 
limited. Its benefit seems more evident in avoiding unnecessary biopsies (i.e. increase 
negative predictive value) when FAM19A4 is positive and miR124-2 is negative. Further 
investigation of the use of these methylation markers individually requires large-scale 
clinical trials conducted under careful supervision.
This was a cytology-screened referral population including women who were screened 
opportunistically without prior screening. Therefore, the the prior probability of cyto-
logical and histological abnormalities might have been higher 32 and results from this 
study cannot be directly extrapolated to screening by hrHPV testing alone or co-testing 
with cytology. The consistency, however, with other studies of primary HPV screening 
suggest that the principles identified here could be applied to different screening strate-
gies 33-35. Colposcopy was used to identify possible lesions. To address the limitations to 
the accuracy of colposcopy and taking of biopsies 36, 37, multiple biopsies were taken, 
endocervical curettage, and a random biopsy in every woman who had less than four 
lesion directed biopsies to improve detection of lesions.
This study shows the potential for early accurate identification of HSIL/CIN3+ by testing 
for hrHPV and methylation of human tumor suppressor genes in routine liquid-based 
cervical cytological samples. It suggests that HSIL/CIN3 is a heterogeneous group, con-
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sisting of methylation positive lesions and methylation negative lesions. We hypothesize 
that methylation positive HSIL/CIN3 lesions are advanced transforming lesions and are 
mostly detected in women ≥30 years of age with a persisting hrHPV infection 28. The 
methylation negative HSIL/CIN3 lesions may be found in younger women caused by 
HPV infections of a shorter duration or infections that follow a different pathway 29, 38. 
Further, larger, follow-up studies in different screened populations are needed to inves-
tigate whether a combination of HPV16/18 typing and methylation testing is feasible for 
stratifying clinical management.
To evaluate further the heterogeneity of high-grade precancer lesions, more markers 
should be evaluated. Such potential markers include methylation of more human genes, 
methylation of HPV DNA, study of miRNAs, study of somatic and germline SNPs and 
use of immunohistochemical marker patterns such as p16INK4a and HPV E4 to distinguish 
transforming and productive elements in CIN lesions. The development and clinical 
evaluation of these markers in prospective studies opens up the possibility of early and 
reliable identification of women who need rapid treatment of HSIL/CIN3 at high risk of 
progression to ICC or have ICC and avoid unnecessary treatment of potentially regress-
ing HSIL/CIN2.
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Objective: HPV16/18 genotyping and detection of hypermethylation of human cell 
genes involved in cervical oncogenesis have shown promising results in triage of high-
risk HPV (hrHPV)-screen positive women on cervical smears. These tests can be per-
formed on self-samples, which contain cervical and vaginal cells. We studied whether 
a self-sample represents the hrHPV type causing the worst cervical lesion and whether 
any differences in hypermethylation of FAM19A4/miR124-2 exist between CIN lesions 
caused by different hrHPV types. These results have important implications for reflex 
triage of self-samples.
Methods: Correlation between genotype found on self-sample using GP5+/6+-PCR-
EIA-LMNX and causative hrHPV genotype in the worst lesion on histology was studied 
using laser capture microdissection (LCM)-SPF10-PCR (N=152). Hypermethylation of 
FAM19A4/miR124-2 in the self-sample was tested in a quantitative methylation specific 
PCR and compared between lesions caused by HPV16/18 and other hrHPV genotypes.
Results: Causative hrHPV genotype of the worst lesion (CIN1, CIN2, CIN3, invasive cervi-
cal cancer) was detected on self-sample in 93.4%. HPV16 was the most frequently found 
genotype on self-sampling (39.2%, 73/186) and causative genotype in CIN3+ (51.4%, 
38/74, all detected on self-sample). There were no differences in the percentages of 
positive FAM19A4/miR124-2 methylation assays between lesions caused by HPV16/18 
(73.8% in CIN3+) or other hrHPV genotypes (66.7% in CIN3+) (p=0.538).
Conclusions: Our results show that hrHPV genotypes found on self-sample were a good 
representation of hrHPV in the worst CIN lesion and that methylation testing on self-
sample for detection of CIN3+ was not significantly different between lesions caused by 
HPV16/18 and other hrHPV genotypes.
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The introduction of population-based screening programs has significantly reduced 
the incidence of and mortality from cervical cancer in western countries 1, 2. Over the 
past decades screening programs were based on cytology, however, high-risk human 
papillomavirus (hrHPV)-based screening is gaining ground in cervical cancer screening 
programs. Advantages of hrHPV testing are its high sensitivity for detection of cervical 
intraepithelial neoplasia (CIN)2+ and CIN3+, compared to cytology, and the possibility 
of performing the test not only on smears taken by a physician, but also on self-collected 
samples 3. The introduction of self-sampling into the screening program can extend the 
reach of the program, as women who do not respond to the initial invitation are more 
likely to hand in a self-sample than to respond to a re-invitation for a physician-taken 
smear 4, 5. This is important, since 50% of women diagnosed with invasive cervical carci-
nomas are non-responders 6. A disadvantage of hrHPV screening is its lower specificity, 
compared with cytology screening, which results in unnecessary colposcopy referrals 
for women with a transient HPV infection who are not in need of treatment. Therefore, a 
sensitive and specific test is needed for triage of hrHPV positive women 7, 8.
Among the various triage strategies that have been evaluated, HPV genotyping and 
DNA methylation testing can be carried out on self-samples 7. The risk of development 
of cancer and precancer differs substantially between HPV genotypes, and in ranking 
order HPV16 and HPV18 are most carcinogenic, causing 70% of cervical squamous cell 
carcinomas 9-11. Therefore, triage of hrHPV positive women by hrHPV genotyping identi-
fies a population of women with HPV 16/18 at the highest risk of cervical cancer 9.
Another triage strategy that can be performed on self-collected material and is non-
inferior to cytology triage is hypermethylation testing of host cell genes involved in cer-
vical carcinogenesis 12. Hypermethylation levels of FAM19A4 and miR124-2 have been 
found to be very high in nearly all cervical carcinomas and to increase with severity of 
the CIN lesion 13, showing positivity in over 70% of CIN3+ lesions. Because CIN2/3 lesions 
associated with a duration of the preceding HPV infection of >5 year have increased 
methylation levels and have many more chromosomal aberrations compared to CIN2/3 
lesions with a shorter duration of their associated HPV infection (<5 years) it has been 
argued that CIN2/3 lesions with a cancer-like methylation pattern are “advanced” CIN 
lesions in need of treatment 14, 15. How methylation levels are correlated to genotype 
specific HPV infections has not been explored.
Several studies have shown good agreement between physician-taken smears and 
self-samples for the presence of hrHPV and specific HPV genotypes 16. When a single 
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HPV genotype is present on a smear or self-sample, this is designated as the “causative” 
HPV type of the worst lesion present on biopsy. However, women can be infected with 
multiple hrHPV types and whether the causative type present in the worst lesion on 
biopsy is detected by the physician-taken smear or self-sample has only received limited 
attention. It is often assumed that the HPV genotype known to be associated with the 
highest risk of cervical cancer found on smear is responsible for the most severe lesion 
on biopsy. While van der Marel et al. found that in women with a CIN2/3 lesion who are 
positive for HPV16 on a physician-taken smear HPV16 is found in 96% of the CIN2/3 
lesions 17, it is not known whether agreement between genotype on a self-sample, 
containing admixed many vaginal cells, and in the worst CIN lesion is similarly high.
For the present study, we selected all women with a hrHPV positive self-sample from the 
PROHTECT-3b trial of self-sampling in non-responders and correlated the causative HPV 
genotype found in the worst lesion on biopsy using LCM to the HPV genotypes found in 
the self-sample. In addition, we explored hypermethylation of FAM19A4 and miR124-2 
in the self-sample between lesions caused by different HPV genotypes.
meTHODs
PROHTeCT-3b study
For the present study, a post-hoc analysis was performed on 456 women who partici-
pated in the PROHTECT-3B study and tested hrHPV positive on the initial self-sample. This 
selection was representative of the self-samples in the study. PROHTECT-3B is a device-
comparative study that invited a large number of non-responders in the screening pro-
gram to return a cervicovaginal self-sample for hrHPV testing 18. The study was performed 
between October 2011 and February 2012. Both brush-based self-samples (Evalyn Brush, 
Rovers Medical Devices, Oss, The Netherlands) and lavage self-samples (Delphi Screener, 
Delphi Bioscience, Scherpenzeel, The Netherlands) were used in the study. Women who 
tested negative for hrHPV using the GP5+/6+-PCR-EIA test 19 on the self-sample returned 
to the screening program. Women who tested positive for hrHPV on the self-sample were 
invited for a physician-taken smear on which cytological examination was performed. 
Women with a cytology result of atypical squamous cells of undetermined significance or 
worse (≥ASC-US) either at baseline or after 6 months in case of a normal smear at baseline 
were referred for colposcopic examination with biopsies of the colposcopically worst 
region or 2 random biopsies in case of a normal colposcopic impression. HrHPV positive 
women with a negative cytology result were invited for a reflex physician-taken smear 
after 6 months, which was tested for cytological abnormalities and hrHPV positivity using 
GP5+/6+-PCR-EIA. If either of these tests was positive, a colposcopy with directed biopsies 
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as described above followed. Histology results were H&E based supported by p16 immu-
nohistochemistry and were retrieved from the hospital systems and the nationwide his-
topathology and cytopathology registration network (PALGA, Utrecht, The Netherlands).
laboratory testing
hrHPV testing of self-samples
After receiving a self-sampling kit with either a brush device or a lavage device, women 
collected and returned the cervicovaginal self-sample to the designated laboratory, 
for processing in Thinprep. Specimens were tested for hrHPV using the clinically vali-
dated GP5+/6+-PCR-EIA 19. Participants were notified of the result and followed-up as 
described in the study protocol. For the present study, an aliquot of 1 ml of the Thinprep 
buffered self-sample was sent to DDL Diagnostic Laboratory, Rijswijk, The Netherlands, 
for additional hrHPV genotyping using GP5+/6+-PCR with genotyping (HPV16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) using the LMNX kit HPV GP HR test (Labo 
Bio-medical Products, Rijswijk, the Netherlands) 20, 21. Samples were tested for DNA con-
centration and inhibition using a qPCR quantifying the human reference gene RNaseP 
and a Phocine Herpesvirus as an internal control.
Histology processing, HPV testing of whole tissue sections (WTS) and worst lesions 
selected for laser-capture microdissection (LCM)
Formalin fixed paraffin embedded (FFPE) tissue blocks were retrieved from the differ-
ent hospitals and were sent to the Radboud university medical center, Nijmegen, The 
Netherlands, where they were processed according to the sandwich method. Slides for 
H&E staining were obtained, followed by a membrane slide for laser-capture microdis-
section, two tubes for HPV-PCR testing, one slide for p16 staining and three additional 
slides for any immunohistochemical staining, and finally one H&E after slide to confirm 
that the lesion of interest is present in all tested material 18.
H&E and p16 stained slides were reviewed by an expert gynaeco-pathologist and the 
worst lesion present on the slide was noted. This diagnosis was compared to the original 
local diagnosis, resulting in a consensus diagnosis when both diagnoses were the same. 
In case of a discrepancy, a third pathologist was consulted to reach a majority diagnosis.
DNA was isolated from the whole tissue sections (WTS) with the proteinase K procedure 
22. DNA was tested for HPV using the analytically sensitive SPF10-PCR-DEIA-LiPA version 
1 system (LBP, Rijswijk, The Netherlands) which contains probes for 25 different HPV 
genotypes [HPV genotypes 6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 
54, 56, 58, 59,66, 68/73, 70, and 74] 23. SPF10-PCR targets a small region on the L1 gene, 
allowing accurate HPV detection in fragmented DNA.
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WTS that showed positivity for multiple HPV genotypes were selected for LCM. Worst 
lesions were annotated based on the H&E and p16 slide. In case of multiple regions with 
the same histological grade, multiple regions were selected for LCM. Slides were scanned 
using digital microscopy (Pannoramic Flash II 250, 3DHistech, Budapest, Hungary). Se-
lected regions were excised with the Zeiss P.A.L.M. microbeam UV laser micro-dissection 
system and transferred to an AdhesiveCap500 opaque tube (Carl Zeiss B.V., Sliedrecht, 
The Netherlands). DNA isolation and genotyping of LCM regions was performed in the 
same way as for the WTS.
The HPV genotype present as a single infection in the WTS or the HPV genotype that 
was found in the worst lesion selected for LCM was considered the causative genotype.
Methylation testing
Methylation testing on self-samples was previously conducted as part of another study 
and the testing protocol is described elsewhere 24. Testing results describing positiv-
ity for either FAM19A4 and/or miR124-2 were retrieved from the dataset. Methylation 
results were correlated to causative HPV genotype and to the presence of the causative 
genotype on self-sample.
selection of patients
A flow-chart describing the selection and inclusion of women is shown in Figure 1.
Self-samples and the corresponding biopsies containing the worst lesions of women 
who tested hrHPV positive on the initial self-sample were selected for this study. A total 
of 125 women did not have a biopsy taken as they had normal cytology during the 
first and normal cytology and hrHPV negativity during the second visit to the physician. 
These women were considered to have no precursor lesions. Biopsies were sought for 
the remaining 331 women. Biopsies from 40 women were not available for testing, and 
96 women had a histological endpoint of normal cervical squamous cell epithelium. 
Both these groups of women were excluded from the study.
selection based on self-sample suitability
Self-samples of 195 remaining women were included in further analyses and consisted 
of 106 samples that were collected using the Delphi-Screener lavage device and 89 us-
ing the brush-based device Evalyn-Brush. Two self-samples could not be tested because 
there was less than 250µl of sample present upon arrival at DDL Diagnostic Laboratory 
and these samples were excluded. No hrHPV genotypes were found in 7 samples of which 
one also tested negative for the internal LMNX control implying that no human DNA was 
amplified. All remaining 186 samples tested positive for human DNA in the RNaseP qPCR.
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456 women included in 
PROHTECT-3B
Excluded (261):
 No histological endpoint because no 
suspected lesion: 125
 Biopsy not suitable for analysis: 40
 Worst lesion  Normal : 96
195 women with 
histological endpoint 
 CIN1
Excluded based on self-sample result (9):
 Self-sample not suitable 
        for analysis: 2
 Self-sample hrHPV negative: 7
186 women with histological 
endpoint  CIN1 and hrHPV+ self-
sample:
 129 single infections in SS
 57 multiple infections in SS
Exclusion of single infections WTS (24):
 Worst lesion HPV negative: 18
 Worst lesion unknown HPV genotype: 2
 Worst lesion lrHPV: 4
162 women with self-samples hrHPV+ 
and worst lesion HPV+:
 115 single infections in WTS
 47 multiple infections in WTS
Exclusion of multiple infections WTS (10):
 No suitable membrane slide: 4
 Worst lesion HPV negative: 4
 Worst lesion lrHPV: 2
152 women with self-samples hrHPV+ 
and worst lesion ( CIN1) hrHPV+:
 108 single infections in SS
 44 multiple infections in SS
Excluded based on methylation result (13):
 Methylation testing self-sample not 
performed: 13
139 women with self-samples hrHPV+ and 







Figure 1. Flow-chart describing the selection of women for analyses, with reason for exclusion on study, 
self-sample, WTS, LCM and methylation level shown on the right.
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selection based on biopsy material suitability
Whole tissue sections of the study group of 186 women who had one or multiple geno-
types detected on the self-sample were tested, but 18/186 WTS tested were HPV nega-
tive on SPF10-PCR-DEIA, 2 WTS were HPV positive on DEIA but could not be genotyped 
by SPF10 LiPA25 and 4 were positive for low-risk HPV genotypes only. In the remaining 
162 WTS, 115/162 (71.0%) showed a single infection and 47/162 (29.0%) showed mul-
tiple infections.
Of the 47 WTS that were positive for multiple genotypes, no suitable membrane slide 
was available for 4 biopsies and LCM could not be performed. A causative hrHPV geno-
type was found in 37/43 biopsies; 4 worst lesions (all CIN1) were HPV negative and 2 
were positive for lrHPV (HPV43 in CIN1 and HPV53 in CIN2).
Exclusion of these materials resulted in a group of 152 women with a hrHPV positive 
self-sample and a worst lesion (≥CIN1) which was also hrHPV positive.
Statistical analyses
Statistical analyses were performed using IBM SPSS Statistics version 22.0 (Chicago, IL, 
USA) and R (Open Source). Results of comparisons are presented as percentages, with 
95% confidence-intervals. P-values were calculated using the Chi-squared test and the 
level of significance was set at <0.05.
ResulTs
152 included women had a mean age of 39 (range 33-63) and were mainly from areas 
with more than 100,000 inhabitants (69.7% compared to 30.3% from areas with less than 
100,000 habitants). No other demographics were available.
self-samples
Figure 2 describes the relation between genotyping results of self-sample and biopsy 
material from the 152 women with a hrHPV+ self-sample and a worst lesion (≥CIN1) 
which was also caused by hrHPV. There were 108 women with a single hrHPV infection 
on self-sample and 44 with a multiple infection on self-sample. Most single infections on 
self-sample were HPV16 infection (42/108, 38.9%), followed by HPV31 (15/108, 13.9%). 
Most multiple infections were HPV16 infections in combination with another hrHPV 
genotype (20/44, 45.5%), followed by a combination containing HPV18 (12/44, 27.3%).
85




samples hrHPV+ and 
worst lesion ( CIN1) 
hrHPV+:
152
Single infections on 
self-sample: 
108 (71.1%) 









Causative type detected on 
self-sample: 
87/95 (91.6%)
Lesions caused by HPV type 
not detected on self-
sample: 
CIN1: 31, 51, 52, 66












Causative type detected on 
self-sample: 
18/20 (90.0%)
Lesions caused by HPV type 









Causative type detected on 
self-sample: 
142/152 (93.4%)
  LCM   LCM
Figure 2. Flow chart describing the genotyping results of self-sample and biopsy material (single or mul-
tiple infection) in 152 women with a hrHPV positive self-sample and a ≥CIN1 lesion on biopsy caused by 
hrHPV.
genotyping of wTs and lCm regions
Because some patients had multiple regions that were marked as the worst grade of 
lesion and which were caused by diff erent hrHPV genotypes, a total of 157 lesions from 
152 biopsies were included: 32 CIN1 lesions, 51 CIN2 lesions, 66 CIN3 lesions and 8 
carcinomas.
The causative hrHPV genotype was defi ned as the hrHPV genotype detected in the 
worst lesion as a single infection on WTS or LCM level. Figure 3 shows an example of a 
biopsy with multiple HPV genotypes found in WTS in which the causative genotype of 
the worst lesion was detected using LCM-PCR.
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Figure 3. H&E slide (A), p16INK4A (B) slide and Haematoxylin slide (C) for LCM analysis of a multiple infec-
tion with hrHPV 33, 51, and 56 on self-sample, 33 and 51 on the whole tissue section, with worst diagnosis 
CIN3. Three regions of CIN3 were selected for laser capture microdissection to identify the causative geno-
type of CIN3. HPV33 was found in all three regions and was marked as the causative genotype of the worst 
lesion present.
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The causative genotypes that were found in diff erent grades of CIN and carcinomas 
are shown in Table 1. Overall, the most frequently found genotype was HPV16 (55/157, 
35.0%) and this was also the most frequently found genotype in CIN3 (n=35) and carci-
noma (n=5). HPV18 was the causative type of 11 lesions including 5 CIN3 lesions and 2 
carcinomas. 45/74 (60.8%) CIN3+ lesions were caused by HPV16/18 and 29/74 (39.2%) 
were caused by other hrHPV genotypes.
Figure 4. Probability of diff erent hrHPV genotypes in self-sample being present in the worst lesion (≥CIN1).
Performance of self-sample for detection of the causative type of the worst lesion
Of the 152 patients of whom one or multiple causative genotypes for the worst lesion 
present on biopsy was found, the causative genotype was compared to the genotypes 
detected on self-sample.
The self-sample of 108/152 women included in this analysis contained a single HPV 
infection. This was also the causative genotype of the worst lesion in 100/108 (92.6%) 
women. Multiple infections on self-sample were found in 44/152 included women and 




Table 1. Distribution of causative genotypes in different grades of CIN. Genotypes found in multiple in-
fections on LCM were counted separately and multiple lesions per sample were found, resulting in 157 
causative genotypes in 152 studied biopsies.
Diagnosis
Causative HPV genotypes found in WTS or by LCM
HPV16 HPV18 HPV31 HPV33 HPV35 HPV39 HPV45 HPV51 HPV52 HPV56 HPV58 HPV59 HPV66
CIN1 5 1 4 2 0 2 2 6 4 3 1 0 2
CIN2 12 3 9 9 2 1 3 2 6 0 3 1 0
CIN3 35 5 8 7 1 0 3 1 5 0 1 0 0
Carcinoma 3 2 0 2 0 0 1 0 0 0 0 0 0
At least one of the causative genotypes was detected in 142/152 (93.4%) self-samples. 
Ten self-samples contained an HPV genotype different from the causative genotype: 
four patients with worst lesions CIN1, four with CIN2 and two with CIN3. The causative 
type was found on self-sample in 27/31 (87.1%, 95% CI 71.2-94.9) CIN1 lesions; 47/51 
(92.2%, 95% CI 81.5-96.9) CIN2 lesions; 60/62 (96.8%, 95% CI 90.0-99.1) CIN3 lesions and 
in all 8/8 (100%, 95% CI 67.6-100) carcinomas.
The probability of different hrHPV genotypes detected on self-sample being present in 
the worst lesion (≥CIN1) is shown in Figure 4. In self-samples in which HPV16 was found 
as a single or in a multiple infection from women with ≥CIN1, HPV16 was the causative 
type of the worst lesion in 55/63 (87.3%) women. In the 18 self-samples of women in 
which HPV18 was found with ≥CIN1 lesions, this was the causative type in 10 (55.6%), 
for HPV31 this was the case in 20/26 (77%) women, for HPV33 in 19/23 (83%), for HPV35 
in 3/7 (43%), for HPV39 in 3/12 (25.0%), for HPV45 in 8/14 (57.1%), for HPV51 in 6/16 
(37.5%), for HPV52 in 11/13 (84.6%), for HPV56 in 3/11 (27.3%), for HPV58 in 5/7 (71.4%), 
for HPV59 in 1/5 (20.0%) and for HPV66 in 1/9 (11.1%) women.
Association between hypermethylation of host-cell genes and HPV genotype
Methylation results on self-samples of 152 women of whom the self-sample was geno-
typed and a histological ≥CIN1 diagnosis was available, were used. Methylation results 
were available for 139/152 of these women with worst diagnoses: 27 CIN1, 46 CIN2, 59 
CIN3 and 7 carcinomas. Methylation positivity was found in 67/139 (48.2%) self-samples, 
detecting 47/66 (71.2%) CIN3+ lesions, including all carcinomas, and 20/73 CIN1-2 
(27.4%, 95% CI 18.5-38.6).
The relationship between hypermethylation in a self-sample and the causative HPV 
genotypes (HPV16/18 or other hrHPV) is shown in Table 2. No significant differences 
in positivity of the methylation assay were found between CIN3+ lesions caused by 
HPV16/18 and CIN3+ lesions caused by other hrHPV types (p=0.538). The levels of hy-
permethylation were compared between CIN3+ caused by HPV16/18 and other hrHPV 
89
Defining hrHPV genotypes in cervical intraepithelial neoplasia by laser capture microdissection supports reflex triage of self-samples
 
4
and did not show any significant differences; nor differences were observed for <CIN3 
caused by HPV16/18 and other hrHPV (data not shown).
Results for lesions caused by HPV16 were also analysed separately. Of all tested self-
samples of women with HPV16 as a causative genotype, 32/50 (64.0%) were methylation 
positive, with a positivity rate in CIN3+ of 80.0% (95%CI 64.1-90.0) and in CIN1-2 26.7% 
(4/15, 95% CI 10.9-52.0).
Table 2. Positivity rate of methylation testing on self-sample for different causative HPV genotypes found 








rate CIN3+ (%, 95% CI)
Methylation positivity
rate CIN1-2 (%, 95% CI)
HPV16/18 60 42 (70.0%) 31/42 (73.8%, 58.9-84.7) 4/18 (22.2%, 9.0-45.2)
Other hrHPV 82 27 (32.1%) 18/27 (66.7%, 47.8-81.4) 16/55 (29.1%, 18.8-42.1)
DIsCussIOn
This study explored the association between the HPV genotypes that can be found in 
self-samples taken for screening purposes, and the causative genotype found in the 
worst lesion on histology.
The causative genotype was found in the large majority of self-samples (93.4%), with a 
non-significant increase of association with increasing severity of the CIN lesion: 87.1% 
in CIN1, 92.2% in CIN2, and 96.8% in CIN3+. HPV16 was the most frequently found 
causative genotype in CIN3+ lesions, followed by HPV33, HPV31, and HPV18. There 
were no differences in methylation positivity between lesions caused by HPV16/18 or 
other hrHPV genotypes. Overall, the methylation positivity rate, irrespective of hrHPV 
genotype, for CIN3+ detection was 71.2% and for CIN1-2 was 27.4%.
This is the first study using a combination of WTS-PCR and LCM-PCR to study the agree-
ment between HPV genotypes found on self-sample and HPV genotypes found in the 
worst lesion on biopsy in a population that was hrHPV screened using a self-sampling 
device. The results are in line with the results of a study performed by van der Marel 
et al., which compared the HPV genotypes found on physician-taken samples to the 
genotype found in the worst lesion 17. We found multiple hrHPV genotypes in 30.6% 
(57/186) of the hrHPV positive self-samples, which again is consistent with findings for 
physician-taken samples 17. With the growing use of HPV DNA detection in screening, 
our results argue for further support of the use of self-sampling devices in screening to 
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reach non-responders or women who prefer to collect a self-sample over visiting their 
physician.
On self-sample, HPV16 was the most frequently found genotype, and on biopsy HPV16 
was the most frequently found causative genotype (35.0% of all lesions, 51.4% of CIN3+ 
lesions, respectively). In most cases where HPV16 was found on the self-sample, it was 
the causative type of the worst lesion on biopsy (87.3%). HPV18 was the causative type 
of 55.6% of the worst lesions of women with HPV18 on the self-sample. This partially 
supports previous studies that used the Cobas 4800 test (Roche) and attributed HPV16 
or HPV18, when present, to the worst lesion on biopsy 9. However, the relation between 
HPV16 on self-sample and the worst lesion present on biopsy seems stronger than for 
HPV18.
Partial genotyping for HPV16/18, in combination with cytology, has proven to be an 
attractive triage method for hrHPV positive women9, 25, 26 since the prevalence of HPV16 
and HPV18 in cervical cancers is high 27. HPV genotyping can predict an increased risk 
of (high-grade) CIN but cannot differentiate between productive and transforming HPV 
infection. Detailed study of the relation between each HPV genotype and the specific 
lesions is important to understand the biology and natural history of each lesion and to 
evaluate the clinical importance of different HPV genotypes.
Hypermethylation levels of FAM19A4 and miR124-2 increase with severity of underly-
ing lesion and duration of (hr)HPV infection and testing can be carried out on both 
physician-taken and self-collected material. However, differences in performance of 
methylation between lesions caused by different HPV genotypes were not previously 
studied. Based on our results, methylation testing seems to be a reliable test for lesions 
caused by all hrHPV genotypes.
This study shows that self-sampling for HPV-screening detects the causative genotype 
in the large majority of hrHPV positive cases with an underlying lesion. Comparison of 
HPV16/18 caused lesions with lesions caused by another hrHPV genotype in relation to 
the performance of FAM19A4/miR124-2 methylation indicate that methylation detects 
CIN3+ lesions caused by any hrHPV genotype. This study represents a sub analysis of a 
large screening trial which was not designed or powered to address this specific issue. 
Our results suggest an interesting new approach to using molecular biomarkers in tri-
age after self-screening. Given that HPV16 and 18 have an increased relative risk for CIN3 
and cancer, and hypermethylation of FAM19A4 and miR124-2 detects all carcinomas 
and advanced CIN lesions, our results support the combined use of HPV16/18 genotyp-
ing and hypermethylation of FAM19A4/miR124-2 as triage test for HPV positive women, 
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resulting in a high sensitivity for CIN3 and strong reassurance against cancer 25, 28. Used 
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Presence or absence of signifi cant HPVE4 
Expression in High-grade anal intraepithelial 
neoplasia with p16/Ki-67 positivity indicates 
distinct patterns of neoplasia




Progression of anal intraepithelial neoplasia (AIN) involves transition from productive 
to transforming human papillomavirus (HPV) infection. Grading aims to distinguish 
productive low-grade AIN from high-grade (HG)AIN with risk of cancer. We describe 
immunohistochemical patterns in AIN adding a novel marker for initiation of the pro-
ductive phase of the HPV life cycle (panHPVE4) to those for cell cycle activity (Ki-67) and 
transforming activity of HPV E7 gene (p16).
We studied 67 anal biopsies for suspected anal neoplasia (17 normal, 15 AIN1, 20 AIN2, 
15 AIN3) from 54 men who have sex with men (MSM) at New York Presbyterian Hospital, 
USA. Two pathologists generated consensus AIN and immuno-grades. Whole tissue and 
laser capture microdissection (LCM) samples from multiple HPV-infected biopsies were 
tested for HPV with SPF10-PCR-DEIA-LiPA25 version 1.
(Para)basal Ki-67 expression distinguished normal from AIN (≥ lower-third Ki-67) with 
sensitivity 0.92 and specificity 1.0. Ki-67 did not distinguish grades of AIN.
Null/patchy P16 versus diffuse ≥lower-third patterns discriminated HGAIN (sensitivity 
1.0; specificity 0.84). There was marked heterogeneity in E4 expression within HGAIN. 
Most AIN2 (14/20) was E4 positive versus 0/15 AIN3 (sensitivity: 0.70; specificity 1.0). 
HPV was detected in 63 (94%) biopsies, with 49 (77.8%) high-risk HPV positive. HPV16 
was the most frequent (13%). Multiple HPV genotypes were found in 15 (24%) biopsies 
and LCM-PCR confirmed specific HPV types in E4 +/- AIN.
While Ki-67 discriminated AIN and p16 high-grade AIN, E4+/p16+ staining shows that 
most AIN2 is different from transformed AIN3 in showing both entry into productive 
HPV infection and transforming activity.
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Over the last few decades, the incidence of anal cancer and its precursor anal intraepithe-
lial neoplasia (AIN) has increased among specific groups including men who have sex with 
men (MSM), immunocompromised patients and women with a history of cervical or vulvar 
cancer 1-3. The etiology of anal cancer is comparable to that of cervical cancer, with high-
risk (hr)HPV detected in over 90% of anal cancers 4, 5, but, unlike cervical cancer, HPV16 has 
been detected in 80-90% of invasive anal cancer 6, 7. HPV18 is uncommon and HPV33 is the 
second most important type, being found in 6% of anal cancers. Early detection of disease 
might improve survival and screening of high-risk groups such as MSM and HIV+ patients 
is advocated 8. Anal Pap smear screening has been implemented in several clinics 9.
Abnormal anal Pap smear results are followed-up by high-resolution anoscopy (HRA) 
and biopsy. High-grade anal intraepithelial neoplasia (HGAIN; ≥AIN 2) is treated by 
either infrared coagulation (IRC) or electrocautery ablation (ECA) of the lesion. The cure 
rates are similar: 67%-75% for HIV+ patients and 80%-85% for HIV- patients 10, 11.
The histopathological grading of HGAIN is poorly reproducible and includes a very 
heterogeneous group of lesions, some of which regress spontaneously and others that 
progress to cancer. The overall risk of progression to cancer after treatment for HGAIN 
is low: 1.97% at 3 years 12 and 3.2% at 5 years 13. It is therefore important to distinguish 
lesions with transforming characteristics that are likely to progress to cancer from 
productive lesions that are likely to regress. Biomarkers are needed that can be used 
in routine pathology practice, scored objectively and show distinguishing expression 
patterns between transforming and productive lesions. Immunohistochemical staining 
with p16 and Ki-67 has been identified as a valuable marker in diagnosis of HGAIN 14, 15. 
Although Ki-67  is used widely as a marker of cell proliferation, it in fact identifies all 
cells that are undergoing cell cycle progression, including those supporting genome 
amplification in low-grade disease caused by both high- and low-risk (lr)HPV. These 
cells are ‘in cycle,’ but not proliferative 16. P16 is a marker of transforming potential of 
hrHPV E7 gene 17. The novel HPV-encoded marker panE4 is a surrogate for initiation of 
the productive phase of the papillomavirus life cycle, and is expressed in productive HPV 
infection 18. It is currently being evaluated as an IHC marker of self-limiting productive 
HPV infection 19 in CIN.
An important feature of AIN in MSM and in HIV infection is the presence of multiple HPV 
types and we have previously shown by laser capture microdissection PCR (LCM-PCR) 
that each HPV type produces a separate lesion, although these lesions can sometimes 
overlap 20. We therefore performed LCM-PCR on biopsies with multiple hr HPV types.
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The aim of this study was to investigate if staining for E4 in addition to Ki-67 and p16 




Consecutive biopsies with diagnoses of normal anal transitional zone (N=17), AIN grade 
1 (AIN1) (N=17), AIN grade 2 (AIN2) (N=17) and AIN grade 3 (AIN3) (N=17) were selected 
from the surgical pathology files of the New York Presbyterian Hospital. Biopsies were 
taken from 54 different MSM, among whom 48 (89%) were HIV positive. Diagnoses were 
based on the consensus diagnosis of two pathologists who individually reviewed the 
hematoxylin-eosin (H&E) sections of each biopsy.
The paraffin embedded biopsies were sent to DDL Diagnostic Laboratory. Sectioning 
was done using a sandwich method to give one 4-µm-thick section for confirmation of 
diagnosis (H&E before); 2 sets of 3*8-µm-thick (24 mm) sections for whole-tissue section 
(WTS)-PCR analysis; 1 slide covered with a polyethylene naphthalate membrane (Zeiss 
Microimaging GmbH, Jena, Germany) for LCM; and finally, 3 4-µm-thick section for im-
munohistochemical staining. An expert pathologist reviewed H&E slides from this new 
sandwich and an adjudicated consensus diagnosis of the original and review diagnoses 
was used as the histological reference outcome.
Immunohistochemistry
4 µm thick formalin-fixed paraffin embedded (FFPE) sections were used for immuno-
histochemical staining with p16INK4a, Ki-67 and panHPVE4 using heat induced epitope 
retrieval with citrate buffer (Dako) and a primary mouse mAb anti-p16INK4a clone E6H4 
(Ventana Medical Systems Inc, Roche, Mannheim, Germany), Ki-67 mAb (Dako, Agilent 
Technologies Inc, Santa Clara, USA) and panHPVE4 mAb FH1.1 (Labo Biomedical Prod-
ucts (LBP), Rijswijk, The Netherlands). The panHPVE4 antibody has been found to be 
reactive against HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 
and 70 19. Reactivity was visualized using the EnVision Detection System (Dako, Agilent 
Technologies Inc, Santa Clara, USA).
scoring of immunohistochemistry
p16INK4a (p16) immunostaining was classified as (0) no, or patchy (1) p16 positivity, (2) dif-
fuse p16 staining restricted to the lower third of the epithelium, (3) diffuse p16 positivity 
up to two third of the epithelium or (4) diffuse full-thickness staining. In the evaluation 
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of p16 scores in relation to HGAIN, diffuse p16 staining of the lower one third of the 
epithelium or above (grade 2, 3 and 4) was considered positive.
Ki-67 was scored as (1) (para)basal up to lower third of the epithelium, (2) staining up to 
two third of the epithelium or (3) full thickness staining. In the evaluation of Ki-67 scores 
in relation to HGAIN, staining in the upper two third of the epithelium (grades 2 and 3) 
was considered positive.
PanHPVE4 immunoreactivity was scored as (0) negative, (1) focal —restricted to groups 
of cells in the upper quarter of the epithelium, and (2) extensive—upper half of the 
epithelium or more. Any grade of E4 positivity (grade 1 and 2) in the highest grade lesion 
identified was considered E4 positive in the detection of productive lesions. E4 positivity 
at the edge of a high-grade lesion adjacent to a low-grade lesion or normal epithelium 
was considered negative.
All slides were reviewed by two expert pathologists together, resulting in a consensus 
diagnosis.
HPV genotyping and laser capture microdissection
DNA for WTS-PCR was isolated from the FFPE material using a proteinase K procedure. To 
each sample, 100 µl of proteinase K lysis buffer was added and samples were incubated 
at 56 °C for 16–24 h. Proteinase K was heat-inactivated by incubation at 96 °C for 10 
min. Specimens were tested for HPV DNA using the analytically sensitive SPF10-PCR-
DEIA-LiPA25 version 1 system. The SPF10 PCR primer set ampliﬁes a small fragment of 
65 bp from the L1 region of mucosal HPV genotypes 21. Ampliﬁcation products were 
detected using the HPV SPF10PCR (version 1) DNA enzyme immunoassay (DEIA) system. 
DEIA-positive SPF10 amplimers were used to identify the HPV genotype by reverse 
hybridization with the HPV line probe assay (LiPA25), containing probes for 25 different 
HPV genotypes [HPV genotypes 6, 11, 16, 18, 31, 33, 34,35, 39, 40, 42, 43, 44, 45, 51, 52, 
53, 54, 56, 58, 59,66, 68/73, 70, and 74]; SPF10HPV LiPA25 version 1 (LBP, Rijswijk, The 
Netherlands).
LCM was performed on all specimens with multiple high-risk HPV genotypes in the 
WTS-PCR. Regions from all lesions and normal epithelium were selected by an expert 
pathologist using H&E and p16 stained slides. Slides were scanned using digital micros-
copy (Aperio Technologies Inc, Vista, CA, USA). The number of selected regions ranged 
from 4 to 23, with an average region size of 49657µm² (range 8173µm²-200390µm²). Se-
lected regions were excised with the Zeiss P.A.L.M. microbeam UV laser micro-dissection 
system and transferred to an AdhesiveCap500 opaque tube (Carl Zeiss B.V., Sliedrecht, 
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The Netherlands). In all specimens containing sufficient stroma, two stromal regions 
were selected as negative controls at the beginning and end of the LCM procedure. All 
PCR was performed as in WTS-PCR.
statistical analysis
Analyses were performed using IBM SPSS version 22.0 (SPSS Inc, Chicago, IL) for Win-
dows. Results were presented as absolute numbers and percentages. Sensitivities and 
specificities were calculated. The McNemar test was performed for analyses of nominal 
variables and P-values ≤0.05 were considered statistically significant.
ResulTs
A total of 67 blocks were graded on H&E slides and scored for IHC markers: 17 showed 
normal mucosa from the anal transitional zone, 15 AIN1, 20 AIN2, 15 AIN3. One sample 
was not adequate for grading and was excluded from analyses.
Immunohistochemistry
Sections were scored for p16, Ki-67 and E4 in the area of the most severe lesion identi-
fied on the H&E slide. Figures 1-3 show examples of AIN1-3 lesions stained for p16, Ki-67 
and E4.
Figure 1. AIN1 lesion with patchy p16, Ki-67 staining in the lower 1/3 of the epithelium and extensive E4 
staining. Note that the E4 and the Ki-67 staining overlap. This is cell cycle entry without cell division. The 
Ki-67 positive cells in the lower 1/3 of the epithelium are in cycle and some of these may be proliferating.
103
Presence or absence of significant HPVE4 Expression in High-grade anal intraepithelial neoplasia with p16/Ki-67 positivity indicates distinct patterns of neoplasia
 
5
Figure 2. AIN2 lesion with HPV18 in the WTS, showing p16 staining in the lower 2/3 of the epithelium, Ki-
67 staining in the lower 2/3 of the epithelium and extensive E4 staining of the superficial layers.
P16
P16 staining was negative or patchy in 27 lesions (40%), diffuse up to one third in 6 
lesions (9%), up to two third in 14 (21%) and full thickness in 20 (30%). Biopsies of normal 
mucosa were completely negative or showed patchy staining for p16 in 16 (94%) speci-
mens (Table 1). One biopsy (6%) graded on H&E as normal showed strong p16 staining in 
the lower 1/3 of the epithelium. In the AIN1 group, the majority of lesions (73%) showed 
patchy p16 staining, with the four lesions showing p16 positivity. All AIN2 lesions were 
p16 positive, with 85% showing p16 positivity above the lower 1/3 of the epithelium. In 
AIN3, p16 positivity was above 2/3 of the epithelium to full thickness in 60% of the cases. 
Of all HGAIN lesions, 89% showed p16 staining above the lower 1/3 of the epithelium.
Ki-67
Ki-67 was scored (para)basal to lower one third in 21 (31%), staining up to two third in 24 
(36%) and full thickness in 22 (33%). Table 2 shows the Ki-67 positivity in biopsies from 
normal mucosa, AIN1, AIN2 and AIN3. Of all normal biopsies, 100% showed (para)basal 
Ki-67 staining or staining in the lower 1/3 of the epithelium. Most AIN (92%) showed 
Ki-67 positivity above the lower 1/3 of the epithelium. AIN1 showed different patterns of 
Ki-67 positivity, but in AIN2 staining mostly (65%) extended between the lower 1/3 and 
2/3 of the epithelium, whereas the majority (67%) of AIN3 showed staining above the 
lower 2/3 of the epithelium to full thickness. Of the HGAIN lesions, 92% showed Ki-67 




None of the normal biopsies were E4 positive. E4 positivity was very frequent in AIN1 
(53%) and AIN2 lesions (70%). AIN1 lesions showed both extensive E4 positivity in 40% 
and focal positivity in 13%. A total of 9 (45%) AIN2 lesions showed extensive E4 positivity 
and focal positivity was seen in 5 lesions (25%). The division of focal or extensive positiv-
ity of E4 did not differ significantly between AIN1 and AIN2 (p=0.604).
Of the 15 AIN3 lesions, none showed E4 positivity in the AIN3 lesion (Table 3). Three AIN3 
lesions showed E4 positivity located at the edges of the lesion (Figure 3). This should not 
be interpreted as representing E4 positivity in AIN3.
There was no significant difference in E4 positivity between cases with multiple and 
single HPV infections, HPV16 positivity and other HPV positivity or HIV positive and HIV 
negative patients.
Table 1 P16 scores in different grades of AIN.
P16 score
Negative Patchy <Lower 1/3 Lower 1/3-Lower 2/3 >Lower 2/3
Normal (N=17) 8 (47%) 8 (47%) 1 (6%) 0 (0%) 0 (0%)
AIN1 (N=15) 0 (0%) 11 (73%) 1 (7%) 2 (13%) 1 (7%)
AIN2 (N=20) 0 (0%) 0 (0%) 3 (15%) 7 (35%) 10 (50%)
AIN3 (N=15) 0 (0%) 0 (0%) 1 (7%) 5 (33%) 9 (60.0%)
Table 2 Ki-67 scores in different grades of AIN.
Consensus diagnosis
Ki-67 score
<Lower 1/3 Lower 1/3-Lower 2/3 >Lower 2/3
Normal (N=17) 17 (100%) 0 (0%) 0 (0%)
AIN1 (N=15) 1 (6%) 7 (47%) 7 (47%)
AIN2 (N=20) 2 (10%) 13 (65%) 5 (25%)
AIN3 (N=15) 1 (6%) 4 (27%) 10 (67%)
Table 3 E4 positivity (negative, focal or extensive) in different grades of AIN.
Consensus diagnosis
E4 score
Negative Focal positivity Extensive positivity
Normal(N=17) 17 (100%) 0 (0%) 0 (0%)
AIN1 (N=15) 7 (47%) 2 (13%) 6 (40%)
AIN2 (N=20) 6 (30%) 5 (25%) 9 (45%)
AIN3 (N=15) 15 (100%) 0 (0%) 0 (0%)
105
Presence or absence of significant HPVE4 Expression in High-grade anal intraepithelial neoplasia with p16/Ki-67 positivity indicates distinct patterns of neoplasia
 
5
Figure 3. AIN3 lesion with HPV35 in the WTS, showing full thickness p16 positivity, full thickness Ki-67 
staining and focal E4 staining at the edge of the AIN3 lesion where it merges with low-grade AIN. This 
should not be interpreted as E4 positivity in the AIN3 lesion.
HPV Dna
HPV DNA status of biopsies
With the analytically sensitive SPF10-PCR-DEIA-LiPA version 1, 63 (94%) of the biopsies 
were HPV positive, out of which 49 (77.8%) were hrHPV positive. Only 4/17 (24%) normal 
whole tissue sections were HPV negative, and these were also E4 and p16 negative. 
There were 48/63 (76%) HPV-positive samples with single HPV types detected. hrHPV 
types 16, 18, 31 or 33 were found in 19 (30%) of the HPV positive biopsies, with HPV16 
found the most frequently (13%). Multiple HPV genotypes were found in 15 (24%) of 
HPV-positive biopsies, of which 7 contained multiple hrHPV genotypes. In 8 specimens 
a single hrHPV type was found in combination with lrHPV in WTS-PCR although multiple 
lrHPVs were also found and in 7 specimens there were multiple hrHPVs present. The 
genotype distribution based on these biopsies with a single type found by WTS-PCR 
and based on LCM-PCR of the worst lesions in a biopsy with a multiple infection with 
multiple hrHPV is shown in Table 4.
Relation between AIN grade and HPV type in cases with multiple hrHPV types 
selected for LCM-PCR
AIN grade and HPV type in multiple hrHPV infections by LCM-PCR
Seven WTS with multiple high-risk HPV genotypes were selected for LCM-PCR. One 
WTS had a highest lesion grade AIN3, five had AIN2 and one was normal. Four had 2 
genotypes found in the WTS (58%), one had 3 genotypes (14%), one had 4 genotypes 
(14%) and one had 5 genotypes (14%). Four samples contained a multiple infection with 
HPV16 DNA and other genotypes.
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In four lesions, not all genotypes were found with LCM-PCR (57%). In one lesion (14%), 2 
additional HPV genotypes were detected with LCM-PCR and in the remaining 3 lesions 
(42%), all genotypes found in the WTS.
Figure 4 shows the distribution patterns of immunohistochemical staining of an AIN2 
lesion for the three markers together with annotated regions selected for LCM-PCR. On 
WTS-PCR, genotypes 16, 31, 51, 52 and 70 were detected. Both p16 and Ki-67 showed 
full thickness staining and the E4 showed extensive positivity. With LCM-PCR, HPV51 was 
found in the p16 positive, Ki-67 positive and E4 positive AIN2 region and was designated 
as the causative type of the lesion. HPV 16, 31, 52 and 70 were all detected in regions of 
adjacent AIN1 lesions. HPV 18 was found by LCM-PCR in two small regions although not 
detected by WTS-PCR in the presence of multiple other types.
Table 4. Frequencies of single HPV genotypes detected in WTS-PCR and LCM-PCR of 51 biopsies with dif-


































Normal 2 1 0 0 1 0 1 0 0 0 0
AIN1 1 0 1 0 0 1 0 0 0 0 0
AIN2 2 3 1 2 0 2 1 2 1 2 0


































Normal 0 0 0 0 2 0 0 0 0 0 0
AIN1 0 0 1 4 2 1 1 0 0 0 0
AIN2 1 0 0 0 0 0 0 2 0 0 0
AIN3 0 1 0 0 0 0 0 0 0 0 0
Classification of AIN lesions by patterns of E4, p16 and Ki-67 expression in relation to 
HGAIN grade and associated hrHPV
Patterns of positivity for the IHC markers E4, p16 and Ki-67 in 67 specimens are shown 
in Table 5. In this analysis the cut-off used for each marker was for E4 any positivity 
(E4≥1) as a marker of productive activity; and for p16 positivity involving 1/3 or more 
(p16≥2) of the epithelium as a marker of transformation. For Ki-67 abnormal expression 
was defined as Ki-67 positivity above the lower 1/3 of the epithelium (Ki-67≥2). HPV 
genotype association was categorized as low-risk HPV (LR), when only low-risk HPV is 
found, high-risk HPV (HR) when at least one high-risk HPV genotype was found, or HPV 
negative.
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P16 E4 Ki-67 
Figure 4. P16 (full thickness staining), E4 (extensive staining) and Ki-67 (full thickness staining) slides with 
the worst diagnosis of AIN2, with HPV genotypes 16, 31, 51, 52 and 70 detected in the whole tissue section 
SPF10-PCR-DEIA-LiPA25. LCM-PCR analysis assigned all genotypes to different lesions in the biopsy, and in 
addition, detected HPV 18 concentrated in two discrete regions.
Normal epithelium showed no positivity for E4 or p16 by the criteria defined above and 
only Ki-67 expression confined to the lower 1/3, although both lrHPV and hrHPV DNA 
could be detected in this group. In AIN1 14/15 (93%) lesions were Ki-67 positive, but 
only 3/15 (20%) were p16 positive (all hrHPV) and 6 with hrHPV were p16 negative. E4 
was expressed in 8/15 (53%) AIN1 cases of which 6 were lrHPV and 2 were hrHPV and 7/8 
(87%) E4 expressing AIN1 were p16 negative.
In AIN2, all were p16 positive of which 2 were Ki-67 negative. All were hrHPV positive. 
E4 positivity was seen in 12/17 (70%) p16 positive cases and in 2/3 p16 negative cases. 
E4 positivity was not seen in AIN3; none were E4 positive. However, all AIN3 cases were 
hrHPV positive and p16 positive.
Almost all AIN1, AIN2 and AIN3 lesions showed extensive Ki-67 positivity above the lower 
1/3 of the epithelium. There is a clear relation between p16 expression and presence of 
HGAIN, with 100% of HGAIN being positive compared to 4/15 (27%) AIN1.
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Table 5. The expression of E4, p16 and Ki-67 in different grades of AIN, identifying productive lesions 
(E4≥1) and transforming lesions (p16≥2) and proliferative activity (Ki-67≥2) and the detection of low-risk 
(LR) and high-risk (HR) HPV in the WTS.
Diagnosis


























Normal 16 0 0 0 0 1 0
HPV HR: 8         HR: 1  
  LR: 4         LR: 0  
 
HPV 
negative: 4        
HPV 
negative: 0  
AIN1 0 5 6 1 1 0 2
HPV   HR: 4 HR: 0 HR: 1 HR: 1   HR: 2












AIN2 0 0 0 0 14 2 4
HPV         HR: 14 HR: 2 HR: 4
          LR: 0 LR: 0 LR: 0







AIN3 0 0 0 0 0 1 14
HPV         HR: 1 HR: 14
          LR: 0 LR: 0





There is, however, an important difference in expression of E4 within HGAIN, between 
AIN2 and AIN3. Most, 12/17 AIN2 (70%) cases were E4 positive whereas all AIN3 cases 
were E4 negative. The presence of E4 associated with strong p16 positivity in HGAIN 
lesions indicates that HGAIN includes cases (14/35; 40%) where there is evidence of 
continuing productive phase of the HPV life cycle associated with productive infection 
alongside evidence of transforming activity. This pattern of E4 and p16 expression is 
seen in AIN2.
DIsCussIOn
This is the first comprehensive study showing that a panel of immunohistochemical 
markers consisting of E4, P16 and Ki-67 makes it possible to differentiate between 
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normal anal mucosa and discrete lesions of AIN1, AIN2, and AIN3 in a representative 
population of MSM with a high frequency of HIV infection. Our results indicate that Ki-67 
is a useful marker discriminating AIN from normal, p16 is useful in discriminating high-
grade AIN from normal/low-grade AIN, and E4 is useful in discriminating AIN2 from AIN3 
and shows that AIN2 is not a homogeneous group.
Between normal and AIN1, AIN2 and AIN3 there is a change in expression of markers 
indicating productive HPV infection with initiation of the productive phase of the HPV 
life cycle (E4), cell cycle entry (Ki-67) and potential transforming activity of the HPV 
E7 gene (p16). Importantly it shows that HGAIN (AIN2 and AIN3) which is the current 
threshold for treatment is far from homogeneous with regard to the balance between 
HPV productive activity and transformation, reflected partially in histological grading 
into AIN2 and AIN3.
Ki-67 staining extended above the lower third in most AIN of all grades. Its expression is 
a consequence of entry into an incomplete cell cycle for viral genome amplification in 
productive infections associated with both lrHPV and hrHPV, as well as an increase in cell 
proliferation in transforming hrHPV infection 22. Expression of p16 increases with grade 
of AIN and is negative or patchy in all normal biopsies. AIN1 showed usually only patchy 
p16 staining but almost 1/3 lesions showed diffuse staining of at least the lower third. In 
HGAIN there was extensive p16 staining above the lower 1/3 of the epithelium in 89% 
lesions, compared to 19% AIN1. E4 was negative in all normal biopsies. Many (56%) AIN1 
lesions were E4 positive. Importantly we found that in HGAIN, although all were p16 
positive and also Ki-67 positive there was marked heterogeneity in E4 expression. AIN2 
lesions showed E4 positivity in 70% of the cases, within which most showed extensive E4 
positivity. In AIN3 lesions, no E4 positivity was seen in the lesion. These results indicate 
that there is an important difference in the balance between initiation of the productive 
phase of the HPV life cycle and transforming activity between AIN2 and AIN3. This switch 
may be linked to increasing HPV genomic integration.
Previous biomarker data based on p16 with or without the addition of Ki-67 23-26 sup-
ported a 2-tiered system separating low-grade lesions and high-grade lesions, with 
recommendations for treatment of all HGAIN, rather than a 3-tiered system separating 
AIN1-3 and CIN1-3 27). There is, however, other evidence that intraepithelial neoplasia 
grade 2 (–IN2) represents a mixture of regressive and progressive disease. The present 
data supports the view that a division into LGAIN and HGAIN may be too simplistic, 
and needs further investigation in relation to the known infrequency of progression of 
HGAIN to invasive cancer.
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The marker patterns do not precisely conform to the conventional histological grades. 
These findings indicate 4 distinct patterns of lesion development with likely progression 
from HPV infection to productive and increasingly transforming HPV-induced lesions. 
Lesions called AIN1 include early or resolving HPV lesions or non-HPV-associated pathol-
ogy, even if HPV DNA is being carried (E4 negative, Ki-67 positive, p16 negative), with 
a proportion of AIN1 being mature productive HPV lesions (E4 positive, Ki-67 positive, 
p16 negative) completing the HPV life cycle. AIN2 is predominantly composed of lesions 
that show both productive and transforming features (E4 positive, Ki-67 positive, p16 
positive) and AIN3 is predominantly a transforming lesion (E4 negative, Ki-67 positive, 
p16 positive). The presence of two patterns of Ki-67 and p16 expression with or without 
E4 expression is consistent with the suggestion that –IN2 includes both progressive and 
regressive lesions. However, the presence of E4 expression, indicating that some HPV 
infected basal cells in a lesion have matured and complete the HPV life cycle, does not 
mean that all basal cells are not transforming. Transformation of basal cells might occur 
concurrently or sequentially following the progress of E4 positive cells up the epithelial 
differentiation pathway. It is also possible that as proposed for the cervix, different zones 
of anal epithelium, particularly immature cells in the transformation zone, may be more 
susceptible to transforming than productive hrHPV infection 28. However, full transfor-
mation is not a single stage process and the continued expression of some E4 is likely to 
indicate an early stage in the process.
This hypothesis needs further exploration in progression studies of AIN and of CIN using 
E4 and other markers such as methylation of tumor suppressor genes and expression of 
other cellular transforming genes in relation to progression and regression.
Attention to the distribution of E4 is important. E4 expression can be a result of produc-
tive low risk HPV infections 29 30. Therefore, interpretation of E4 staining patterns in mul-
tiple infections needs to be done carefully. Focal E4 expression may also be seen at the 
edges of HGAIN lesions (Figure 3), where the more normal, local epithelial microenviron-
ment is different from that within the lesion and may promote epithelial differentiation 
and entry into the productive phase of the HPV life cycle rather than representing the 
true nature of the lesion as a whole. It is also important to distinguish E4 expression in 
the lesion from E4 expression in collision areas between a HSIL caused by hrHPV and 
an adjacent AIN1 expressing E4 in cases of multiple infection. This AIN1 lesion might 
develop from basal cells that follow a different pathway leading to a productive infec-
tion and such independent event does not represent a precursor of the adjacent AIN3.
We confirmed the importance of understanding the role of multiple genotypes by laser 
capture microdissection analysis of whole tissue sections that contained multiple hrHPV 
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genotypes to assign one HPV genotype to the worst lesion according to the one virus 
one lesion theory 20, 31. In the case of multiple infection in the whole tissue section, single 
HPV genotypes can be found in different regions of the specimen. It was previously 
shown in cervical specimens that HPV DNA can also be found in normal epithelium and 
these genotypes can be considered passengers or latent infections 31.
We did not analyze all non-dysplastic regions using LCM-PCR. Most lesional areas con-
tained only a single HPV type, but multiple genotypes were found in 10/97 LCM regions. 
These all appeared to be collision of 2 different lesions infected with different genotypes.
AIN1 lesions that do not express p16 and/or E4 need to be explored further, particularly 
as similar lesions in the cervix are poorly reproducible in diagnosis by pathologists 19, 
and may represent developing or regressing productive HPV-induced lesions or lesions 
due to other causes in which HPV DNA is found coincidentally. E4 is a marker of comple-
tion of the life cycle and therefore is not necessarily expressed in very early developing 
CIN1 lesions, in resolving CIN1 or in latent infections. In the present descriptive study, we 
found that 5/15 (33%) of AIN1 lesions express no E4 and no diffuse p16 staining. These 
lesions might fall into a not-HPV-related category, or represent early or resolving HPV 
infections. Furthermore, 2/15 AIN1 lesions (13%) express no E4 but did show diffuse p16 
staining, suggesting that these lesions are more like AIN2.
The findings in this study of AIN are similar to those in previous studies of CIN. Van Baars 
et al. found E4 positivity in 21.5% of the CIN3 lesions, 47.4% of the CIN2 lesions, 58.8% 
of the CIN1 lesions and 0% of the negative biopsies 32. The proportions of E4 positivity 
in CIN correspond generally to the E4 positivity found in AIN lesions. The E4 positivity 
that is found in AIN2 lesions (70%) however is considerably higher than in CIN2. Even 
though the HPV genotypes and marker patterns of AIN and CIN are comparable, there 
are important differences between HIV+ MSM in AIN and women in the reproductive 
age in CIN. In the present study, the group of HIV negative cases was very small (11%) 
and therefore did not allow comparative analyses between HIV+ and HIV- cases. Most 
studies on inter-observer agreement of immunohistochemical markers have been done 
on cervical specimens, with good to excellent interobserver agreement for immunohis-
tochemical markers E4, p16 and proliferation marker MCM 32 in cervical biopsies.
Combining p16 and Ki-67 with E4 raises the possibility of distinguishing between pro-
ductive and transforming AIN lesions. Studies are needed to explore further the clinical 
utility of E4/p16 biomarkers in identifying progressive HGAIN lesions requiring treat-
ment. The relation of these markers to other molecular markers, such as methylation of 
tumor suppressor genes, with the ability to identify advanced transforming lesions as 
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proposed in CIN3 is important 33, 34. Demonstration of effective differentiation between 
transforming and productive lesions could prevent current over-treatment of all HGAIN 
lesions, the majority of which do not progress and many of which may go into spontane-
ous regression.
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Grading immunohistochemical markers 
p16INK4a and HPV E4 identifi es productive 
and transforming lesions caused by low- and 
high-risk HPV within high-grade anal squamous 
intraepithelial lesions




Aims: Current LAST guidelines recognise high- and low-grade anal squamous intraepi-
thelial lesions (HSIL, LSIL) and recommend treatment of all HSIL, but not all HSIL progress 
to cancer. This study aims to distinguish transforming and productive HSIL by grading 
immunohistochemical (IHC) biomarkers p16 and E4 in lr- and hr-HPV- associated SIL as a 
potential basis for more selective treatment. 
Methods and results: Immunostaining for p16 and HPV E4 was performed and graded 
in 183 biopsies from 108 HIV+ MSM. Causative HPV genotype of the worst lesion was 
identified using SPF10-PCR-DEIA-LiPA25v1, with laser capture microdissection (LCM) for 
multiple infections. Worst lesions were scored for p16 (0-4) to identify activity of hrHPV 
E7 gene, and panHPV E4 (0-2) marking HPV production and life-cycle completion. There 
were 37 normal, 60 LSIL and 86 HSIL with 85% LSIL caused by lrHPV and 93% HSIL by 
hrHPV. No normal biopsy showed E4 but 43% of LSIL and 37% of HSIL were E4 positive. 
No differences in E4 positivity rates were found between lrHPV and hrHPV lesions. Most 
(90%) lesions caused by lrHPV showed very extensive patchy p16 staining. p16 grade in 
HSIL was variable with frequency of productive HPV infection dropping with increasing 
p16 grade. 
Conclusions: Combined p16/E4 IHC identifies productive and non-productive HSIL asso-
ciated with hrHPV within the group of HSIL defined by the Lower Anogenital Squamous 
Terminology recommendations. This opens the possibility of investigating selective 
treatment of hrHPV-caused advanced transforming HSIL and a “wait and see” policy for 
productive HSIL.
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The incidence of squamous cell carcinoma of the anal canal and anal intraepithelial neo-
plasia (AIN), also called squamous intraepithelial lesions (SIL), is increasing, especially in 
high-risk populations such as men who have sex with men (MSM), HIV infected patients 
and women with a history of a vulvar or cervical HPV-related malignancy 1-3. High-risk 
(hr)HPV is detected in over 80% of the anal cancers 4-8 and carcinoma associated with 
low-risk (lr)HPV is rare 9. Because of the similarities in aetiology and pathology between 
cervical and anal intraepithelial neoplasia, the clinical approaches to these lesions are 
similar. In the case of a suspected anal high-grade SIL (HSIL), patients are subjected to 
a high-resolution anoscopy during which biopsies are taken of abnormal appearing 
regions, and treatment follows after confirming diagnosis of HSIL by histopathology, 
which has low inter and intra observer agreement 10, 11.
The Lower Anogenital Squamous Terminology (LAST) recommendations recognise 
only low and high-grade SIL 12. This separation is based on the assumption that LSIL 
represents a productive HPV infection that will regress whereas HSIL is considered to be 
a transforming HPV infection that has a high chance of progression to cancer and is in 
need of treatment. However, it is estimated that only 10% of anal HSIL ultimately prog-
ress to cancer 7 if left untreated and about 47% of shows regression 13, 14. The LAST recom-
mendations for pathological diagnosis make only limited use of immunohistochemical 
biomarkers. The LAST recommendations state that diagnosis of HSIL should be made 
using H/E histopathology supported by the use of p16 as a surrogate marker for hrHPV 
E7 transforming gene activity, only to confirm HSIL diagnosis in case of uncertainty or 
disagreement about LSIL versus HSIL to show presence of diffuse p16 positivity 12. 
A biomarker specific for productive HPV infection such as HPV E4, in combination with 
patterns of diffuse p16 expression as a marker of the transforming activity of the hrHPV 
E7 gene, might help to classify more objectively anal intraepithelial lesions (AIN), both 
LSIL and HSIL, and provide a basis for more selective treatment, avoiding unnecessary 
intervention for self-limiting lesions. Currently the LAST recommendations recommend 
all HSIL is treated. There are several treatment modalities for anal HSIL including infrared 
coagulation, electrocautery, surgical excision and topical application of trichloroacetid 
acid or imiquimod. Currently, electrocautery is the treatment of choice for intra-anal 
HSIL in many centers 15. However, there is no international consensus guideline, recur-
rence rates are high for all modalities and all can cause side effects like pain and anal 
blood loss 16. Selective treatment of only men HSIL with a higher chance of progression 
to cancer could prevent overtreatment with negative side effects.
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E4 is a marker of completion of the HPV life cycle seen in productive HPV infection as-
sociated with low-grade CIN or AIN 17, 18. Expression of E4 in HPV infected differentiated 
squamous cells results in disruption of the keratin filamentous network of the squamous 
cell, inhibits formation of the cornified envelope, and plays a role in virus release and 
transmission 19. 
p16 is diffusely overexpressed in high-grade intraepithelial lesions and carcinomas 
driven by hrHPV, and is induced by HPV E7 of high-risk HPV types 12, 20, 21. It is a protein 
regulating the G1 to S phase checkpoint of the cell cycle. 
Previously we have shown that AIN2 differs from AIN3 in its expression of abundant 
E4 and no HPV E4 was found in AIN3 lesions 22. In this study we demonstrate the het-
erogeneity of HSIL lesions using a combination of IHC biomarkers p16 and E4 within 
the category of HSIL defined by current practice using LAST recommendations 12. We 
determined the causative HPV genotype of SIL and related the HPV genotype to the p16 
and HPV E4 biomarker expression pattern to show that based on patterns of biomarker 
expression of p16/E4, we can identify productive HSIL associated with hrHPV and SIL 
associated with lrHPV. This provides a potential basis for selection of cases currently 




For the present study, 183 biopsies from two studies were used:
Biopsies from the H2M2 cohort study were selected23. 
H2M2 is a multicentre prospective cohort study of HIV-infected MSM aged ≥18, con-
ducted at several clinics in Amsterdam. Men had anal HPV testing every 6 months for 
2 years and in the course of regular care they were offered anal screening using high-
resolution anoscopy (HRA). At the initial HRA, biopsies were taken from HSIL suspected 
areas, detecting HSIL in at least 1 biopsy in 50 men. All other biopsies from these 50 men 
were also included, resulting in a total number of 116 biopsies. 
A second group was selected from the pathology files of the New York Presbyterian 
Hospital . This group consisted of 67 biopsies from 53 MSM of whom 47 were HIV+. 60/67 
were from HIV+ MSM. Biopsies from this second group had been previously stained with 
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biomarkers p16, Ki-67 and E4 for the description of expression patterns in different 
grades of AIN 22.
Histology processing and review
The formalin-fixed paraffin-embedded (FFPE) material of all included biopsies was cut 
at DDL, Rijswijk Subsequent slides were used for: 4µm slides for Haematoxylin and Eosin 
(H/E) staining (before and after), 3 x 4µm slides for immunohistochemical staining (p16 
and E4), 1 membrane slide for laser capture microdissection (LCM) and 1 tube (3*8µm) 
for HPV detection.
Two specialized pathologists reviewed the H/E slide first individually and then together 
and made a diagnosis which was used as our consensus diagnosis. Then, the p16 slide 
was used to confirm detection of HSIL in a set of AIN1 and all AIN2, in an approach based 
on the LAST recommendations: 
·	 Histologically normal: normal.
·	 Histologically AIN1 (no suspicion of AIN2): LSIL.
·	 Histologically AIN1 (suspicion of AIN2 by at least one pathologist) or AIN2, p16 nega-
tive: LSIL.
·	 Histologically AIN1 (suspicion of AIN2 by at least one pathologist) or AIN2, p16 dif-
fusely positive: HSIL. 
·	 Consensus diagnosis AIN3: HSIL.
In further analyses, the consensus diagnosis and the LAST diagnosis were used for 
comparison.
HPV genotyping and lCm
HPV genotyping of whole tissue sections was done using the analytically sensitive 
SPF10-PCR-DEIA-LiPA25 version 1, genotyping 25 lr- and hr-HPV types 24. The caus-
ative genotype of the highest graded lesion present on biopsy was attributed to the 
genotype found in the whole tissue section (WTS) in case of a single infection in ≥AIN1 
biopsies. From biopsies in which multiple HPV genotypes were found, the worst lesions 
was selected for laser capture microdissection to identify the causative type of this worst 
lesion. Laser captured worst lesions were analysed according to the same HPV testing 
algorithm (SPF10) 25. 
Immunohistochemistry
4 µm thick FFPE sections were used for immunohistochemical staining with p16INK4a and 
panHPVE4 using heat induced epitope retrieval with citrate buffer (Dako) and a primary 
mouse monoclonal antibody anti-p16INK4a clone E6H4 (Ventana Medical Systems Inc, 
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Roche, Mannheim, Germany), and XR-E4-1 (Labo Biomedical Products (LBP), Rijswijk, 
The Netherlands). The panHPVE4 antibody has been found to be reactive against at least 
HPV genotypes 6,11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, and 7017, 22. 
Reactivity was visualized using the EnVision Detection System (Dako, Agilent Technolo-
gies Inc, Santa Clara, USA). 
All slides were scored jointly for p16 grade and E4 positivity by two expert pathologists, 
resulting in an immunoscore for each marker.
p16InK4a immunohistochemistry
p16INK4a (p16) immunostaining was classified as no staining (grade 0) or patchy p16 
positivity (grade 1), diffuse p16 positivity restricted to the lower third of the epithelium 
(grade 2), diffuse p16 positivity restricted to the lower two third of the epithelium (grade 
3) or diffuse staining above the lower two third up to full-thickness staining (grade 4). In 
the evaluation of p16 scores in relation to LAST classification of HSIL, diffuse p16 staining 
(grade 2, 3 and 4) was considered positive. 
HPV e4 immunohistochemistry
Pan HPVE4 immunoreactivity in the worst lesion was scored as negative (grade 0), focal 
—restricted to groups of a few cells in the upper layers of the epithelium (score 1), and 
extensive—upper half of the epithelium or more (score 2) 17. Any E4 positivity (score 1 
and 2) in the highest-grade lesion identified was considered E4 positive. E4 positivity at 
the edge of a high-grade lesion adjacent to a low-grade lesion or normal epithelium was 
considered negative as in previous studies 22.
statistical analyses
Results were analysed using IBM SPSS version 22.0 for Windows (Chicago, IL). Data were 
presented as absolute numbers and percentages. Percentages were compared using the 
Chi-square test and the level of statistical significance was set at p<0.05. 
ResulTs
In 183 biopsies from 108 patients, classified by the LAST recommendations applied by 
two expert pathologists there were 37 normal, 60 LSIL, and 86 HSIL as the worst lesions 
seen in the biopsies. Expert H/E consensus diagnosis using the AIN classification was 
negative in 37 biopsies, AIN1 in 67 biopsies, AIN2 in 43 biopsies and AIN3 in 36 biopsies. 
Table 1 compares consensus AIN diagnoses with LAST diagnoses. 
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Results of p16 and E4 scoring of the worst areas of lesions in different grades of AIN and 
SIL are shown in Tables 2 and 3.
p16 score increased with the severity of the lesion, with 83% (86/104) of all negative/AIN1 
lesions and 93% (90/97) negative/LSIL lesions by LAST criteria showing no or patchy p16 
staining. Of all ≥AIN2 lesions, 89% (70/79) showed diffuse p16 staining above the lower 
1/3 of the epithelium, with 58% of AIN2 showing diffuse staining above the lower 2/3 of 
the epithelium and 78% of AIN3 showing this pattern. Using the LAST diagnosis of HSIL, 
only 1% (1/86) showed patchy staining and 67% showed staining of >2/3 epithelium. 
E4 was negative in 100% of the normal biopsies, while 49% (33/67) of the AIN1 lesions 
scored positive for E4. In AIN2, 56% (24/43) of the lesions were E4 positive and only one 
of the AIN3 lesions was E4 positive (3%, 1/36) (p<0.001). When using the LAST diagnosis, 
26/60 (43%) of LSIL and 32/86 (37%) of HSIL were E4 positive (p=0.457).
Table 1: Consensus diagnosis based on H/E using AIN classification compared to p16-supported LAST di-
agnosis.
Consensus Diagnosis (%) LAST diagnosis (%)
Normal (N=37) LSIL (N=60) HSIL (N=86)
Normal (N=37) 37 (100%) 0 0
AIN1 (N=67) 0 56 (84%) 11 (16%)
AIN2 (N=43) 0 4 (9%) 39 (91%)
AIN3 (N=36) 0 0 36 (100%)















Normal (N=37) 20 (54%) 16 (43%) 1 (3%) 0 0
AIN1 (N=67) 1 (2%) 49 (73%) 4 (6%) 7 (10%) 6 (9%)
AIN2 (N=43) 0 4 (9%) 3 (7%) 11 (26%) 25 (58%)
AIN3 (N=36) 0 1 (3%) 1 (3%) 6 (16%) 28 (78%)











Normal (N=37) 20 (54.1%) 16 (43.2%) 1 (2.7%) 0 0
LSIL (N=60) 1 (2%) 53 (88%) 3 (5%) 2 (3%) 1 (2%)
HSIL (N=86) 0 1 (1%) 5 (6%) 22 (26%) 58 (67%)
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Table 3: E4 scores (negative, focal or extensive) in biopsies with different grades of AIN by the consensus 
diagnosis (3a) and the LAST diagnosis (3b).
3a. Consensus Diagnosis E4 score
Negative (grade 0) Focal positivity (grade 1) Extensive positivity (grade 2)
Normal (N=37) 37 (100%) 0 0
AIN1 (N=67) 34 (51%) 7 (10%) 26 (39%)
AIN2 (N=43) 19 (44%) 8 (19%) 16 (37%)
AIN3 (N=36) 35 (97%) 0 1 (3%)
3b. LAST Diagnosis E4 score
Negative (grade 0) Focal positivity (grade 1) Extensive positivity (grade 2)
Normal (N=37) 37 (100%) 0 0
LSIL (N=60) 34 (57%) 5 (8%) 21 (35%)
HSIL (N=86) 54 (63%) 10 (12%) 22 (25%)
HPV genotyping of the worst lesion
Single HPV infections
Whole tissue sections (n=183) were tested for HPV positivity and genotyped, resulting 
in 9 HPV negative biopsies, 120 with a single HPV genotype, of which 11 could not be 
genotyped (type X), and 54 with multiple genotypes present. The most frequently found 
HPV genotype as a single infection was HPV6 (22 biopsies from 18 patients), followed by 
HPV16 (17 from 16 patients). 
The causative genotype of the worst lesion present on biopsy was attributed to the 
genotype found in the WTS in case of a single infection in ≥LSIL biopsies. Biopsies in 
which no abnormal epithelium was found were excluded when identifying the causative 
type (19/120 single infections). 
Multiple HPV infections
The causative type of the worst lesion in the 45/54 biopsies with multiple infections was 
identified using LCM: nine biopsies contained normal anal epithelium only and were not 
further analysed. The worst diagnosis of the remaining 45 biopsies was LSIL in 10 and 
HSIL in 35. 
In total, a causative genotype was identified for 139/146 worst lesions and seven worst 
lesions were HPV positive but could not be genotyped (type X). Supplementary table 1 
shows the causative genotype in LSIL and HSIL according to LAST diagnosis. Most LSIL 
was caused by lrHPV (51/60, 85%) and most HSIL was caused by hrHPV (80/86, 93%, 
p<0.001), making an important distinction between disease caused by lrHPV and by 
hrHPV. 
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Immunohistochemical staining patterns in lesions caused by lr- and hr-HPV 
infections
The relationship between expression patterns of p16 and E4, and causative HPV infec-
tion (lr- or hr-HPV) was explored in relation to the LAST classification. Of the lesions 
caused by lrHPV (57), most showed an extensive patchy p16 staining pattern (51/57, 
90%) as shown in Figure 1, but 6/57, 11% showed diffuse p16 staining and were called 
HSIL. Lesions caused by hrHPV showed a diffuse p16 staining pattern in 96% (85/89) of 
cases (example in Figure 2), and the remaining 4 lesions showed a less extensive patchy 
staining pattern that was restricted to the lower one third of the epithelium. There was 
no significant difference in E4 positivity between lesions caused by lr- or hrHPV (E4 
positivity: 22/57, 38.6% of lesions and 36/89, 40.4%, respectively, p=0.823). 
Figure 1: Consensus diagnosis AIN2/HSIL with genotypes HPV 6, 31 and 40 detected in the WTS. Six regions 
were selected for LCM-PCR and HPV40 was identified as the causative genotype of the worst lesion present 
(a). The p16 immunohistochemical stain shows an extensive patchy staining pattern (b, 20.0X magnification 
below) and there is no HPV E4 expression (c, 20.0X magnification below). 
Figure 2: Consensus diagnosis AIN2/HSIL with genotypes HPV 16 and 18 detected in the 
WTS. Six regions were selected for LCM-PCR and HPV16 was identified as the causative 
genotype of the worst lesion present (a). The p16 immunohistochemical stain shows 
full thickness diffuse p16 staining (b, 20.0X magnification below) and there is extensive 
superficial HPV E4 expression (c, 20.0X magnification below). 
Table 4 shows the relation between p16 grade and E4 positivity in HSIL. There was one 
HSIL/AIN3 that had a patchy p16 staining pattern, E4 negativity and was associated with 
lrHPV. In the group of 85 HSIL that showed diffuse p16 positivity (≥grade 2), there was a 
gradual decrease in E4 positivity from 60% (3/5) in HSIL showing p16 in the lower 1/3 of 
the epithelium, to 41% (9/22) of HSIL with p16 in the lower 2/3 and 35% (20/58) in HSIL 
with p16 in more than 2/3 of the epithelium.
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Table 4: The relation between p16 grade and E4 positivity in HSIL.
p16 grade E4 Total
Negative Positive
1 - patchy 1 (100%) 0 1
2 - ≤lower 1/3 2 (40%) 3 (60%) 5
3 - ≤lower 2/3 13 (59%) 9 (41%) 22
4 - > lower 2/3 38 (66%) 20 (34%) 58
Total 54 (63%) 32 (37%) 86
DIsCussIOn 
This study showed that anal HSIL is heterogeneous, with p16 and E4 making comple-
mentary, specific contributions to defining the nature of an anal SIL. This enabled 
separation of HSIL into those expressing both HPV E4 and p16, and those only express-
ing p16. Increasing p16 expression was associated with decreasing E4 expression. This 
variation was partly reflected in the H/E grading of AIN2 and AIN3.
p16 is a surrogate marker for the activity of high-risk HPV E7 26, which has transforming 
activity, but is also necessary for production of viral particles. Its grade increases with 
lesion severity both between LSIL and HSIL and with AIN grading. Its expression pattern 
can largely separate lrHPV infections from hrHPV infections. Importantly, there were two 
distinct extensive patterns of p16 staining, one being extensive patchy staining caused 
by lrHPV infection and the other being diffuse p16 staining caused by hrHPV infection. 
Recognizing the difference is important for accurate classification of lesions. Several 
studies have found similar differences in expression of p16 between lrHPV and hrHPV 
infection in cervical biopsies 27, 28. Some patchy p16 expression is also seen in certain 
physiological states such as metaplasia in the cervix 29, but this is not as extensive as 
seen here.
E4 indicates the continued presence of completion of the life cycle of HPV 19, which 
is found in both LSIL and HSIL. We showed that hrHPV-positive HSIL with evidence of 
transformation as defined by diffuse p16 positivity are not homogeneous: almost half 
show evidence of continuing completion of the HPV life cycle and productive infection 
as indicated by E4 expression. 
We showed that as p16 expression increases there was a decrease of E4 positivity with 
increasing p16 grade. Scoring of p16 and E4 IHC markers has previously been shown to 
be reproducible and separates productive from more advanced transforming infections 
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18, 30. This provides a more reliable potential approach to selecting patients for treatment 
than AIN/SIL diagnosis. 
In this set of biopsies (176/183 from HIV+ MSM, 96.2%), few LSIL lesions (9/60, 15%) 
are associated with hrHPV, and only 6/86 (7%) of HSIL was associated with lrHPV. In the 
case of HIV+ MSM, the clinical implications of HSIL associated with lrHPV are uncertain 
31. Such HSIL/AIN2 lesions showing extensive patchy p16 staining in the absence of E4 
might represent an abortive, non-productive low-risk HPV infection overexpressing HPV 
E7 and not completing the HPV life cycle. The mechanism for strong patchy expression 
of p16 in lrHPV infections is unclear 32.
This study supports the suggestion that anal HSIL represents a very heterogeneous 
group of lesions, consisting of productive lesions that are potentially self-limiting as well 
as transforming lesions with a risk of progression to cancer 14. It also supports the use of 
p16 as a surrogate for hrHPV identification.
Scoring based on immunomarkers has a better inter- and intra-observer agreement com-
pared to grading based on morphology 18, 33 and opens up the possibility of reproducible 
subclassification of the heterogeneity of HSIL. In our study, 37% of HSIL according to our 
LAST diagnosis showed E4 positivity as evidence of productive infections. Previous re-
search in cervical intraepithelial neoplasia (CIN) showed that a dual biomarker approach 
using E4 and p16 can distinguish HPV-associated CIN1 from other pathologies and may 
be used to divide the CIN2 group according to the extent of life-cycle deregulation 17. 
The percentage of E4 positive HSIL lesions (37%) is in line with the percentage of E4 
positive CIN2 lesions that was found by van Baars et al. (43.5%) 18. 
Based on the biomarker expressions used in this study, E4 positive hrHPV associated HSIL 
expressing p16 and lrHPV associated SIL with extensive patchy p16 warrant investiga-
tion of a “wait and see” management policy rather than immediate treatment. Studies of 
serial biopsies and well documented clinical follow-up studies are necessary to establish 
the optimal use of immunohistochemical markers in routine practice and to optimize 
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Expression of p16 and HPV E4 on biopsy 
samples and methylation of FAM19A4 and 
miR124-2 on cervical cytology samples 
in the classifi cation of cervical squamous 
intraepithelial lesions




The decision to treat a cervical squamous intraepithelial lesion (SIL) by loop electrosurgi-
cal excision procedure (LEEP) relies heavily on a colposcopy-directed biopsy showing 
high-grade (H)SIL. Diagnosis is often supported by p16, an immunohistochemical (IHC) 
biomarker of high-risk (hr)HPV E7 gene activity. Additional potential markers include 
methylation of tumour suppressor genes FAM19A4/miR124-2 in cervical cytology for 
advanced transforming HSIL and the IHC marker HPV E4 for productive, potentially re-
gressing lesions. In 318 women referred for colposcopy, we investigated the relationship 
between staining patterns of p16 and E4 IHC in the worst biopsy, and the relation of 
these to FAM19A4/miR124-2 methylation status in cytology. 
E4 positive staining decreased with increasing SIL/CIN grade from 41% in LSIL to 3% in 
HSIL/CIN3. E4 positivity increased with grade of p16 when p16 expression was limited 
to the lower 2/3 of the epithelium (r=0.378), but fell with expression over. Loss of E4 
expression in the worst lesion was associated with methylation of FAM19A4/miR124-2. 
We also examined whether these biomarkers can predict the histological outcome of 
the LEEP biopsy in a subgroup of 119 who underwent LEEP treatment. 85% of women 
with ≥lower 2/3 p16 staining/E4-negative HSIL biopsies and 65% with limited p16 stain-
ing/E4-positive HSIL biopsies had ≥HSIL in the LEEP specimen (p=0.025).
p16 expression in a biopsy is related both to viral production and transformation, while 
decreased E4 expression relates to methylation, indicating advanced HSIL. p16 expres-
sion in ≥2/3 of the epithelium and absent E4 indicate likely HSIL on a subsequent LEEP 
specimen.
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In cervical cancer (CC) prevention, women with an abnormal screening result are sub-
jected to colposcopy to detect of high-grade squamous intraepithelial lesions/cervical 
intraepithelial neoplasia grades 2 and 3 (HSIL/CIN2-3), or CC. Since histological diagnosis 
of HSIL/CIN2-3 is the basis for surgical treatment, accuracy of diagnosis is key. However, 
Hematoxylin and Eosin stain (H&E) diagnosis is subjective and substantial inter-observer 
and intra-observer variability has been reported 1. Previous reports have shown that 
HSIL/CIN3 is more reproducible, but important variation exists in the diagnosis of HSIL/
CIN2. This diagnosis includes both productive lesions that might regress and advanced 
transforming lesions that require treatment and can result in overtreatment 2-4.
The use of biomarkers, whose results are unambiguous and reproducible, may provide 
a solution. Immunohistochemical (IHC) staining with p16, single or in combination with 
the proliferation marker Ki-67, has been identified as a valuable marker in diagnosis of 
≥HSIL/CIN2 5. p16 is a surrogate marker of the cell cycle deregulation by the high-risk hu-
man papillomavirus (hrHPV) E7 gene. The HPV-encoded marker panE4 is a novel marker 
for initiation of the viral productive phase and hence, completion of the papillomavirus 
life cycle 6. It is expressed in productive HPV infection in differentiated, mature epithelial 
cells 7-9. HSIL/CIN3 is almost always negative for E4, while HSIL/CIN2 and LSIL/CIN1 can 
be either E4-positive or negative 7, 9. Current SIL/CIN classifications do not discriminate 
between different biomarker patterns corresponding to productive or transforming 
infection. Grading patterns of expression of biomarkers such as E4 and p16, might play 
an important role in predicting progression of a lesion, deciding treatment and might 
reduce overtreatment of productive lesions that can regress.
Hypermethylation of the CpG islands in promotor regions of several tumour suppres-
sor genes is extremely high in cervical cancer 10 and has been linked to the duration of 
hrHPV infection and the severity of the underlying neoplastic lesion 11. The combination 
of FAM19A4 and miR-124-2 shows particularly high levels of positivity in women with 
cervical cancer and high-grade lesions with a longer duration of a preceding hrHPV infec-
tion 12. Lesions with a cancer-like methylation pattern have been defined as “advanced” 
SIL/CIN lesions. The relation between hypermethylation detected on cytology sample, 
and p16 and E4 expression on biopsy has not previously been studied in a population 
undergoing routine colposcopy for an abnormal screening result.
This study aims to describe the relationships between the immunohistochemical ex-
pression patterns of markers p16 and HPV E4 in hrHPV-positive colposcopy-directed 
cervical biopsy, and also the relationship of these to methylation markers FAM19A4/
Chapter 7
138
miR124-2 in cervical cytology samples of women referred to a colposcopy due to an 
abnormal screening test. In addition, we studied if biomarkers p16/E4 on biopsy and 
methylation on cytology can predict the histological outcome on LEEP in a subgroup of 
119 who underwent LEEP treatment.
meTHODs
Population
The EVAH-study is a follow-up study of women referred to the colposcopy clinic of Hos-
pital Clínic, Barcelona, Spain because of abnormal cytology (≥ASC-US) 13. At colposcopy, 
women had a physician-taken cervical cytology sample and 1-4 colposcopy-directed 
biopsies. Women were treated by LEEP when a HSIL/CIN2-3 diagnosis was found on 
biopsy, when underlying HSIL/CIN2-3 was expected on colposcopic impression, or when 
there was persisting HSIL cytology. Women were invited for a physician-taken cytology 
sample and a colposcopy with biopsies when indicated every six months for two years. 
At the exit visit, a biopsy was taken in all women to collect a histological endpoint. All 
women enrolled before April 2014 were eligible for the present study. The study was ap-
proved by the medical ethical board of Hospital Clínic and signed informed consent was 
obtained from all women. This study is registered in the Dutch Trial Register (NTR3464).
Collection of cervical cytology samples, hrHPV and methylation testing 
Physician-taken cervical cytology samples were collected using a Cervex-Brush (Rov-
ers Medical Devices B.V., Oss, The Netherlands) and were rinsed in 20mL of Thinprep 
medium (Hologic, Marlborough, MA), before colposcopy. Samples were stored at room 
temperature for up to six months before DNA was isolated for hrHPV testing. An input 
volume of 250 μL was used to obtain 100 μL of eluate with the QIAamp MinElute Virus 
Spin kit (QIAgen Inc., Valencia, CA). hrHPV detection was performed using the GP5+/6+-
PCR-EIA (Labo Bio-medical Products, Rijswijk, Netherlands). The EIA-positive GP5+/6+ 
amplimers were genotyped using a strip-based test by the Genotyping kit HPV GP (Labo 
Bio-medical Products, Rijswijk, Netherlands) genotyping hrHPV types 16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 58, 59, 66 and 68. 
Residual material after HPV testing and cytology was concentrated and sent to DDL Di-
agnostic Laboratory for methylation testing 14. DNA was isolated using the MagNA Pure 
96. The level of amplifiable human DNA was assessed using a qPCR of the in-house refer-
ence gene RNaseP with the Phocine herpesvirus as an internal control for the absence 
of PCR-inhibition 15. All samples with a DNA concentration of 2.2 ng/µl or higher were 
subjected to bisulfite conversion using the EZ DNA Methylation kit (Zymo Research, 
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Orange, CA, USA). Samples with a DNA concentration below the threshold allowing reli-
able methylation testing in a physician-taken sample were excluded. Up to 250 ng/45µl 
of DNA was used, with 3µl carrier RNA if samples contained less than 100ng/45µl. A stan-
dardized multiplex qMSP, targeting for the promotor regions of FAM19A4 and miR-124 
(QIAsure Methylation Test, Qiagen, Hilden, Germany), was performed on the bisulfite 
converted DNA. The bisulfite-converted human reference gene beta-actin was included 
in the multiplex to determine the total amount of converted human DNA. Samples were 
scored methylation positive when at least one of the markers had a target gene/beta-
actin ratio above the threshold according to the kit insert. Results of marker FAM19A4 
were also studied individually.
sectioning and HPV testing of histology
Histologic samples were fixed in 10% neutral buffered formalin and embedded in paraf-
fin following routine procedures. Four micrometre sections were obtained for H&E and 
p16 staining and these were assessed by an expert local pathologist following morpho-
logic criteria supported by p16 staining according to the LAST recommendations 5. This 
diagnosis was used to decide treatment. Diagnoses on the LEEP specimens were made 
following the same procedure.
Biopsies were recut at DDL Diagnostic Laboratory, Rijswijk, The Netherlands according to 
the sandwich methods, producing one 4-µm-thick H&E before slide, two tubes with three 
8-µm-thick sections for HPV testing, three 4-µm-thick slides for immunohistochemistry, 
a 4-µm-thick H&E after slide and up to three 4-µm-thick back-up slides. Diagnoses based 
on H&E and IHC recut slides were considered as the definitive diagnosis. DNA for HPV 
detection and genotyping was isolated using proteinase K isolation and SPF10-PCR-
DEIA-LiPA25 (version 1, Labo Biomedical Products BV, Rijswijk, The Netherlands). Women 
for whom the worst diagnosis on the local histology slide was more than one SIL/CIN 
grade different from the recut histology slides were excluded. This was done as the study 
histology could not be considered a reliable indicator of the lesion on which treatment 
was based. Those whose biopsy was hrHPV-negative by SPF10-PCR-DEIA-LiPA25v1 were 
also excluded. 
p16 and e4 immunohistochemistry on biopsies
The biopsy with the worst diagnosis was then stained for p16, using p16INK4a antibody 
(Roche, CINtec®, Clone E6H4™) and panHPVE4 mAb (LBP, Clone FH1.1), respectively, after 
heat-induced epitope retrieval with citrate buffer (Dako, CA, USA). Reactivity was visual-
ized using the EnVision Detection System (Dako, CA, USA).
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Two expert pathologists, blinded to the local histological diagnosis, were asked to score 
the worst lesion for E4 and p16. Biomarker p16 was scored negative (0) when no staining 
or patchy staining was observed, diffuse staining restricted to the lower third of the epi-
thelium was scored as 1, staining restricted to the lower two third of the epithelium was 
scored as 2 and staining above the lower third of the epithelium, including full thickness 
staining, was scored as 3. E4 staining was scored negative (0), focal when limited positive 
staining was seen in the superficial layer of the epithelium (1) or extensive when there 
was widespread positive staining in the superficial layer of the epithelium and or below 
(2). This grading system has been previously validated as reproducible 9, 16. p16 score ≥1 
and E4 score ≥1 were considered positive scores for these markers.
To investigate further the relation between p16 and E4 expression and outcome we 
combined scores of p16 and E4, and used this to predict the presence of ≥HSIL/CIN2 
and ≥HSIL/CIN3 on LEEP treatment. Lesions with p16 expression restricted to the lower 
1/3 of the epithelium, or less, and all lesions with E4 positivity regardless of p16 expres-
sion were classified as combined IHC negative. In line with the LAST recommendations, 
all biopsies expressing p16 above the lower 1/3 of the epithelium 5, and no E4 were 
considered combined IHC positive.
statistical analysis
Results were analysed using IBM SPSS version 22.0 for Windows (Chicago, IL, USA). The 
level of statistical significance was set at p≤0.05 for all tests. Correlation coefficients for 
HPV E4 positivity and methylation positivity were calculated using Spearman’s correla-
tion test and differences in positivity percentages were calculated using the Chi-squared 
test. 
ResulTs
A total of 538 women had a smear which was eligible for methylation testing and in-
terpretation of the result 14. Of these women, 482 remained after exclusion of biopsies 
which had a worst diagnosis on the newly sectioned slide which was more than 1 grade 
apart from the consensus diagnosis on the locally produced histology slide. Exclusion of 
hrHPV negative biopsies (87.2% histologically negative biopsies) resulted in a selection 
of 318 women who met the inclusion criteria.
The definitive diagnoses on the recut biopsy used for new H&E and IHC slides were: 
90 no CIN (28.3%), 67 LSIL/CIN1 (21.1%), 95 HSIL/CIN2 (29.9%), 62 HSIL/CIN3 (19.5%), 4 
cervical carcinomas (CC) (1.2%). 
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Hypermethylation of fam19a4 and/or miR124-2 on cytology sample 
The methylation positivity for markers FAM19A4 individually and combined with miR124-
2, in the cytology samples of these women according to the definitive histological diag-
nosis are shown in Table 1. Methylation positivity for markers FAM19A4 and miR124-2 
increased with the severity of the lesion: 23.2% of women with no CIN biopsies were posi-
tive for one or more markers compared with 66.1% of women with HSIL/CIN3 biopsies.
FAM19A4 was more frequently positive than miR124-2 in both ≤LSIL/CIN1 (23.6%, 
37/157 compared to 8.9%, 14/157 for miR124-2, p<0.001), and in ≥HSIL/CIN2 (54.7%, 
88/161 compared to 37.9%, 61/161 for miR124-2, p<0.001).
expression of p16 and HPV e4 on colposcopic biopsy
The grades of p16 positivity and HPV E4 positivity by worst SIL/CIN grade on the worst 
histological lesion found on colposcopy-directed biopsy are shown in Table 2. p16 grade 
increased with the severity of the lesion, with 85/90 (94.4%) no CIN biopsies showing no 
or patchy p16 staining and all HSIL/CIN3 lesions showing p16 in at least the lower 2/3 
of the epithelium or above. None of the no CIN biopsies and only 2/64 (3.1%) of HSIL/
CIN3 and none of the ICC showed any E4 positivity, while 27/67 (40.3%) LSIL/CIN1 and 
21/95 (22.1%) HSIL/CIN2 were E4 positive. The highest percentage of E4 positivity was 
found among lesions with p16 expression in the lower 2/3 of the epithelium (p16 score 
2) (37.3%; 22/59), containing 44.0% (22/50) of all E4 positive lesions.
Table 1: Hypermethylation of single marker FAM19A4, and FAM19A4 and miR124-2 combined in cytology 
samples related to different histological grades of CIN (N=318). 
Diagnosis (N) FAM19A4 positive (%) FAM19A4 and/or miR124-2 positive (%)
Negative (90) 20 (22.2%) 21 (23.2%)
LSIL/CIN1 (67) 17 (25.4%) 17 (25.4%)
HSIL/CIN2 (95) 43 (45.3%) 44 (46.3%)
HSIL/CIN3 (62) 41 (66.1%) 41 (66.1%)
CC (4) 4 (100%) 4 (100%)




No CIN (N=90) LSIL/CIN1 (N=67) HSIL/CIN2 (N=95) HSIL/CIN3 (N=62) CC (N=4)
E4 positive E4 positive E4 positive E4 positive E4 positive
0 – negative (N=103) 0/85 (0%) 7/15 (47%) 0/3 (0%) 0/0 (0%) 0/0 (0%)
1 - lower 1/3 (N=27) 0/2 (0%) 7/20 (35%) 1/5 (20%) 0/0 (0%) 0/0 (0%)
2 - lower 2/3 (N=59) 0/3 (0%) 7/15 (47%) 13/27 (48%) 2/14 (14%) 0/0 (0%)
3 - >lower 2/3 (N=129) 0/0 (0%) 6/17 (35%) 7/60 (12%) 0/48 (0%) 0/4 (0%)
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Relation between p16 and e4, and p16 and methylation
Figure 1 shows the relation between p16 grade of worst lesion on colposcopy-directed 
biopsy, methylation of markers FAM19A4 and miR124-2 as detected on cytology sample 
and E4 grade of worst lesion on biopsy. 
Expression of E4 increased with increasing p16 expression with the highest percent-
age of E4 positivity seen in lesions with p16 in the lower 2/3 of the epithelium (37.3%). 
However, in lesions that express p16 above the lower 2/3 of the epithelium, E4 positiv-
ity dropped to 10.1% (p<0.001). In biopsies showing p16 up to 2/3 of the epithelium 
(n=189), there was a significant correlation between p16 expression and E4 expression 
(r=0.378, p<0.001).
Of the women with lesions showing no or patchy p16 expression, 26.2% (27/103) had 
a FAM19A4 and/or miR124-2 methylation positive cytology sample. The frequency 
dropped to 18.5% methylation positive cytology samples in women with lesions show-
ing p16 in the lower 1/3 of the epithelium but increased to 42.4% methylation positivity 
in women with p16 in the lower 2/3 of the lesion and 54.3% in women with lesions 
showing p16 above the lower 2/3 of the epithelium. There was a significant correlation 
between grade of p16 expression on biopsy and methylation positivity on cytology 
sample (r=0.261, p<0.001).
Relation between methylation and p16/e4 expression in ≥lsIl/CIn1 lesions
The relation between hypermethylation of markers FAM19A4 and/or miR124-2 on cytol-
ogy sampling and E4/p16 on the worst histological lesion on biopsy was explored by se-
lecting all ≥LSIL/CIN1-3 lesions and ICC’s with diffuse p16 expression in at least the lower 
1/3 of the epithelium (n=210). In this group, an inverse relation was found between E4 
and FAM19A4/miR124-2. Figure 2 shows the positivity for marker FAM19A4 as a single 
marker and combined with (and/or) miR124-2 in E4 negative and E4 positive lesions. 
Of the biopsies negative for HPV E4, 52.1% belonged to women with cytology samples 
positive for methylation marker FAM19A4, which was a significantly higher percentage 
than the 27.9% of women with E4 positive biopsies who had a cytology sample positive 
for methylation marker FAM19A4 (p=0.005). The same pattern was observed for the 
combination of FAM19A4 and/or miR124-2 methylation markers, which was positive in 
52.1% of the women with E4 negative biopsies and 30.2% of the women with E4 positive 
biopsies (p=0.010). 
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0 - negative 1 - lower 1/3 2 - lower 2/3 3 - >lower 2/3-full
thickness
E4 and methylation positivity in women with cervical lesions 
with different grades of p16 (n=318)
E4 positive FAM and/or miR positive
Figure 1: E4 positivity on biopsy (Normal-ICC) and methylation positivity on cytology sample (FAM19A4 












E4 negative E4 positive
All ≥CIN1 with p16≥1 (n=210)
FAM19A4 Positive FAM19A4 and/or miR124-2 Positive
Figure 2: Positivity for marker FAM19A4 and markers FAM19A4 and miR124-2 combined (and/or) in cytol-
ogy samples, in E4 negative and E4 positive LSIL/CIN1 lesions with diffuse p16 expression in at least the 
lower 1/3 of the epithelium (p16≥1). 
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Relation of p16/e4 status of worst colposcopic biopsy lesion and methylation 
status to detection of ≥HsIl/CIn2 on leeP treatment
To find out whether p16/E4 marker patterns on colposcopy-directed biopsy or FAM/miR 
on the cytology sample were predictive for ≥HSIL/CIN2 found on LEEP, 119 women with 
HSIL/CIN2-3 on biopsy treated by LEEP were investigated. Of these women, 22 (18.5%) 
with a mean age of 40.1y had a worst diagnosis of ≤LSIL/CIN1 on LEEP, and 97 (81.5%) 
women with a mean age of 37.5y had a worst diagnosis of ≥HSIL/CIN2 on LEEP. 
Table 3 shows the relation between biopsy diagnosis, worst diagnosis on LEEP specimen, 
and p16/E4 on biopsy and methylation positivity on cytology sample. Of the treated 
≥HSIL/CIN2 lesions, 17 (14.3%) were E4 positive and 102 (85.7%) were E4 negative. How-
ever, grade of p16 expression in relation to E4 expression was important. Lesions with 
p16 expression restricted to the lower 1/3 of the epithelium, or less, and all lesions with 
E4 positivity were classified as combined IHC negative. All biopsies expressing p16 in 
at least the lower 2/3 of the epithelium and no E4 were considered combined IHC posi-
tive. Of the combined IHC negative lesions on biopsy 65.2% (15/23) were confirmed as 
≥HSIL/CIN2 lesions on LEEP, and 85.4% (82/96) combined IHC positive lesions on biopsy 
were ≥HSIL/CIN2 on LEEP (p=0.025). The same was done for the outcome of ≥HSIL/CIN3 
on LEEP, showing that 26.1% (6/23) of women with combined IHC negative biopsies and 
49.0% (47/96) of women with combined IHC positive biopsies had ≥HSIL/CIN3 on LEEP 
(p=0.047).
Table 3: Women treated after HSIL/CIN2-3 on biopsy (N=119) and the relation to p16/E4 positivity on bi-
opsy, methylation positivity (FAM19A4 and/or miR124-2) on cytology sample and worst diagnosis on LEEP.
Lesions with p16 expression restricted to the lower 1/3 of the epithelium, or less, and all lesions with E4 
positivity regardless of p16 expression were classified as combined IHC negative.
All biopsies expressing p16 in at least the lower 2/3 of the epithelium and no E4 were considered combined 
IHC positive.










≤LSIL/CIN1 ≥HSIL/CIN 2 ≤HSIL/CIN2 ≥HSIL/CIN 3
Count (%) Count (%) Count (%) Count (%)
Combined IHC 
on biopsy
Combined IHC negative (23) 8 (34.8%) 15 (65.2%)
0.
02




Combined IHC positive (96) 14 (14.6%) 82 (85.4%) 49 (51.0%) 47 (49.0%)
Methylation 
on cytology 
Methylation negative (47) 11 (23.4%) 36 (76.6%)
0.
26




Methylation positive (72) 11 (15.3%) 61 (84.7%) 35 (48.6%) 37 (51.4%)
Of the 119 women who were treated after a ≥HSIL/CIN2 lesion on biopsy, 60.5% (72/119) 
had a FAM and/or miR methylation positive sample and 39.5% (47/119) had a meth-
ylation negative sample. ≥HSIL/CIN2 on LEEP occurred in 84.7% (61/72) methylation 
positive women and 76.6% (36/47) methylation negative women (p=0.264). Among the 
methylation negative women there were 34.0% (16/47) with ≥HSIL/CIN3 on LEEP (all 
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HSIL/CIN3), and among women with methylation positive samples there were 51.4% 
(37/72) with ≥HSIL/CIN3 (including 2 CC’s) (p=0.063).
DIsCussIOn
This study shows that in women who have hrHPV positive SIL/CIN there are complex 
relationships between expression patterns of the widely used immunohistochemical 
marker p16 and novel immunohistochemical marker E4 on biopsy. They also show 
relationships between these biopsy markers and the methylation markers FAM19A4/
miR124-2 on cervical cytology sample. Firstly, there is an inverse relation between pro-
ductive infection as shown by HPV E4 positivity in the worst lesion present on biopsy, 
and methylation of markers FAM19A4 and miR124-2 on cytology which are associated 
with transforming HPV infection. In women with diffusely p16 positive ≥LSIL/CIN1, a dif-
ference in FAM19A4 and/or miR124-2 positivity rates was found between women with 
lesions expressing E4 and those that did not: 52.1% of women with E4-negative and 
30.2% with E4-positive biopsies were positive for the methylation markers (p=0.010).
These results are consistent with previous studies on selective series of expression of 
somatic tumour suppressor gene methylation markers and IHC for p16 and E4 and 
extend the observations to women attending routine colposcopy for an abnormal cervi-
cal cytology sample 17. Van Zummeren et al. found an inverse relation between HPV E4 
expression and methylation positivity for marker combination CADM1/MAL/miR124-2 
detected on biopsy. 
In addition, previous work showed that a cumulative immunoscore of p16 and Ki-67 
improved accuracy and reproducibility of CIN grading compared to current practice 18. 
These studies and the present study showed that whereas cervical cancer shows no E4 
expression and often expresses both p16 and methylation marker positivity, LSIL/CIN1 
and HSIL/CIN2 are very heterogeneous and complex groups, consisting of productive in-
fections expressing E4 and transforming lesions expressing variable p16, some of which 
show methylation marker positivity. The use of the E4 immunomarker and methylation 
markers in this group could offer more detailed information beyond current SIL/CIN 
grading practice and the use of p16 alone.
E4 positivity was related to p16 positivity and histology in hrHPV-positive biopsies in a 
rather complex way. E4 was absent in no CIN biopsies, was 40% in LSIL/CIN1, decreased 
to 22% in HSIL/CIN2 and 3% in HSIL/CIN3 and was again absent in cancer. The rate of E4 
positivity increased with grade of p16 expression (r=0.378) up to 37% in lesions with p16 
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in the lower 2/3 of the epithelium, but fell to 10% when p16 expression was above 2/3 
of the epithelium. 
Hypermethylation of FAM19A4 and/or miR124-2 on cervical cytology sample increased 
with the grade of SIL/CIN, but there was some positivity (24%) in ≤LSIL/CIN1, rising to 
66% in HSIL/CIN3 and was seen in all cancers. Methylation positivity progressively in-
creased with grade of diffuse p16 positivity (18.5% in lesions with p16 in the lower 1/3 to 
54.3% in lesions with p16 up to full thickness). There was also some (26.2%) methylation 
in samples of women with lesions negative or patchy for p16 IHC. 
p16 is widely used as marker of transformation in hrHPV associated cervical cancer and 
precancer, but this study shows that it is also expressed in up to the lower 2/3 of cervical 
epithelium in lesions showing completion of the HPV life cycle and HPV production by 
E4 expression, and that increasing extent of p16 expression up to 2/3 of the epithelium 
is associated with more frequent E4 expression. This is consistent with expression of 
p16 as a surrogate for hrHPV E7 expression and the important role of E7 in driving the 
increased epithelial proliferation above the basal layer necessary for viral reproduction, 
as well as playing a part in driving neoplastic transformation. This finding explains the 
difficulty of using p16 on its own as a reliable transformation marker in SIL/CIN diagno-
sis. Only expression of p16 above 2/3 of the epithelium is associated with infrequent 
E4 expression showing loss of viral life-cycle completion with virus production and 
increased frequency of methylation of tumour suppressor genes. 
We also found evidence that p16 expression and E4 positivity on the worst colposcopy-
directed biopsy related to the frequency of finding HSIL/CIN2 and HSIL/CIN3 on LEEP in 
women treated for ≥HSIL/CIN2. Our results support the view that lesions with diffuse 
p16 expression limited to the basal third and E4 positivity are likely to be smaller and/
or more regressive lesions. Luttmer et al. have previously shown an increasing positivity 
rate for FAM19A4 analysis performed on cervicovaginal self-samples and cervical cytol-
ogy samples with the severity and volume of the lesion 19. In the present study, a meth-
ylation positive cytology sample showed no significant relation to treatment outcome.
This study was performed in a selected group of women who were referred for col-
poscopic examination after an abnormal Pap-smear result, who had a hrHPV-positive 
cervical biopsy and had cervical cytology samples suitable for methylation testing. 
Methylation status was only determined in the cervical cytology samples and not on 
biopsy. However, a previous study from van Baars et al. confirmed that the methylation 
status of the cervical cytology sample represents the methylation status of the worst 
lesion present on the cervix when taking biopsies of all lesions detected during col-
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poscopy together with a random biopsy of normal appearing tissue 9. Sensitivity of 
colposcopy for the detection of ≥HSIL/CIN2 is between 50-70% 20-23 and methylation 
positivity on cytology in the absence of high-grade disease on biopsy could possibly 
originate from a high-grade lesion that was missed on colposcopy.
We used a reference standard diagnosis in which the opinion of at least three patholo-
gists was reflected, and which assured that the worst lesion was present in all tested 
material. It is known that reproducibility of diagnosis of LSIL/CIN1 and HSIL/CIN2 is 
limited and intra- and inter-observer agreement is moderate 5, 24. By excluding women 
in which the SIL/CIN colposcopy-directed biopsy diagnosis of the worst lesion on the 
newly produced slide differed more than one histological grade from the consensus 
diagnosis on the local slide, we attempted to use the most accurate reference standard 
diagnosis as possible, still allowing for biomarker expression identification. 
Large prospective studies are needed to investigate the outcome of E4 positive and 
negative LSIL/CIN1 and HSIL/CIN2. Currently available methylation markers have shown 
good clinical performance in the detection of advanced transforming precursor lesions 
and cervical cancer in hrHPV positive women. In addition, results from a large follow-up 
study have shown a low cervical cancer risk for hrHPV positive women with a negative 
FAM19A4/miR124-2 triage test result, offering an objective triage test in hrHPV-based 
screening programs 25. We found that FAM19A4 has the major contribution to predicting 
presence of HSIL/CIN3 as compared to miR124-2. We scored methylation markers posi-
tive or negative, without taking into account the hypermethylation levels. Studies on 
tumor suppressor genes CADM1 and MAL showed increasing levels of hypermethylation 
towards cervical cancer 11. Future studies are needed to demonstrate whether FAM19A4 
and miR124-2 methylation positivity levels differ between women with E4 positive and 
E4 negative lesions. 
Our results show that there is a possibility of more specific diagnosis of CIN when us-
ing grading of patterns of immunohistochemical expression of HPV E4 in combination 
with p16INK4A. Lesions with diffuse, but limited p16 positivity and E4 positivity most 
likely represent early transforming and productive lesions with variable HPV life-cycle 
completion and might have a higher probability of spontaneous regression. Exten-
sively p16 positive, E4 negative lesions in patients and those with a methylation positive 
cervical cytology sample are more often ≥HSIL/CIN3 lesions and most likely represent 
advanced transforming lesions that require LEEP treatment. Further studies are required 
to establish the progression risk of different biomarker expression patterns in women 
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Development of a patient-friendly, reproducible and accurate approach to identifying 
women at risk of cervical cancer, and men and women from high-risk populations at 
risk of anal cancer is the focus of this and other research trying to improve screening 
and cancer prevention. The aim is that the approach should improve the specificity and 
sensitivity of existing screening and simplify or circumvent the complex multi-stage 
triage processes in use in screening in developed countries. It is important that any 
new test is also cost-effective and easily implementable in current Western health care 
systems, addressing other current limitations, particularly incomplete coverage. Ac-
curate identification and simplification of the follow-up of screen-positive people with 
accurate selection for treatment is also an important aim for developing screening in 
low- and middle-income countries (LMIC). Costs and finding the most optimal screening 
are subject to various factors and influences and cannot always be determined at an 
early stage of development. Accurate assessment of test reproducibility and accuracy is 
the key to initially evaluating new tests.
Optimal risk assessment for an individual and a test has to take into account a thorough 
understanding of natural history of HPV infection and cancer development, including 
differences and similarities between the infected sites and relevant cell types, HPV 
genotypes, subtypes or isolates1. Patient related factors such as immune status or 
demographics need to be considered when searching for a strategy with optimal perfor-
mance 2. A full assessment involves the patient, policy makers, clinicians, pathologists, 
molecular biologists, epidemiologists and other health care providers. This makes it 
complex to come up with a safe and efficient algorithm for the detection and evaluation 
for treatment in both cervical and anal cancer prevention 3, 4.
This thesis is focussed on the evaluation of molecular markers that can be used in cervi-
cal screening and in anal cancer prevention. One important aspect is the investigation of 
the performance of molecular markers for use on the primary screening sample in cervi-
cal screening. This especially studies those that could be carried out on self-sampled 
material and provide less ambiguous results than current practice of hrHPV testing with 
or without limited HPV typing to separate patients in need of direct treatment from pa-
tients for whom close follow-up is appropriate and patients with a low cancer risk. Both 
viral factors such as type and multiple infections, and host factors such as methylation 
of tumour suppressor genes involved in cancer development were explored in relation 
to cervical and anal cancer prevention.
The second focus is on the use of cervical and anal biopsy at the stage of colposcopic 
or anoscopic evaluation of detected lesions. This is a key part of the decision to treat a 
screen-detected lesion but is based on subjective assessment by a pathologist. More 
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reproducible tests at this stage that can specifically identify progressive lesions needing 
surgical treatment are needed to avoid over-treatment. In this general discussion, the 
findings in both these areas of practice are placed in the light of the wider research 
progress, and a possible future perspective is outlined.
biomarkers at the screening sample level
Cervical cancer screening
Very importantly, the change to primary hrHPV screening has made the introduction 
of self-sampling into the cervical screening programme possible. Self-sampling is more 
convenient than visiting the doctor’s office for a clinician-taken smear and has proven 
to extend the reach of the screening program by including a proportion of former 
non-responders 5-9. Several self-sampling devices have been evaluated and the Evalyn 
Brush is currently used in the Dutch screening program. This brush-based self-sampling 
device is inserted in the vagina, collecting cervicovaginal cells which cannot be used for 
cytological reviewing but are suitable for HPV testing 10. Urine self-sampling has been 
found convenient and acceptable by women and is even less invasive 11.
In chapter two, we studied the sensitivity of hrHPV and genotyping in self-collected 
urine samples in the morning and later on during the day, brush-based self-samples, and 
clinician-taken smears for the detection of CIN2+ in a cytology-screened colposcopic 
referral population. We found a high agreement for hrHPV detection and genotyping in 
paired urine samples, brush-based self-samples and clinician-taken smears. Our study 
shows that, in a referral population, CIN2+ detection using HPV testing of first-void urine 
samples shows a sensitivity similar to that of clinician-taken samples or brush-based 
self-samples. In addition, urine self-sampling was found convenient to use for women.
It is still unclear whether a triage test could be carried out on urine. Urine samples 
work because they collect the shed cells from the cervix, among other cells from the 
urogenital tract 12. However, the contribution of cervical cells in relation to that of 
cells originating from other epithelial sites is not known. In triage tests such as meth-
ylation testing, differences in sampled cells might be important. Firstly, because a low 
proportion of cervical cells might lead to missing cervical lesions. Secondly, because 
some methylation markers are not tumor specific but are general tumor markers and a 
positive test might not only detect cervical dysplastic lesions, but also lesions residing 
in the bladder or elsewhere in the urinary tract 13. Studies have shown that methyla-
tion testing to detect cervical cancer in urine samples is possible when using the right 
work-up and markers 14, 15. Whether these markers are also sensitive for the detection of 
other cancers is not known. In addition to determining the possibilities and limitations 





be used for a test-of-cure after LEEP treatment of cervical precancer. Such a test could be 
self-collected at home after treatment and prevent unnecessary visits to the colposcopy 
clinic for cervical sampling.
Currently, hrHPV genotyping for HPV16/18 is the most frequently used triage test after 
cytology-based, hrHPV-based or co-testing-based screening 16-18 and has as a great 
advantage that it can be performed on both clinician-taken samples and self-collected 
samples. In the search for an objective and reproducible triage strategy with good clini-
cal performance, we tested various molecular markers on clinician-taken samples and 
self-samples.
In Chapter 3, the performance of hrHPV-testing and genotyping (GP5+/6+), and 
methylation testing of human tumor suppressor genes FAM19A4 and/or miR124-2, 
and different combinations of those, for the detection of CIN3 and cervical carcinoma 
was compared in women with an ASC-US/LSIL or ASC-H/AGC/HSIL Pap smear result. By 
combining HPV16/18 genotyping and methylation analysis we found a very sensitive 
strategy for the detecting of women with HSIL/CIN3+, which offered improved specific-
ity compared to hrHPV alone. The study shows that testing for hrHPV and methylation 
performed on liquid-based cytology samples in a cytology-screened population could 
help early and accurate identification of HSIL/CIN3+. It also demonstrated that HSIL/
CIN3+ is a very heterogeneous group which consists of both methylation positive and 
methylation negative lesions.
A methylation negative cytology sample in a woman with HSIL/CIN3+ on biopsy may 
be found in younger women with a shorter duration of HPV infection or an infection 
following a different pathway 19, 20. Also, colposcopy has its limitations with a sensitivity 
of CIN2+ of 50-70% 21-24 and lesions might be missed, especially when higher up in the 
cervical canal. hrHPV genotyping or moreover methylation testing of screening sample 
and histology sample might provide important information about representability of 
both sampling modalities.
Chapter 4 studied whether genotyping for HPV16/18 as a triage test on hrHPV positive 
brush-based self-samples can identify the worst underlying lesion. In addition, we stud-
ied whether any differences in hypermethylation of FAM19A4/miR124-2 exist between 
CIN lesions caused by different hrHPV types. We observed that the causative genotype 
of the worst underlying lesion is detected in almost all self-samples. And we found that 
there are no significant differences in positivity for these markers between CIN lesions 
caused by different types of hrHPV 25.
Chapter 8
156
However, this finding does not explain why infections with certain hrHPV genotypes, 
particularly HPV16 are more prone to develop into cancer. In addition, hypermethyl-
ation detects long-lasting hrHPV infections resulting in advanced transforming lesions 
but far from all of these lesions will actually develop into cancer 26. The combination of 
methylation markers FAM19A4/miR124-2 that was used in our studies does not only 
detect women at risk of progression to cancer, but also detects hypermethylation in 
women with persisting hrHPV infection and women of older age 27, 28. Follow-up stud-
ies of women with a positive methylation test at baseline are needed to address this 
important question before methylation testing can be introduced in clinical practice 29.
Anal cancer screening
In anal cancer screening, collecting representative anal cytology sampling and more-
over anal self-sampling is challenging because of the anatomy of the anal canal with its 
folds and circular configuration, because of contamination with faeces. In addition, the 
prevalence of HPV DNA in the anal canal is high, but a correlation between anal HPV 
infection and a suspicious anal cytology is infrequently observed 30 31. Samples are taken 
with a dacron swab and not with a cervix brush because of the fragility of the anal canal, 
making it more difficult to collect a sample with sufficient cell density. This limits the 
tests that can be performed on an anal swab: an anal cytology result of HSIL is specific, 
but anal cytology lacks sensitivity 32 33. Immune stainings give the same problem. Low 
cell count of anal swabs results in low human DNA concentrations, making methylation 
testing challenging. Special brushes are being developed and possibly better instruc-
tions for talking samples and better preservatives could help 34. In HIV positive MSM, 
HPV screening in anal samples is not an option because of the high prevalence of HPV in 
this population 35. Studies have shown that a genotype specific persistent hrHPV infec-
tion could help detect underlying AIN2+ lesions 36 37. hrHPV detection on anal samples 
could open the possibility of selective HRA.
biomarkers at the histology sample level
There are a lot of improvements that could be made regarding identification of men 
and women with a true high-grade lesion that might progress to cancer. Firstly, we 
need better and more objective and reproducible markers to grade lesions, so that we 
can better compare lesions and results between centres, studies and countries. These 
markers should provide us with more information about the natural history. Current 
nomenclature groups lesion types that are molecularly significantly different under the 
same diagnosis 38, 39 . We need improved differentiation of lesions to discriminate those 





The immunohistochemical markers that were studied in this thesis, p16 and HPV E4, 
could provide part of the solution. Besides the fact that these immunohistochemical 
markers are easier to interpret, are more objective and more reproducible 40, they also 
tell us something about the current status of the lesion.
In Chapter 5, we used p16, HPV E4 and Ki-67 to describe different immunohistochemical 
staining patterns in anal biopsies. The patterns that we found suggest that division of 
lesions into LSIL and HSIL is simplistic and that by combining p16 and Ki-67 with E4 
productive AIN lesions can be distinguished from advanced transforming AIN. Ki-67 
helps separate LSIL from normal tissue, while the combination of HPV E4 and p16 helped 
identify productive infections, which are E4 positive, and advanced transforming infec-
tions which are diffusely p16 positive and E4 negative.
In AIN in HIV+ MSM, both lrHPV and hrHPV can be found in LSIL and HSIL.
In Chapter 6, we used the combination of HPV E4 and p16 immunohistochemistry to 
improve definition of lr- and hr-HPV associated AIN in HIV+ MSM. Our study showed that 
combined p16/E4 staining identifies both productive and non-productive LSIL associ-
ated with lrHPV and HSIL associated with hrHPV, proving detailed information about 
AIN which is not provided by H/E staining alone. E4 positivity in the worst lesion on 
biopsy identifies a productive infection, while absence of E4 in a diffusely p16 positive 
HSIL uncovers a possibly advanced transforming infection which might be methylation 
positive.
The exact position of concurrent use of both immunohistochemical markers in routine 
pathology practice is not clear yet, p16/E4 dual staining and better define progression 
risk of the different biomarker expression patterns, performing this double stain on all 
≥CIN1/AIN1 would be highly recommendable. Before we will be able to do this, more 
research on the p16/E4 staining patterns in relation to other markers such as other im-
munohistochemical markers (SCJ markers), methylation markers (both human tumour 
suppressor gene methylation and viral methylation markers) and markers that can tell 
us more about immune response and cell origin (HPV E6/E7 serology, messenger RNA) 
should be done.
The use of additional immunohistochemical (IHC) markers such as Ki-67 have shown 
to not significantly improve histological diagnosis of HSIL or improve reproducibility of 
a HSIL diagnosis when interpreted together with H/E and p16 41. When interpreting all 
together, p16 staining seems to be leading in detecting HSIL and Ki-67 staining patterns 
are more difficult to interpret 42. However, when H/E morphology is no longer considered 
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and p16 and Ki-67 are used to provide an objective immunoscore, van Zummeren et al 
found that CIN3+ lesions can be detected in a highly sensitive and specific manner when 
a maximum score for both markers is set as the cut-off, and that this immunoscore im-
proves agreement between pathologists 43. Thus, this immunoscore was not developed 
to provide additional information on biology of the lesion or progression risk, but to 
improve agreement between pathologists. An objective and reproducible gold standard 
diagnosis is important for epidemiologic research studying risk factors for progression 
risk, and when introduced in routine pathology could reduce overtreatment.
In Chapter 7, the relationships between the immunohistochemical expression patterns 
of markers p16 and HPV E4 in biopsies and methylation markers FAM19A4/miR124-2 in 
cervical smears of women with different grades of CIN and negative controls associated 
with hrHPV infection was studied. The inverse relation that we demonstrated between 
HPV E4 expression on biopsy and methylation marker positivity on both biopsy and 
cervical swab is important, but implications for carcinogenesis and clinical management 
are not clear yet. HSIL lesions that are both E4 and methylation positive are not well 
understood. New hypotheses suggest that productive lesions arise from other cell types 
than advanced transforming infections, and that lesion development is possibly not a 
continuum but represents a difference in origin with different progression risk. The use 
of IHC markers to identify lesions arising from HPV infections of the squamocolumnar 
junction (SCJ), with a higher chance of progression to cancer, has been studied by Herfs 
et al. And although other groups have not found associations as strong, the idea that 
different cell origins produce lesions with different progression risks is carried widely 
across the scientific population 19. Doorbar et al have used immunofluorescence to 
show differences between lesions located at the ectocervix and lesions called atypical 
metaplasia, arising from the reserve cells in the squamocolumnar junction 44. In these 
studies, proliferation marker MCM and p16 and E4 showed different biomarker expres-
sion patterns between the different lesion types using immunofluorescence. Such a 
study in respect to immunohistochemical marker scoring of p16 and E4 has not yet been 
performed but might help explain the significance of the different biomarker expression 
patterns found in this thesis. For example, HSIL with p16 up to 1/3 and no E4 expression 
in the upper cell layers could represent a regressing ectocervical lesion and its recogni-
tion could lead to an important reduction in overtreatment.
In addition, we need to better understand what the molecular differences mean for can-
cer risk. As long as all women with CIN2+ are treated, removing the entire transforma-
tion zone, it is very hard to discover markers of progression or regression. This however is 





and future markers. The first studies of methylation markers in women undergoing ac-
tive surveillance for CIN2/3 are now being conducted 45, 46.
AIN treatment can only be done through local ablation and AIN therefore has a high 
recurrence rate after treatment 47. The efficacy of treatment has therefore not very well 
been defined and so AIN natural history studies not treating anal HSIL do exist, with 
two large trials currently ongoing (SPANC and ANCHOR) 48, 49. Results from those studies 
might also teach us about both AIN and CIN since there are various great similarities 
between AIN and CIN, but they are not the same and the patient populations are not 
the same. Although the same types of epithelium cover both the anal canal and the 
cervix, they are different sites with different microbiomes 50, 51. Another difference, which 
possibly has to do with the fact that a lot of the AIN patients in studies are HIV+ MSM, is 
that lrHPV is often found in AIN lesions 52-54. Most lrHPV infections will cause condylomas 
and flat LSIL, but some of these condylomas also harbour a HSIL area with hrHPV, or 
even cause a HSIL lesion on their own 55. Therefore, genotyping might not be sufficient 
as a stand-alone test for risk assessment, but it is a very helpful tool in getting better un-
derstanding of natural history and in diagnostics can also help us find the worst lesion.
use of biomarkers at the patient level
With all new developments in both primary and secondary cervical cancer prevention, 
cervical cancer screening guidelines are in constant evolution. So far, extended screen-
ing intervals for HPV-negative women above the age of 40 years have been the first 
step towards more personalized screening. Findings from this thesis regarding sampling 
modality, triage strategy and risk assessment based on molecular profiling might con-
tribute to a future model in which individual patient preferences and patient risks are 
taken into account. Such a model should also take into account differences between 
populations.
Firstly, there is a difference between responders and non-responders, and moreover 
people who are screened and people who are not. People who do not regularly attend 
screening have a higher risk of developing cancer 56. Immune status, as demonstrated 
by differences between patient with and without HIV, also alters the risk of developing 
cervical or anal cancer 57, 58. A combination of the two factors mentioned above is most 
likely the main but not sole reason for differences in cervical cancer between the de-
veloped and developing world. Factors such as ethnicity, smoking status, age of sexual 
debut, number of lifetime sexual partners and contraceptive of choice also influence the 
risk of cancer 59-63. In addition, because of the different cancer risks of different hrHPV 
genotypes and because of the altered risk of progression to cancer in case of genotype 
specific persisting hrHPV infection, genotyping could become increasingly important in 
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population based and personalized screening. Every HPV genotype has its own risk of 
developing into a cancer, with >70% of all cervical cancers caused by HPV16, and most 
likely there are subtypes and isolates that are more cancerous than others. Mirabello 
et al found that the more the HPV E7 region of an HPV16 is conserved, so the less SNPs 
it has, the more likely it is to cause a cancer 1. In addition, most women will have the 
same HPV16 isolate on multiple sites of their genital tract (cervical, vulvar, anal). Over 
time, women might have the same isolate present as a persisting infection or gain a new 
HPV16 infection with a different isolate.
Another important question that needs to be addressed is: who to screen? For cervical 
cancer, this is mostly clear. In the majority of screening countries, women are screened 
starting at the age of 30. Younger women more often have HPV infections but are less 
likely to have CIN lesions that need treatment 64. In Chapter 3, we have shown that there 
is a difference in performance of methylation markers FAM19A4/miR124-2 between 
women under and over the age of 30, which can partly be explained by the fact that 
hypermethylation is a result of persistent HPV infection and, in addition, the process in-
creases with age 65-67. However, there is a group of women that develops cervical cancer 
at a young age (<25) and carcinogenesis in this group might follow a different pathway 
than in older women and developing more quickly, requiring other tumour markers for 
risk assessment 68, 69.
For anal cancer, it is unclear how to screen, and moreover who and when to screen. 
Targeted screening of high-risk populations such as HIV+ MSM is done increasingly, 
however, anal cancer is more frequently found in women and therefore identification 
and screening recommendations of women at risk could result in better disease control 
30, 70-72. Feasibility of expansion of targeted screening, or even incorporation into the 
cervical cancer screening programme, will largely depend on costs, invasiveness and 
performance of the screening test, which is yet to be selected. 32
Impact of HPV vaccination on cervical screening
In the Western world, prophylactic vaccination will change cervical cancer screening 
when the first vaccinated cohorts reach the screening age. Women who have been vac-
cinated will have a lower cancer risk, allowing for longer screening intervals and less 
lifetime screens 73. Until full herd-immunization has been reached, personalized risk as-
sessment and screening algorithms, possibly including other clinical risk factors such as 
smoking status and number of sexual partners, might therefore apply and registration of 
vaccination status is important. To eradicate HPV related cancers, including penile, vul-
var, vaginal and oropharyngeal cancer, boys also need to be vaccinated in order to reach 





as Australia and Austria, gender neutral vaccination has already been implemented. In 
addition, studies have shown that targeted vaccination of high-risk populations such as 
MSM is achievable and cost-effective and could substantially reduce the burden of HPV-
related diseases among men 75, 76. Seroconversion and protection against HPV-related 
disease after prophylactic vaccination has been studied in girls and boys and have 
shown comparable results 77. Studies comparing heterosexual men and MSM under the 
age of 26 showed that immunogenicity is lower among MSM 78, 79. Research on efficacy 
and safety of HPV vaccination of men, both heterosexual and MSM, over 26 years of age 
is ongoing.
Improving colposcopy
Colposcopy and high resolution anoscopy both rely on the subjective identification of 
visual features of dysplasia by a clinician, resulting in a sensitivity of 50-70% for HSIL 
detection 22-24, 80-82. Alternative or supportive tools for colposcopy, such as fluorescence 
and reflectance spectroscopy, might result in increased sensitivity and specificity, but 
have not been introduced in standard clinical practice 83. Digital colposcopy has given 
us the opportunity to build a digital database of colposcopic images. In combination 
with histological data 84, this database could be used to develop artificial intelligent 
algorithms that can identify at risk lesions. Techniques are still under development and 
have to be evaluated in randomized controlled trials comparing them with conventional 
colposcopy in order to determine their clinical value.
The future of methylation markers
Many tumor suppressor gene-based methylation markers have been discovered. So far, 
over 100 human genes have been proposed as markers of cervical precancer and cancer 
but none of the found markers can be used as a sole marker to detect CIN3+ lesions: a 
combination of at least 2 markers always has to be made to reach acceptable sensitiv-
ity and specificity 85. Discovery of an accurate and acceptable endpoint for malignant 
transformation could help to identify new methylation markers. With the help of next 
generation sequencing, relevant methylated regions between controls and cancers, but 
also between progressing and regressing precursor lesions can be identified. Most desir-
ably, a method with high coverage that only requires low DNA input would be used 86. 
This way, markers that are specific for one histological cancer type or a general tumour 
marker for anogenital cancer could be identified, allowing anogenital cancer risk assess-
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Human papillomavirus (HPV) infections are common in both men and women and are 
in most cases cleared within 2 years after infection. When not cleared by the immune 
system, an infection with high-risk HPV genome expression can cause instability of 
the human DNA that can lead to cellular aberrations which are reflected in histological 
morphology of the epithelium. These changes are called intraepithelial neoplasia or 
squamous intraepithelial lesion. A lot of these lesions represent productive infections 
that will regress spontaneously without treatment, but some are transforming infec-
tions that will progress to cervical or anal cancer without interference. Identification 
of molecular differences that can distinguish between productive lesions which might 
regress spontaneously and advanced transforming lesions with a higher risk of progres-
sion to cancer could help identify those patients that require treatment and differentiate 
those patients in which close follow-up would be more appropriate. This thesis aimed 
to identify biomarker expression patterns corresponding with different grades of cervi-
cal and anal precursor lesions in cytological and histological specimens, opposing an 
important tool for diagnosis and clinical management of patient at risk of cervical and 
anal cancer.
Chapter 1 provides an overview of existing cervical and anal cancer prophylaxis, screen-
ing, triage, diagnosing and treatment. Current knowledge on natural history of HPV 
infection is summarized and gaps in current knowledge are mentioned. Finally, the 
biomarkers that have been used throughout this thesis are introduced and their role in 
improving diagnosing and clinical management are discussed.
PaRT 1 – bIOmaRKeRs In CeRVICal CanCeR sCReenIng anD TRIage
The introduction of hrHPV testing as a primary screening test has provided us with a 
more sensitive approach to detecting women with CIN2+/HSIL compared to cytology-
based screening. By increasing the detection of women at risk of cervical precancer 
and cancer, cancer incidence can be decreased. Another way to lower cervical cancer 
incidence is increasing the participation rate of the screening programme. Currently, 
half of all carcinomas are found in women who have not attended screening and these 
so-called ‘non-responders’ are more likely to hand in a self-sample when offered than 
attend the doctor’s office after an invitation for a Pap smear. Brush-based self-samples 
collect cervicovaginal cells from the vagina with a brush that is inserted in the vagina, 
and its performance for detection of CIN2+/HSIL using hrHPV testing has been found 
comparable to that of hrHPV testing on a clinician-taken smear.
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Chapter 2 describes how first-void urine, which is collected less invasively than a 
brush-based self-sample, can be used to detect women with high-grade lesions. We 
compared the sensitivity of hrHPV detection and genotype detection in self-collected 
urine samples in the morning and later on during the day, in brush-based self-samples 
and clinician-taken smears (CTS). We measured CIN2+ detection in women referred 
for colposcopy using two different HPV testing algorithms (SPF10 and GP5+/6+). We 
found that all three sample types detected all CIN3 cases with both tests. The sensitiv-
ity for CIN2+ with the SPF10 system was 100% in clinician-taken smears, brush based 
self-samples and the second urine sample, and was 95% in the morning first-void urine 
sample. With the GP5+/6+ assay, sensitivity was 95% in all sample types. The sensitivities 
and specificities for both tests on each of the sample types did not significantly differ. 
Looking at the agreement of found genotypes in the paired samples of a woman, we 
found a discordance of 10–14% on hrHPV genotype. We concluded that CIN2+ detec-
tion using HPV testing of first-void urine samples shows a sensitivity similar to that of 
clinician-taken smears or brush-based self-samples, and in addition is convenient to use 
for women. There was substantial to almost excellent agreement between all samples 
on genotype with both hrHPV assays.
hrHPV screening has a higher sensitivity, but lower specificity than cytology-screening 
and therefore, a triage test is needed for hrHPV-positive women to prevent unnecessary 
colposcopy referrals. In the search for an objective and reproducible triage test with 
good clinical performance, various molecular tests have been evaluated.
In Chapter 3 we compared the performance of hrHPV-testing and genotyping (GP5+/6+), 
and methylation testing of human tumor suppressor genes FAM19A4 and/or miR124-2, 
and different combinations of those, for the detection of CIN3 and cervical carcinoma 
in women with an ASC-US/LSIL or ASC-H/AGC/HSIL Pap smear result. Both women 
younger than 30 and women of 30 years of age and over were included, and results of 
these groups of women were interpreted both together and separately. Overall sensitiv-
ity and specificity for CIN3+ were respectively 90.3% and 31.8% for hrHPV, 77.8% and 
69.3% for methylation biomarkers, and 93.1% and 49.4% for combined HPV16/18 and/
or methylation positivity, which was the best combination that we found. Excluding can-
cers, in CIN3, the markers performed equally well. In women aged ≥30, the sensitivity of 
combined HPV16/18 and methylation was increased (98.2%) with a specificity of 46.3%. 
And in younger women, this test had an optimal balance between sensitivity (75.0%) 
compared to methylation alone and specificity (55.5%) compared to hrHPV testing 
alone as well. We concluded that the combination of HPV16/18 and methylation analysis 





rapid treatment for these women and follow-up for women with potentially regressive, 
less advanced, HSIL/CIN2 lesions.
Our study about HPV16/18 genotyping and detection of hypermethylation of human 
cell genes involved in cervical oncogenesis and others have shown promising results 
in triage of high-risk HPV (hrHPV)-screen positive women on cervical smears. These 
tests can be performed on self-samples of cervicovaginal cells. In Chapter 4 we studied 
whether a self-sample represents the hrHPV genotype causing the worst cervical lesion, 
using the GP5+/6+ assay. This has important implications for hrHPV genotyping triage 
on self-samples. In addition, we studied whether any differences in hypermethylation of 
FAM19A4/miR124-2 exist between CIN lesions caused by different hrHPV types. For this 
study, we used self-samples collected from former non-responders to the Dutch screen-
ing programme from the PROHTECT-3b trial. We found the causative hrHPV genotype 
of the worst lesion on self-sample in 93.4%, with HPV16 the most frequently detected 
type on self-sample and also the most frequently found causative genotype in CIN3+, 
and all of these women with HPV16-caused CIN3+ also had HPV16 detected on self-
sample. There were no differences in the percentages of positive FAM19A4/miR124-2 
methylation assays between lesions caused by HPV16/18 (73.8% methylation positivity 
in CIN3+) or other hrHPV genotypes (66.7% methylation positivity in CIN3+).
PaRT 2 – bIOmaRKeRs exPRessIOn PaTTeRns In aIn
Classical H/E interpretation of biopsies is subject to inter and intra observer variation 
and does not reflect cellular transformation, not allowing for the identification of ad-
vanced transforming lesions with a higher risk of progression to cancer and in need of 
treatment and productive infections with a higher chance of spontaneous regression. 
This leads to differences in diagnosis between pathologists, centres and clinical stud-
ies on the one hand, and to overtreatment of women with CIN and men and women 
with AIN. CIN treatment has a risk of adverse pregnancy outcome and AIN treatment 
is burdensome and has a high percentage of recurrent lesions. There are biomarkers 
can differentiate between productive and transforming lesions, of which a selection of 
immunohistochemical markers was used in sets of anal biopsies in Part 2 of the thesis.
In Chapter 5 we used immunohistochemical marker p16, which is a surrogate marker 
of transforming activity of the HPV E7 gene, and Ki-67, a marker of cell cycle activity, 
and the novel marker HPV E4 which is a marker for completion of the productive phase 
of the HPV life cycle to describe different immunohistochemical staining patterns in 
AIN biopsies. Biopsies were taken from the anal canal of men who have sex with men, 
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and most were HIV positive. We identified the causative HPV genotype of lesions using 
the SPF10 assay and laser capture microdissection (LCM) in case of multiple infections. 
Using the three immunohistochemical markers, we were able to identify four main bio-
marker expression patterns: p16 negative, E4 negative, Ki-67 positive (p16-,E4- Ki-67+ ), 
representing early or resolving AIN1 (1); p16 negative, E4 positive, Ki-67 positive (p16-, 
E4+, Ki-67+), representing mature productive AIN1 (2); p16 positive, E4 positive, Ki-67 
positive, (p16-, E4+, Ki-67+) representing productive and early transforming infection 
mostly seen in AIN2 (3); and finally p16 positive, E4 negative, Ki-67 positive (p16+, E4-, 
Ki-67+), representing advanced transforming infection mostly seen in AIN3 (4). Our 
results suggested that division of lesions into LSIL and HSIL might be too simplistic and 
that by combining p16 and Ki-67 with E4 productive AIN lesions can be distinguished 
from advanced transforming AIN.
Findings from Chapter 5 showed us that Ki-67 is a useful marker, mostly helpful in 
discriminating between normal tissue and AIN1/LSIL. However, the most important 
improvement of clinical management will result from better identification of productive 
LSIL and HSIL with a higher chance of spontaneous regression, and this could well be 
identified using a combination of p16 and E4 only.
In Chapter 6, we therefore used a combination of E4 and p16 to improve definition of 
lr- and hr-HPV associated AIN in HIV+ MSM. We compared this approach to current LAST 
criteria, which uses p16 in a subset of lesions to categorize lesions as either LSIL or HSIL. 
Worst lesions were scored for p16 (0-4), used to identify transforming activity of HPV, and 
panHPV E4 (0-2) to identify HPV production and life-cycle completion. LAST diagnosis 
found 37 normal biopsies, 55 LSIL and 91 HSIL. 92.6% of LSIL was caused by lrHPV and 
92.4% of HSIL was caused by hrHPV. No normal biopsy showed E4; 41.8% of LSIL and 
38.5% of HSIL were E4 positive, and no differences in E4 positivity were found between 
lesions caused by lrHPV and hrHPV. Most lesions caused by lrHPV showed extensive 
patchy p16 staining (89.5%). From our results we concluded that combined p16/E4 IHC 
identifies both productive and non-productive LSIL associated with lrHPV and HSIL asso-
ciated with hrHPV and can provide detailed information about AIN beyond supporting 
H/E. Using p16/E4 could potentially allow more selective treatment of hr-HPV-caused 






PaRT 3 – bIOmaRKeR exPRessIOn PaTTeRns In aIn
The final part of this thesis focussed on how different combinations of biomarkers p16/
E4 and methylation markers FAM19A4/mir124-2 can be used to identify women with or 
at risk of ≥CIN2/HSIL.
Chapter 7 describes a cross-sectional study in which the relationships between the 
immunohistochemical expression patterns of markers p16 and HPV E4 in biopsies and 
methylation markers FAM19A4/miR124-2 in cervical smears of women with different 
grades of CIN and negative controls associated with hrHPV infection was explored. Also, 
we studied the relation between the biomarker expression pattern and the grade of 
CIN or invasive cancer found on excision treatment. Most importantly, we show that 
there is an inverse relation between HPV E4 expression on biopsy and hypermethylation 
of markers FAM19A4/miR124-2 detected on cervical smear. Both p16 and methylation 
positivity increase with lesion severity and identify neoplastic transformation. Most HPV 
E4 positivity was found in lesions with p16 expression in the lower 2/3 of the epithelium, 
suggesting that there is also a role for p16, which is a surrogate marker of HPV E7 over-
expression, in driving the increased epithelial proliferation necessary for viral reproduc-
tion. Expression patterns confirm that CIN1 and CIN2 are very heterogeneous groups, 
consisting of productive infections expressing E4 and transforming lesions expressing 
p16, some of which show methylation marker positivity. Our work shows that the use of 
the E4 immunomarker and methylation markers in this group could offer more detailed 
information than current CIN grading practice.
Finally, in Chapter 8, results described in this thesis were interpreted in a broader sense. 
Our results were discussed in the light of various factors that influence the effectiveness 








Human papillomavirus (HPV) infecties zijn veelvoorkomend in zowel mannen als 
vrouwen en worden in de meeste gevallen binnen 2 jaar opgeruimd door ons afweer-
systeem. Wanneer de infectie niet wordt opgeruimd door het immuunsysteem, kan een 
infectie met een hoog-risco HPV type zorgen voor instabiliteit van het humane DNA 
wat kan zorgen voor cellulaire veranderingen die zorgen voor afwijkingen in de histo-
logische morfologie van het epitheel. Dit wordt intraepitheliale neoplasie of ‘squamous 
intraepithelial lesion’ genoemd. Veel van deze laesies zijn productieve HPV infecties die 
spontaan in regressie zullen gaan wanneer deze niet worden behandeld, maar sommige 
zijn transformerende infecties welke progressie naar cervix- of anuscarcinoom kunnen 
vertonen wanneer zij niet worden behandeld. Identificatie van moleculaire verschillen 
tussen productieve laesies die mogelijk regressie zullen vertonen en vergevorderde 
transformerende laesies met een hoger risico op progressie naar kanker kunnen hel-
pen bij het herkennen van patiënten die een behandeling nodig hebben en patiënten 
waarbij een behandeling niet noodzakelijk is. Dit proefschrift had als doel om biomar-
ker expressie patronen te identificeren in cytologische en histologische monsters die 
verschillende gradaties van cervicale en anale laesies weergeven. Zulke biomarkers 
kunnen een belangrijke rol spelen bij het diagnosticeren van verschillende stadia van 
intraepitheliale neoplasie en het bepalen van het klinische beleid van patiënten met een 
risico op baarmoederhalskanker en anuskanker.
Hoofdstuk 1 geeft een overzicht van bestaande profylaxe, screening, triage, diagnose 
en behandeling van baarmoederhalskanker en anuskanker. De huidige kennis over het 
beloop van een HPV-infectie wordt in dit hoofdstuk samengevat en hiaten in de huidige 
kennis worden genoemd. Ten slotte worden de biomarkers geïntroduceerd die in dit 
proefschrift zijn gebruikt en hun rol bij het verbeteren van de diagnose en het klinisch 
management van patiënten wordt besproken.
Deel 1 - bIOmaRKeRs In baaRmOeDeRHalsKanKeR  sCReenIng en 
TRIage
De introductie van hrHPV-testen als primaire screeningstest heeft geresulteerd in een 
screeningsprogramma met een hogere sensitiviteit voor het detecteren van vrouwen 
met CIN2+/HSIL in vergelijking met op cytologie gebaseerde screening. Met een ver-
hoogde sensitiviteit van het screeningsprogramma kan de baarmoederhalskankerinci-
dentie worden verlaagd. Een andere manier om de incidentie van baarmoederhalskan-
ker te verlagen, is het verhogen van de participatiegraad van het screeningsprogramma. 
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Momenteel wordt de helft van alle carcinomen aangetroffen bij vrouwen die niet aan de 
screening deelnemen. Deze zogenaamde ‘non-responders’ zullen eerder een zelfmon-
ster inleveren dan naar de arts gaan voor een uitstrijkje. Zelfmonsters kunnen worden 
genomen met zelfafname borstels welke door een vrouw zelf wordt ingebracht in de 
vagina en daar cervicovaginale cellen verzamelt. De detectie van CIN2+/HSIL met be-
hulp van hrHPV-testen uitgevoerd op een zelfafname borstel is vergelijkbaar met die 
van hrHPV-testen uitgevoerd op een door een arts afgenomen uitstrijkje.
Hoofdstuk 2 beschrijft hoe de eerste fractie van de mictie in een urinemonster kan wor-
den gebruikt om vrouwen met hooggradige CIN laesies te detecteren. We vergeleken de 
gevoeligheid van hrHPV-detectie en genotypering in in de ochtend verzamelde urine-
monsters, in later gedurende de dag verzamelde urinemonsters, in zelfafnamen gedaan 
met een borstel en in door de arts gemaakte uitstrijkjes (clinician-taken samples: CTS). 
We hebben de CIN2+-detectie bij vrouwen die werden verwezen voor colposcopisch 
onderzoek in de verschillende sample typen met behulp van twee verschillende HPV-
testalgoritmen (SPF10 en GP5+/6+) onderzocht. Alle CIN3-gevallen werden met behulp 
van beide HPV-tests in alle sample typen opgespoord. De gevoeligheid voor CIN2+ met 
het SPF10-systeem was 100% in door de arts genomen uitstrijkjes, zelfafname borstels 
en het tweede urinemonster van de dag, en was 95% in het ochtend urinemonster. Met 
de GP5+/6+ test was de gevoeligheid 95% in alle sample typen. De sensitiviteit en speci-
ficiteit voor beide HPV-testen was voor geen enkel sample type significant verschillend. 
De gevonden HPV genotypen in de verschillende sample typen van één vrouw verschil-
den 10–14%. We concludeerden dat CIN2+-detectie met behulp van HPV-testen van het 
eerste gedeelte van een urinemonster een gevoeligheid vertoont die vergelijkbaar is 
met die van door de arts afgenomen uitstrijkjes of zelfafnames met een borstel. Met 
beide testen was er een substantiële tot bijna uitstekende overeenkomst in gevonden 
HPV genotypen in alle sample typen. Daarnaast is het verzamelen van een urinemonster 
handig en makkelijk voor een vrouw zelf.
hrHPV-screening heeft een hogere sensitiviteit, maar een lagere specificiteit dan cytolo-
gie-screening en daarom is een triage test voor hrHPV-positieve vrouwen noodzakelijk 
om onnodige colposcopie-verwijzingen te voorkomen. In de zoektocht naar een objec-
tieve en reproduceerbare triage test met goede klinische waarde werden verschillende 
moleculaire tests geëvalueerd.
In hoofdstuk 3 vergeleken we hrHPV-testen en genotypering (GP5+/6+) en methylatie-
tests van humane tumorsuppressorgenen FAM19A4 en/of miR124-2, en verschillende 
combinaties daarvan, voor de detectie van CIN3 en cervixcarcinoom bij vrouwen met 





wen van 30 jaar en ouder werden in de studie geincludeerd, en de resultaten van deze 
groepen vrouwen werden zowel samen als afzonderlijk geïnterpreteerd. In de gehele 
groep waren de sensitiviteit en specificiteit voor CIN3+ respectievelijk 90,3% en 31,8% 
voor hrHPV, 77,8% en 69,3% voor methylatiepositiviteit en 93,1% en 49,4% voor de 
combinatie van HPV16/18 genotypering en/of methylatiepositiviteit, wat de beste 
combinatie was die we vonden. De markers presteerden even goed voor de detectie van 
CIN3 (exclusief carcinomen). Bij vrouwen van 30 jaar en ouder was de sensitiviteit van 
gecombineerde HPV16/18 en methylatie detectie hoger (98,2%) met een specificiteit 
van 46,3%. Bij jongere vrouwen (<30 jaar) had deze test de beste balans tussen sensitivi-
teit (75,0%) en specificiteit (55,5%). We concludeerden dat de combinatie van HPV16/18 
en methylatie analyse zeer gevoelig was en goede specificiteit voor CIN3+ bood. Het 
gebruik van een dergelijke combinatie biedt de mogelijkheid van snelle behandeling 
van vrouwen positief voor deze combinatie en daarmee een hoge kans op CIN3+, en 
follow-up voor vrouwen negatief voor deze combinatie en daarmee een hoge kans op 
een mogelijk regressieve, minder geavanceerde HSIL/CIN2-laesie.
Onze studie over het gebruik van HPV16/18 genotypering en detectie van hypermethy-
lering van genen die betrokken zijn bij cervicale oncogenese en de studies van anderen 
over het gebruik van deze markers als triage test na een hrHPV-positief screenings 
uitstrijkje hebben veelbelovende resultaten laten zien. HPV genotypering en methyla-
tietesten kunnen ook worden uitgevoerd op zelfmonsters van cervicovaginale cellen.
In hoofdstuk 4 hebben we onderzocht of het hrHPV-genotype dat de meest ernstige 
onderliggende laesie veroorzaakt in een zelfafname kan worden gevonden met behulp 
van de GP5+/6+ HPV test. Dit is van belang voor het gebruik van hrHPV genotypering 
als triage test in zelfafnamen. Daarnaast hebben we onderzocht of er verschillen in 
hypermethylering van FAM19A4/miR124-2 bestaan  tussen CIN-laesies veroorzaakt door 
verschillende hrHPV-typen. Voor dit onderzoek hebben we zelfafnamen gebruikt die zijn 
verzameld in het kader van de PROHTECT-3b-studie bij voormalige non-responders van 
het Nederlandse screeningprogramma. We vonden het veroorzakende hrHPV-genotype 
van de ergste laesie in de zelfafname in 93,4%. HPV16 was het meest frequent gedetec-
teerde HPV type in de zelfafname en was ook het meest voorkomende causale genotype 
in CIN3+. Alle vrouwen met een door HPV16 veroorzaakte CIN3+ hadden ook een HPV16 
positieve zelfafname. Er waren geen verschillen in de percentages FAM19A4/miR124-2 
methylatiepositiviteit tussen laesies veroorzaakt door HPV16/18 (73,8% methylatiepo-
sitiviteit in CIN3+) en andere hrHPV-genotypen (66,7% methylatiepositiviteit in CIN3+).
Chapter 9
180
Deel 2 - bIOmaRKeRs exPRessIePaTROnen In aIn
Klassieke H/E-interpretatie van biopten is onderhevig aan inter- en intra-waarnemer-
variatie en geeft cellulaire transformatie niet weer, waardoor geavanceerde transfor-
merende laesies met een hoger risico op progressie naar kanker niet kunnen worden 
onderscheiden van productieve infecties met een hogere kans op spontane regressie. 
Dit leidt allereerst tot verschillen in diagnose tussen pathologen, centra en klinische 
studies. Daarnaast kan dit leiden tot overbehandeling van vrouwen met productieve 
CIN en mannen en vrouwen met productieve AIN, welke geen behandeling nodig heb-
ben. De behandeling van CIN geeft een risico op nadelige zwangerschapsuitkomsten. 
De behandeling van AIN is belastend voor de patiënt en er worden na behandeling veel 
terugkerende laesies gezien. Er zijn biomarkers die een onderscheid kunnen maken 
tussen productieve en transformerende laesies, waarvan een selectie van immuno-
histochemische markers werd gebruikt in sets van anale biopsieën in deel 2 van het 
proefschrift.
In hoofdstuk 5 hebben we immunohistochemische marker p16, een vervangende 
marker voor transformerende activiteit van het HPV E7-gen, en Ki-67, een marker voor 
celcyclusactiviteit, en de nieuwe marker HPV E4 die voltooiing van de productieve fase 
van de HPV-levenscyclus weergeeft, gebruikt om verschillende biomarker expressiepa-
tronen in AIN-biopten te beschrijven. Biopten werden genomen uit het anale kanaal van 
mannen die seks hebben met mannen (MSM), en de meesten waren HIV-positief. We 
hebben het causale HPV-genotype van laesies geïdentificeerd met behulp van de SPF10 
HPV-test en laser capture microdissection (LCM) wanneer er meerdere HPV-typen in het 
biopt aanwezig waren. Met behulp van de drie immunohistochemische markers konden 
we vier hoofdpatronen van biomarker-expressie identificeren: p16 negatief, E4 negatief, 
Ki-67 positief (p16-, E4- Ki-67+), passend bij vroege of genezende AIN1 (1); p16 negatief, 
E4 positief, Ki-67 positief (p16-, E4+, Ki-67+), passend bij mature productieve AIN1 (2); 
p16 positief, E4 positief, Ki-67 positief, (p16-, E4+, Ki-67+) passend bij productieve en 
vroeg transformerende infectie, meestal AIN2 (3); en ten slotte p16 positief, E4 negatief, 
Ki-67 positief (p16+, E4-, Ki-67+), passend bij een vergevorderde transformerende infec-
tie, meestal AIN3 (4). Onze resultaten suggereerden dat de verdeling van laesies in LSIL 
en HSIL te simplistisch is en dat door p16 en Ki-67 te combineren met E4,  productieve 
AIN-laesies kunnen worden onderscheiden van vergevorderde transformerende AIN.
De bevindingen uit hoofdstuk 5 lieten ons zien dat Ki-67 een nuttige marker is, meest 
bijdragend bij het maken van onderscheid tussen normaal weefsel en AIN1/LSIL. De 
belangrijkste verbetering van klinisch management zal echter het gevolg zijn van een 





gressie, en deze laesies kunnen worden geïdentificeerd met alleen een combinatie van 
p16 en E4. In hoofdstuk 6 hebben we daarom een  combinatie van E4 en p16 gebruikt om 
de definitie van lr- en hr-HPV-geassocieerde AIN bij HIV+ MSM te verbeteren. We hebben 
deze benadering vergeleken met de huidige LAST richtlijn, waarin p16 wordt gebruikt in 
een subset van laesies om deze te categoriseren als LSIL of HSIL. In onze studie werden 
de meest ernstige laesies gescoord voor p16 (scores 0-4), gebruikt om transformerende 
activiteit van HPV te identificeren, en E4 (scores 0-2) om HPV-productiviteit en voltooi-
ing van de levenscyclus te identificeren. LAST diagnose vond 37 normale biopsieën, 55 
LSIL en 91 HSIL. 92,6% van LSIL werd veroorzaakt door lrHPV en 92,4% van HSIL werd 
veroorzaakt door hrHPV. Geen enkel normaal biopt toonde E4; 41,8% van LSIL en 38,5% 
van HSIL waren E4-positief en er werden geen verschillen in E4-positiviteit gevonden 
tussen laesies veroorzaakt door lrHPV en hrHPV. De meeste laesies veroorzaakt door 
lrHPV toonden een patroon van uitgebreide vlekkerige p16-kleuring (89,5%). Uit onze 
resultaten hebben we geconcludeerd dat gecombineerde p16/E4 IHC zowel produc-
tieve als niet-productieve LSIL geassocieerd met lrHPV en HSIL geassocieerd met hrHPV 
identificeert en gedetailleerde informatie over AIN kan bieden. Deze informatie gaat 
verder dan het ondersteunen van H/E alleen. Het gebruik van p16/E4 kan mogelijk een 
meer selectieve behandeling van door hr-HPV veroorzaakte vergevorderde transforme-
rende HSIL mogelijk maken, waardoor onnodige behandeling van productieve HSIL en 
lr-HPV-geassocieerde LSIL wordt voorkomen.
Deel 3 – bIOmaRKeR exPRessIePaTROnen In CIn
Het laatste deel van dit proefschrift richtte zich op hoe verschillende combinaties van 
biomarkers p16/E4 en methylatie markers FAM19A4/mir124-2 kunnen worden gebruikt 
om vrouwen met ≥CIN2/HSIL of met een verhoogd risico op ≥CIN2/HSIL te identificeren.
Hoofdstuk 7 beschrijft een cross-sectioneel onderzoek waarin de relaties tussen de 
immunohistochemische expressiepatronen van markers p16 en HPV E4 in biopten en 
methylatie markers FAM19A4/miR124-2 in cervicale uitstrijkjes van vrouwen met CIN 
en histologische normale, hrHPV positieve controles werd verkend. We onderzochten 
ook de relatie tussen het biomarker expressiepatroon in het biopt en de uitstrijk en de 
meest ernstige laesie die werd gevonden tijdens de behandeling van vrouwen middels 
een LEEP (loop electrosurgical excision procedure) of hysterectomie. De belangrijkste 
bevinding is dat er een omgekeerd verband is tussen HPV E4-expressie in een biopt en 
hypermethylering van markers FAM19A4/miR124-2 in het cervixuitstrijkje. Zowel p16 
als methylatiepositiviteit nemen toe met de ernst van de laesie en identificeren neo-
plastische transformatie. De meeste HPV E4-positiviteit werd gevonden in laesies met 
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p16-expressie in het onderste 2/3 van het epitheel, wat suggereert dat er ook een rol is 
voor p16, een surrogaat marker van HPV E7-overexpressie, bij het stimuleren van de ver-
hoogde epitheliale proliferatie die nodig is voor virale reproductie. Expressiepatronen 
bevestigen dat CIN1 en CIN2 zeer heterogene groepen zijn, bestaande uit productieve 
infecties die E4 tot expressie brengen en transformerende laesies die p16 tot expressie 
brengen, waarvan sommige methylatiemarkerpositiviteit vertonen. Ons werk toont aan 
dat het gebruik van de E4 immunomarker en methylatie markers in deze groep meer 
gedetailleerde informatie zou kunnen bieden dan de huidige CIN-beoordelingspraktijk.
Ten slotte werden in hoofdstuk 8 de resultaten die in dit proefschrift zijn beschreven in 
een breder wetenschappelijk en maatschappelijk kader geplaatst. Hierbij worden ver-
schillende factoren die van invloed zijn op de effectiviteit van screening en de incidentie 
van baarmoederhalskanker en anale kanker mee gewogen en werd bediscussieerd hoe 
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